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ABSTRACT 
 
 
 Azole antifungal resistance has emerged as a significant problem in the 
management of infections caused by fungi including Candida species.  In recent years, 
Candida glabrata has become the second most common cause of mucosal and invasive 
fungal infections in humans second to Candida albicans.  Not only are systemic C. 
glabrata infections characterized by high mortality rates, treatment failures to the azole 
class of antifungals, the most widely used antifungal for treatment of Candida infections, 
have been reported.  Contributing to this problem, C. glabrata exhibits intrinsic reduced 
susceptibility to the azole antifungals, and the development of high-level azole resistance 
during therapy has been reported in oral as well as bloodstream C. glabrata isolates in 
immunocompromised patients. The azole antifungals are fungistatic against Candida 
species, thus C. glabrata also exhibits tolerance to the azoles which may contribute to 
both therapeutic failures and ultimately the development of high-level azole resistance. 
 
 In C. glabrata clinical isolates, the predominant mechanism behind azole 
resistance is upregulated expression of multidrug transporter genes CgCDR1 and 
CgPDH1. It was previously reported that azole-resistant mutants (MIC ≥ 64 μg/ml) of 
strain 66032 (MIC = 16 μg/ml) similarly show coordinate CDR1-PDH1 upregulation, and 
in one of these (F15) a putative gain-of-function mutation was identified in the single 
molecule homologue of Saccharomyces cerevisiae transcription factors Pdr1p–Pdr3p. 
Here we show that disruption of C. glabrata PDR1 conferred equivalent fluconazole 
hypersensitivity (MIC = 2 μg/ml) to both F15 and 66032 and eliminated both constitutive 
and fluconazole-induced CDR1-PDH1 expression. Reintroduction of wild-type or F15 
PDR1 alleles fully reversed these effects; together these results demonstrate a role for this 
gene in both acquired and intrinsic azole resistance. CDR1 disruption had a partial effect, 
reducing fluconazole trailing in both strains while restoring wild-type susceptibility (MIC 
= 16 μg/ml) to F15. In an azole-resistant clinical isolate, PDR1 disruption reduced azole 
MICs eight- to 64-fold with no effect on sensitivity to other antifungals. To extend this 
analysis, C. glabrata gene expression microarrays were generated and used to analyze 
genome-wide expression in F15 relative to its parent. Homologues of 10 S. cerevisiae 
genes previously shown to be Pdr1p–Pdr3p targets were upregulated (YOR1, RTA1, 
RSB1, RPN4, YLR346c and YMR102c along with CDR1, PDH1 and PDR1 itself) or 
downregulated (PDR12); roles for these genes include small molecule transport and 
transcriptional regulation. However, expression of 99 additional genes was specifically 
altered in C. glabrata F15; their roles include transport (e.g. QDR2, YBT1), lipid 
metabolism (ATF2, ARE1), cell stress (HSP12, CTA1), DNA repair (YIM1, MEC3) and 
cell wall function (MKC7, MNT3). These azole resistance-associated changes could affect 
C. glabrata tissue-specific virulence; in support of this, we detected differences in F15 
oxidant, alcohol and weak acid sensitivities. C. glabrata provides a promising model for 
studying the genetic basis of multidrug resistance and its impact on virulence. 
 
 We next examined the genome-wide gene expression profiles in four matched 
azole-susceptible and –resistant clinical isolate sets of C. glabrata in which CgCDR1 
gene expression was upregulated in the resistant isolate. Of all the genes identified in the 
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gene expression profiles for these four matched pairs, there were nine genes that were 
commonly upregulated with CgCDR1 in all four isolate sets (YOR1, LCB5, RTA1, YIM1, 
YIL077c, POG1, HFD1, GLK1, and FMS1). We then sequenced CgPDR1 from each 
susceptible and resistant isolate and found two alleles with novel gain-of-function 
mutations. A third isolate, and its susceptible parent, harbored a CgPDR1 allele with a 
frameshift mutation which presumably results in a truncated CgPdr1p. The final resistant 
isolate had no PDR1 mutation.  CgPDR1 alleles with putative gain-of-function mutations 
were expressed in a common background strain in which CgPDR1 had been disrupted, 
and genome-wide gene expression profiles were examined to determine if different 
mutations in CgPDR1 result in different target gene activation and fluconazole MICs. 
Microarray analysis comparing these re-engineered strains to their respective parent 
strains identified a core set of commonly differentially-expressed genes as well as genes 
uniquely regulated by specific mutations.   
 
 Because understanding the initial stress response of C. glabrata to fluconazole 
may facilitate a better understanding of how this organism is able to survive in the 
presence of fluconazole, we used microarray analysis to determine how fluconazole 
exposure affects the gene expression profile in C. glabrata. We identified four 
transcriptional regulators, CgPDR1, UPC2, RLM1, and CRZ1, and several of their 
respective putative target genes that are upregulated in response to this stress. There were 
also many genes differentially expressed in response to fluconazole that encode proteins 
involved in small molecule transport (CgCDR1, CgPDH1, and YOR1), lipid, fatty acid, 
and sterol metabolism (ERG1, ERG2, and ERG24), cell wall maintenance (CWP1, CRH1, 
and CHS1), and cell stress (DDR48). As CgPDR1 has been implicated as a key regulator 
of azole resistance by activating transcription of the genes encoding ABC transporters 
CgCDR1p and CgPDH1p and has been shown to be activated in response to azole 
exposure, we also identified genes that respond to fluconazole exposure in a CgPDR1-
dependent fashion. Surprisingly, only five genes were Pdr1p-dependent in response to 
fluconazole, including CgCDR1. Our results provide a more comprehensive picture of the 
gene expression changes of C. glabrata in response to fluconazole.  
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CHAPTER 1. INTRODUCTION 
 
 
CANDIDA GLABRATA 
 
 
Biology and Classification 
 
 Candida glabrata is a commensal organism found among normal flora of the 
skin, mouth, vagina, and gastrointestinal tract. It is a budding yeast and belongs to the 
largest taxonomic group of the Fungal Kingdom, ascomycetes, and the class 
Saccharomycotina. C. glabrata is considered a non-dimorphic yeast that exist as small 
blastoconidia (1 to 4 μm) both as a commensal and as a pathogen; however, 
pseudohyphae have been observed in C. glabrata when grown on synthetic low-
ammonium dextrose agar (45). In fact, C. glabrata was once classified in the genus 
Torulopsis secondary to its lack of pseudohyphae production. However, it was later 
determined that the ability to produce pseudohyphae was not a reliable distinguishing 
factor for members of the genus Candida and T. glabrata was reclassified in the genus 
Candida (152).  
 
The evolutionary relationship within the genus Candida was compared by Barnes 
et al. on the basis of homology of 18S rRNA sequence, and it was concluded that despite 
its name, C. glabrata is evolutionarily more related to Saccharomyces cerevisiae than to 
other pathogenic fungi such as Candida albicans (16). However, in contrast to the 
sexually active S. cerevisiae that can shift in its life cycle between diploid and haploid 
forms of cells (226), C. glabrata is exclusively a haploid and asexual organism despite 
the fact that genetic analyses revealed the presence of genes potentially responsible for 
conjugation and mating-type switching (112, 202). Like with S. cerevisiae, C. glabrata is 
a “petite-positive” yeast in that a loss of mitochondrial genome is not lethal. Interestingly, 
these “petite mutants” were found to be more resistant to antifungals than the wild-type 
strains (50).  
 
 
Genetics and Genetic Manipulation 
 
The genome sequence of C. glabrata strain CBS138 was published in 2004 (50). 
It has 13 chromosomes encompassing a total of 12.3 Mbp and consists of approximately 
207 tRNA-encoding genes and 5283 protein-encoding genes. Its G-C content is 38.8% 
which is similar to S. cerevisiae (38.3%)(60). The genomes of C. glabrata and S. 
cerevisiae display a high degree of synteny with a majority of the S. cerevisiae genes 
having C. glabrata orthologs (60). However, C. glabrata has lost many metabolism 
genes, such as genes involved in galactose and sucrose assimilation, phosphate, nitrogen 
and sulfur metabolism, and thiamine, pyridoxine, and nicotinic acid biosynthesis. This is 
possibly a result of its close relationship with the mammalian host. 
 
The lack of a sexual cycle in C. glabrata is a drawback for classical genetics in 
this species. Methods used in C. glabrata for gene disruption rely on integrative 
 2
 
transformation by homologous recombination. Furthermore, two methods have been 
developed for transformation in C. glabrata, lithium acetate transformation and 
electroporation transformation (adapted from Cryptococcus neoformans) (75, 214). There 
are several gene disruption protocols that have been used in C. glabrata (82, 100, 132, 
225, 230); however, all of these methods depend on the use of nutritional markers for the 
selection of prototrophic transformants from auxotrophic host strains. One of these 
systems, modified from a S. cerevisiae method for use in C. glabrata, has been termed 
the PROmoter-dependent DIsruption of Genes (PRODIGE) method (19, 63, 119). This 
method uses polymerase-chain reaction (PCR) rather than cloning to generate disruption 
cassettes. These cassettes are generated with a promoterless marker gene (URA3) such 
that the expression of the selection marker gene is dependent, following recombination, 
on the promoter of the targeted gene. Selection then takes place on minimal medium 
plates lacking uracil. One obvious drawback of this method is that it requires at least a 
minimal level of promoter activity of the targeted gene for URA3 expression. Another 
drawback is that using the PRODIGE method, genes can only be disrupted in C. glabrata 
strains with a URA3-deficient genetic background. 
 
It is becoming increasingly evident that strategies like the one mentioned above 
that make use of auxotrophic markers may cause difficulties in the interpretation of 
mutant phenotypes (204). Recently, a transformation method that makes use of a 
dominant selection marker has been developed (176). This method, originally developed 
for use in C. albicans, relies on the use of a cassette that contains a dominant 
nourseothricin resistance marker (SAT1) for the selection of integrative transformants and 
the FLP recombinase gene under the control of an inducible promoter that allows the 
subsequent excision of the cassette, which is flanked by FLP target sequences, from the 
genome. When used in the diploid C. albicans, two rounds of integration/excision 
generate homozygous mutants that differ from the wild-type parent strain only by the 
absence of the target gene, and reintegration of an intact gene copy for complementation 
of mutant phenotypes is performed in the same way. Transformants are obtained after 
only one day of growth on a selective medium, and integration into the target locus 
occurs with high specificity after adding homologous flanking sequences on both sides of 
the cassette. FLP-mediated excision of the SAT1-flipper cassette is achieved by simply 
growing the transformants for a few hours in medium without selective pressure, and 
nourseothricin-sensitive derivatives can easily be identified by their slower growth on 
indicator plates containing a low concentration of nourseothricin. Although optimized for 
the alternative codon usage in C. albicans, this method has now been successfully used in 
the haploid C. glabrata, and requires only one round of integration/excision (68). This 
approach has allowed for the rapid and efficient generation of disruption mutants in C. 
glabrata.  
 
 
Pathogenicity and Virulence 
 
 Candida species are found as part of normal microflora of human mucosal 
surfaces, although sometimes they can cause infection. They enter the host through the 
urogenital tract, lungs and other mucosal surfaces and induce formation of purulent 
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infiltrates (83). Candida species are known to cause vaginitis, oropharyngeal infections, 
thrush, urogenital tract infections and have been isolated from the feces. Furthermore, the 
increasing number of immunocompromised individuals has added to the problem of 
increasing fungal infections, in particular, oral and systemic candidiasis (15, 24, 191, 
211). Over the past three decades, there has been an increase in non-albicans species 
causing infection, with C. glabrata being the second most common cause of mucosal and 
invasive fungal infections in humans. Although C. glabrata is phylogenetically closer to 
S. cerevisiae than other Candida species like C. albicans, the one distinct difference is 
that C. glabrata can cause infection in humans. It is likely that the differences in the S. 
cerevisiae and C. glabrata genome and the similarities between C. glabrata and C. 
albicans characterize the pathogenicity of C. glabrata; however, the virulence factors of 
C. glabrata are poorly understood. Therefore, the following discussion describes several 
known virulence factors in C. albicans and whether there are orthologs in C. glabrata. 
 
 Secreted hydrolases play an important role in virulence of C. albicans. It is 
thought that secreted hydrolases can contribute to host tissue invasion by digesting host 
cell membranes or cells and molecules of the host immune system, or by degrading host 
surface molecules to enhance adhesion. The most significant hydrolases produced by C. 
albicans are secreted aspartic proteinases (SAPs) and phospholipases. Although the C. 
glabrata genome encodes multiple orthologs of the S. cerevisiae extracellular 
glycosylphosphatidylinositol (GPI)-linked aspartyl proteases, C. glabrata does not 
produce significant levels of extracellular proteinase activity in vivo (94, 129). 
Furthermore, C. albicans secretes phospholipase B which is implicated in the spread of 
the organism from the gastrointestinal tract and in hematogenous dissemination (57, 74, 
142). The C. glabrata genome encodes three phospholipase B genes and it has been 
shown that they do generate phospholipase activity (94). To date, no published studies 
have analyzed the role of C. glabrata phospholipases in virulence; however, one 
unpublished study did find an association between phospholipase B activity and 
persistent C. glabrata candidemia (74). 
 
 Another virulence factor that has been identified in C. albicans is its ability to 
grow in different morphological forms (i.e. yeast, pseudohyphae, and hyphae). Although 
both yeast and hyphal forms of C. albicans are pathogenic, the invasive properties of 
hyphae are suggested by their ability to penetrate several cell layers deeper than yeast 
forms in superficial candidiasis. For example, histological examination of lingual tissue 
from a patient with candidiasis shows yeast and hyphae forms within vacuolated regions 
of tissue whereas only hyphae are present in deeper layers (106, 205). This observation 
suggests that hyphae are more invasive than the yeast form and are thought to increase 
the level of damage to host tissue. Although C. glabrata has been shown to form 
pseudohyphae in response to nitrogen starvation, this form has not been found in clinical 
specimens. However, components of the mitogen-activated protein (MAP) kinase 
signaling cascade that regulates pseudohyphal formation of S. cerevisiae have been 
studied in C. glabrata. Ste12p is a transcriptional regulator in C. glabrata and is required 
for nitrogen starvation pseudohyphal formation. Interestingly, ste12 C. glabrata mutants 
demonstrate attenuated virulence in a mouse model (33). The significance of C. glabrata 
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pseudohyphal growth on virulence is not known, and it is possible that C. glabrata has 
developed different strategies than C. albicans to invade its host. 
 
 One of the ways C. albicans regulates its virulence-associated traits such as 
secretion of proteinases and hyphal formation is by phenotypic switching, a process by 
which the cell can switch between epigenetic metastable states (7, 88, 140, 223). In 
general, phenotypic switching allows for rapid adaptation of the organism to different 
stressful environments. In C. albicans, “white cells” are ovoid, budding yeast cells that 
form white, domed colonies, and “opaque cells” are large, elongated cells that form gray 
flat colonies; these cells have different infectious properties and different transcriptional 
profiles (200). For example, phenotypic switching from the white to the opaque form 
significantly increases mating (133) and allows the organism to survive in different host 
tissues (108, 109). White cells are more suited for bloodstream infection while opaque 
cells are better at colonizing skin surfaces in mice (111). Similar to C. albicans, C. 
glabrata can undergo phenotypic switching exhibiting different colony colors on plates 
that contain copper sulphate: white (Wh), light brown (LB), dark brown (DB) and very 
dark brown (vDB) (28, 110, 112). A second switch phenotype, 'irregular wrinkle' (IWr), 
has been identified, which exhibits a highly wrinkled colony morphology (110). In 
patients infected with a single strain of C. glabrata, differences were seen in the 
proportions of switch phenotypes at oral and vaginal locations. This suggests selection of 
particular switch phenotypes due to differences in microenvironments (28).  
 
 Adherence of Candida species to host cells is an important initial step in the 
establishment of infection. The fungal proteins involved in mediating these adhesive 
interactions are termed “adhesins”. Unlike S. cerevisiae, C. glabrata encodes adhesins, 
specifically a family of GPI-anchored cell wall proteins, the EPA (Epithelial adhesin) 
family. The C. glabrata genome contains at least 23 EPA-related genes most of which are 
encoded in subtelomeric clusters; however, only three, EPA1, EPA6 and EPA7 have been 
shown to mediate adhesion to human epithelial cells in vitro (35, 40). Due to their 
subtelomeric localization, EPA genes are subject to chromatin-based transcriptional 
silencing. In S. cerevisiae, silencing of subtelomeric genes is dependent on a complex of 
proteins encoded by SIR2, SIR3, and SIR4 (79, 172). C. glabrata orthologs of these 
silencing factors have been identified and cells with silencing mutations in these genes 
are hyperadherent to a variety of cultured epithelial cells due to derepression of three 
EPA genes (EPA1, EPA6 and EPA7) (35, 58). Furthermore, hyperadherent ∆SIR3 
mutants have been shown to colonize the kidney more efficiently that wild-type strains in 
a murine model of disseminated candidiasis (35). EPA gene expression may play an 
important role in the virulence of C. glabrata. Although C. glabrata and C. albicans are 
different in respect to their interactions with the host (i.e. hyphal formation and secreted 
hydrolases), the aforementioned similarities are a few potential reasons to why C. 
glabrata is virulent and S. cerevisiae is not. 
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Infections Caused by Candida Species 
 
 Since the early 1980s, the incidence and spectrum of fungal infections have 
increased significantly partly due to the improved supportive care of critically-ill patients 
(165). One study showed the annual incidence of fungal sepsis in the United States 
increased by 207% between 1979 and 2000 (131). The expanding number of 
immunocompromised individuals has added to the problem of increasing fungal 
infections due to mucosal or cutaneous barrier disruption, defects in the number and 
function of neutrophils or in cell-mediated immunity, metabolic dysfunction, and 
extremes of age. Moreover, increasing use of broad-spectrum antibiotics, cytotoxic 
chemotherapies, and transplantation increases the risk for both common and uncommon 
opportunistic fungi (123, 137, 190). Several surveillance studies have reported Candida 
species as the most important cause of mycoses worldwide followed by Aspergillus and 
Cryptococcus species. Although C. albicans is still the most common cause of 
candidiasis, over the last two decades there has been an increase in non-albicans species 
causing infection with C. glabrata being the second most common cause of mucosal and 
invasive fungal infections in humans in the United States. The remainder of this section 
will discuss the clinical spectrum of superficial and systemic infections caused by C. 
glabrata as it compares to C. albicans. 
 
 Candida infections other than those on the skin and mucous membranes are 
referred to as invasive candidiasis, which include candidemia, acute or chronic 
hematogenously disseminated candidiasis, and infection of a single deep organ, either by 
hematogenous seeding or direct inoculation. A majority of these infections are a result of 
bloodstream invasion and hematogenous spread. The frequency of candidemia among 
hospitalized patients has doubled over the last three decades (165). There are 17 Candida 
species known to cause bloodstream infections; however, 90% can be attributed to five 
species: C. albicans, C. glabrata, Candida parapsilosis, Candida tropicalis, and Candida 
krusei (165). Furthermore, the 2004 Surveillance and Control of Pathogens of 
Epidemiological Importance study identified Candida species as the fourth most common 
cause of nosocomial bloodstream infection and the third most common cause of 
bloodstream infections in the intensive care unit (195). Not only has the incidence of 
Candida infections increased, mortality rates from disseminated candidiasis have been 
reported as high as 30-40% (162). Risk factors for invasive candidiasis include immune 
suppression (neutropenia, immunosuppressive drugs including glucocorticoids, cancer 
and cancer chemotherapy) and changes in the physical barriers that facilitate the 
organism’s access to the bloodstream (prior gastrointestinal surgery or perforation, 
hemodialysis, parenteral nutrition, indwelling catheters, treatment with broad-spectrum 
antibiotics, and colonization with Candida species). C. albicans account for 45-60% of 
incidences of invasive candidiasis or candidemia in the United States and worldwide (35, 
159, 165). In North America, C. glabrata accounts for 20-22% of cases invasive 
candidiasis (35, 159, 165). C. glabrata infections are difficult to treat due to intrinsic 
resistance to the most widely used antifungal, fluconazole. In fact, C. glabrata 
candidemia is associated with a 43% mortality rate in adults and 13% in children (159). 
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 Approximately 75% of all adult women have suffered from vulvovaginal 
candidiasis (VVC) at least once in their lives, with 40-50% of women experiencing 
recurrence (89). Candida species can be found as a commensal in the vagina in 10-25% 
of all women (151). Predisposing factors for VVC include: African American, pregnancy, 
contraceptives, diabetes mellitus, and use of antibiotics. Pregnant HIV-infected women 
are at higher risk for VVC with a 40-60% prevalence of vaginitis and colonization (20-
40% in non-HIV pregnant women). C. albicans accounts for 85-95% of yeast strains 
isolated from the vagina (113, 196, 197). Non-albicans Candida species are isolated in 
approximately 10-20% cases of VVC, with C. glabrata being the most common (32, 41, 
153). In small clinical studies, a variety of risk factors have emerged for C. glabrata 
vaginitis which include uncontrolled diabetes mellitus and douching (73). 
 
 Urinary tract infections (UTI) due to Candida species has increased over the past 
three decades (13). In fact, one study found that Candida species accounts for 22% of all 
UTIs in the critical care setting (6). Risk factors for development of Candida UTI are 
elderly, female (vaginal colonization), pregnancy, diabetes mellitus, urinary tract disease 
producing obstruction (i.e. congenital abnormalities, neurogenic bladder), urinary tract 
catherization, and antibiotic exposure (9, 97, 148, 155). Unlike OPC and vaginal 
candidiasis, C. albicans only accounts for about 50% of Candida UTIs with 50% caused 
by non-albicans Candida species. Interestingly, C. glabrata causes approximately 25% of 
Candida UTIs (199); however, no C. glabrata specific risk factors have been reported. 
 
 Symptomatic mucosal candidiasis arises in humans who are colonized with 
Candida and who are immunocompromised (i.e. Human Immunodeficiency Virus (HIV)/ 
Acquired Immune Deficiency Syndrome (AIDS), neonates, elderly) or have local 
reduction in host resistance, thereby promoting the overgrowth of their own endogenous 
yeast flora. The most common mucosal infections include oropharyngeal, esophageal, 
and vaginal candidiasis. Oropharyngeal candidiasis, or thrush, is the general term given 
to oral infection caused by Candida species. Candida species are part of the normal 
mouth flora in 25-50% of healthy individuals (151). OPC is often the first manifestation 
of HIV infection with approximately 80-90% of HIV/AIDS patients ultimately 
developing OPC during their disease progression (54). Although there has been a 
decrease in OPC in HIV-infected individuals since the availability of antiretroviral 
therapy (ART), OPC still remains a significant infection in this population (208).  
 
 The most important predisposing factor for OPC other than HIV is the wearing of 
removable dentures (192). The dentures provide a surface for Candida to adhere; 
therefore, sufficient hygiene care is very important (31). Patients with hematological 
malignancies and solid tumors are also affected by OPC due to the breakdown of natural 
barriers to colonization and invasion after anticancer therapy. C. albicans is the main 
organism isolated from OPC patients; however, other species, such as C. glabrata, have 
often been implicated in patients not only with HIV/AIDS but also patients undergoing 
bone marrow transplantation and patients receiving therapy for head and neck cancer (31, 
174, 175, 177). It is thought that the intrinsic resistance of C. glabrata to fluconazole, the 
most widely used antifungal for treatment and prophylaxis of OPC, allows for the 
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selection of C. glabrata in OPC (177). The emergence of fluconazole resistant organisms 
remains a significant clinical problem. 
 
 The second most common site of gastrointestinal candidiasis is the esophagus. 
Esophageal candidiasis occurs in patients with chronic diseases, usually after the use of 
antibiotics, steroids, or omeprazole; however, the disease most frequently is seen in 
individuals affected with advanced HIV infection (38). In fact 10-15% of HIV/AIDS 
patients will suffer from Candida esophagitis during their disease progression (62, 66, 
138). Recently, there have been case reports linking Candida esophageal candidiasis to 
the use of inhaled corticosteroids (143). Like with OPC, C. albicans is the main causative 
organism of esophageal candidiasis (11). C. glabrata has also been implicated in 
esophagitis but the occurrence is rare (101).  
 
 
Treatment of Candida Infections 
 
 Although the number of antifungal agents has increased since 2000, treatment of 
fungal infections is still limited to only 15 agents currently approved for clinical use. 
There are many similarities between fungal cells and mammalian cells that make the 
development of antifungals difficult. They are both eukaryotes with similar organelles, 
DNA replication, and protein synthesis. Antifungal agents must exploit the differences 
between host and fungal cells; however, there are a few biochemical differences between 
the host and the fungal pathogen. At the cellular level, the greatest difference is that 
fungal cells have cell walls and mammalian cells do not. Inhibitors of bacterial cell wall 
biosynthesis, such as penicillins, have been used for years with little associated toxicities. 
Only recently have a few potent inhibitors of fungal cell wall biosynthesis become 
available for clinical use. Other antifungal targets include inhibitors of DNA 
biosynthesis, disruption of mitotic spindles, and interference with intermediary 
metabolism. The most widely exploited difference between mammalian and fungal cells 
is that the cell membranes contain different sterols. Mammalian cells contain cholesterol 
whereas the fungal cells contain ergosterol.  
 
 The polyenes are natural antifungal compounds discovered in the early 1950s. 
The two commercially-available polyenes are Amphotericin B (AmB) and nystatin. The 
polyenes bind to ergosterol in the membrane bilayer and disrupt cell wall permeability by 
forming oligodendromes functioning as pores, with subsequent efflux of potassium and 
intracellular molecules causing fungal death (20). Due to the toxicities of nystatin, it is 
only used as a topical agent. AmB is not orally or intramuscularly absorbed; therefore, it 
is given intravenously or sometimes through the inhalational route. AmB has a broad 
antifungal spectrum including Candida species except Candida lusitaniae. Although 
AmB is an effective antifungal drug, toxicities associated with its use have limited its 
utility. The most common and most serious side effect of AmB is nephrotoxicity. Some 
degree of reduction of renal function occurs in more than 80% of patients receiving the 
drug, and though this generally recovers after treatment has stopped, some impairment of 
glomerular filtration may remain (27). To allow for higher doses of AmB and to reduce 
its toxic effects to mammalian cells, AmB has been formulated in liposomes, lipid 
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complexes, and colloidal suspensions. Before the development of alternative agents such 
as the azole and echinocandin antifungals, AmB was the drug of choice for invasive 
Candidal infections. However, the most recent candidiasis guidelines recommend the 
newer and less toxic classes of antifungals for first-line use of many conditions caused by 
Candida species with the exception of neonatal candidiasis (158).  
 
 Flucytosine (5FC) is a prodrug that is deaminated by 5-fluorouracil by fungal 
cytosine deaminases. 5-fluorouracil is further converted to 5-fluorodeoxyuridylic acid, 
which interferes with DNA synthesis in the fungus. Mammalian cells lack cytosine 
deaminase allowing for selective inhibition of fungal organisms. This drug is only 
available orally and has a short half-life so it must be administered frequently. 5FC has 
activity against most Candida species, except C. krusei. Because of the rapid 
development of resistance, 5FC is rarely used in monotherapy but used in combination 
with AmB for the treatment of Candida endocarditis or meningitis (158).  
 
 The echinocandins, caspofungin, micafungin, and anidulafungin, are the only 
class of fungal cell wall inhibitors. They exert their mechanism of action by non-
competitively inhibiting 1, 3-β-D glucan synthase, an enzyme that is necessary for the 
synthesis of 1, 3-β-D glucan, an essential component of the fungal cell wall. The 
inhibition of this enzyme destabilizes the integrity of the fungal cell wall, leaving it less 
rigid and unable to resist osmotic pressure resulting in cell lysis (18); therefore, this class 
of antifungals is fungicidal against most Candida species. All of the echinocandins are 
available in parenteral preparations only and have very few side effects. Echinocandins 
have activity against most Candida species but have less activity against some isolates of 
Candida parapsilosis and Candida guilliermondii (163). Each of these drugs has been 
studied in esophageal candidiasis (48, 105, 218, 219) and invasive candidiasis (107, 139, 
160, 173) and each has been shown to be effective in these clinical situations. The new 
updated Candidiasis guidelines recommend use of this class for refractory esophageal 
disease and as an alternative for OPC or when azole-resistant pathogens are suspected or 
when azole antifungals are not tolerated (158). Echinocandins are also recommended as 
an alternative to fluconazole for primary therapy for most non-neutropenic adults with 
candidemia or suspected invasive candidiasis. Echinocandins are favored therapy for 
patients with moderate-to-severe illness, recent azole antifungal exposure, candidemia 
caused by C. glabrata or C. krusei. However, fluconazole is preferred over an 
echinocandin for C. parapsilosis infections. For the treatment of candidemia in a 
neutropenic patient, echinocandins are the drug of choice (158).  
 
 The second class of antifungals that exert their efforts on the fungal cell 
membrane are the azole antifungals. Azole antifungals work by inhibiting lanosterol 
demethylase in the ergosterol biosynthesis pathway which prevents the conversion of 
lanosterol to ergosterol. This mechanism results in the accumulation of toxic 
methylsterols and results in inhibition of cell growth and replication. The azole 
antifungals include two classes, imidazoles and triazoles. Imidazoles have a two-nitrogen 
azole ring; they are predominantly used topically and have been replaced for systemic 
administration by triazoles, which have three nitrogens in the azole ring. Triazoles have a 
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more favorable pharmacokinetic profile than imidazoles and do not significantly inhibit 
human sterol synthesis.  
 
 The triazole antifungals include fluconazole, itraconazole, voriconazole and 
posaconazole. Fluconazole is water soluble and has good bioavailability regardless of 
food or gastric pH (26); therefore, it is available orally and intravenously. In contrast, 
itraconazole and voriconazole are poorly water soluble. Itraconazole capsule is best 
absorbed with food and the oral solution is better absorbed in the fasting state (17) while 
voriconazole as a tablet or solution is better absorbed without food. Both itraconazole and 
voriconazole are available intravenously; however, both are formulated with cyclodextrin 
derivatives and the intravenous form of both of them is contraindicated in patients with 
severe renal dysfunction. Posaconazole, available only as a suspension for oral use, has 
variable bioavailability and must be taken with high fat foods (42). Triazoles as a class 
have numerous clinically significant drug interactions. With exception of posaconazole, 
most of the interactions are due to inhibition of the CYP450 system enzymes specifically, 
CYP3A4, CYP2C9, and CYP2C19. Interestingly, itraconazole and posaconazole inhibit 
gastric P-glycoprotein (222). As a class, the triazoles are generally well-tolerated. Of 
note, itraconazole can often cause significant nausea and vomiting and voriconazole 
treatment can cause visual changes.  
 
 All the triazoles demonstrate similar activity against most Candida species, with 
less activity against C. glabrata and C. krusei (64, 166). Fluconazole is considered the 
standard therapy for OPC, esophageal candidiasis and VVC (76, 198). Fluconazole has 
the greatest penetration into the cerebrospinal fluid and vitreous body; therefore, it is used 
in the treatment of central nervous system and intraocular Candida infections (10). 
Fluconazole concentrates in the urine achieving 10-20 times higher levels than in serum 
making it an optimal drug for treatment of Candida UTIs (158). As few data has 
examined the use of itraconazole in the treatment of invasive candidiasis, it is generally 
reserved for patients with mucosal candidiasis who have failed fluconazole treatment (5). 
Voriconazole is effective for both mucosal and invasive candidiasis. For treatment of 
Candida infections, its major role has been used for step-down oral therapy for patients 
with susceptible C. krusei and C. glabrata infections (158). The use of voriconazole 
versus fluconazole for treatment of esophageal candidiasis has been evaluated (5). 
Voriconazole was found to be as effective as fluconazole but was associated with more 
adverse event-related discontinuation of treatment. Posaconazole does not have an 
indication for primary candidiasis therapy (158).  
 
 
AZOLE RESISTANCE AND TOLERANCE 
 
 
Clinical Impact of Azole Resistance  
 
 Resistance to antifungals relies on two components: clinical resistance and 
microbial resistance. Clinical resistance is the failure of treatment or persistence of fungal 
infection despite appropriate antifungal drug therapy. Successful treatment not only 
 10
 
depends on the susceptibility of the organism to the antifungal, but also on the host 
immune system, drug penetration and distribution, and the absence of a protected or 
persistent focus infection. Microbial resistance is a quantifiable variable and is defined by 
the minimum inhibitory concentration (MIC), the lowest concentration of antimicrobial 
agent which inhibits the growth of the microorganism. Ideally, microbial resistance will 
be predictive of clinical resistance. In other words, above a given MIC for a fungal 
pathogen or a “breakpoint”, the infection will not be cured with that antifungal. There are 
three terms used to describe the susceptibility of any organism to a particular drug; 
“susceptible”, “intermediate” (“susceptible-dose dependent” or SDD) or “resistant”. The 
Clinical and Laboratory Standards Institute (CLSI) Subcommittee  for Antifungal Testing 
has developed and standardized broth microdilution, broth macrodilution and disk 
diffusion methods for in vitro susceptibility testing of Candida species against 
fluconazole (145, 146). Breakpoints for Candida species were determined in 1997 by the 
CLSI Subcommittee for Antifungal Testing which are as follows: susceptible, MIC ≤ 8 
μg/ml; SDD, MIC = 16 to 32 μg/ml; resistant, MIC ≥ 64 μg/ml. However, there were 
concerns over the clinical relevance of these breakpoints in more invasive and microbial 
resistant organisms as they were derived mostly (80%) from studies of mucosal 
candidiasis and there was little clinical data for which the MICs were elevated (178). 
Recently, further evaluation of these breakpoints for fluconazole and Candida have been 
conducted including expanded MIC data and clinical efficacy studies (166). These data 
more strongly validate the CLSI MIC interpretive breakpoints for fluconazole and 
Candida species.  
 
 When discussing resistance in Candida species, one must also differentiate 
between primary or “intrinsic resistance” and secondary or “development of resistance”. 
Intrinsic resistance is the natural or innate resistance of a species to antimicrobial therapy 
even though the organism has had no previous exposure to the agent. In contrast, 
development of resistance develops in previously susceptible organisms after exposure to 
an antimicrobial agent. For example, this occurs in patients infected with HIV who 
receive multiple courses of fluconazole for recurrent OPC. It is thought that exposure to 
fluconazole inhibits the growth of susceptible populations and the less susceptible 
populations are allowed to grow (117). Moreover, this situation also selects for less 
susceptible species, such as C. glabrata, to grow. In fact, over the past two decades there 
has been an increase in fluconazole-resistant non-albicans species causing infection, with 
C. glabrata being the second most common cause of mucosal and invasive fungal 
infections in humans (39). The molecular basis for the intrinsic resistance of C. glabrata 
to azole antifungals remains undefined; however, the molecular basis for the development 
of resistance has been studied (21, 185, 215). 
 
 
Clinical Impact of Azole Tolerance 
 
 Candida species inhabit a range of environments in humans and these 
environments can change as the organism colonizes and spreads within a host. Candida 
species have evolved responses to protect it from environmental changes that cause 
physiological stress to the cell. The administration of antifungal drugs also represents a 
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stress to which the cell must respond (43). The nature of these responses to antifungal 
drugs depends on the organism, the dose, its duration, and the mechanism of action of the 
drug. For fungicidal drugs at appropriate doses above the MIC, stress responses fail to 
prevent cell death. However, for fungistatic drugs, such as the azoles, even above the 
MIC, growth is inhibited but the cells are not killed. This phenomenon is referred to as 
drug tolerance (186). As azole resistance mechanisms are usually due to genetic 
mutations leading to constitutive gene over-expression, tolerance is mediated by 
immediate reversible stress responses. These stress responses are important because they 
give cells time to develop long-term genetically stable resistant mechanisms. Thus, the 
development of a drug that can be used in co-therapy with fluconazole and abolish 
tolerance could prevent the development of azole resistance. 
 
 
Molecular Mechanisms of Azole Tolerance 
 
 Fluconazole is fungistatic against Candida species, thus C. glabrata exhibits 
tolerance to azoles. It has recently been shown that the calcineurin inhibitors cyclosporine 
A and FK506 exhibit potent fungicidal synergism with azoles against C. albicans, C. 
glabrata, and C. krusei (44, 121, 126, 127, 154). Calcineurin is a serine/threonine-
specific protein phosphatase that functions as a heterodimer composed of a catalytic 
subunit and a regulatory subunit B. In the presence of calcium, the phosphatase activity 
of calcineurin is activated when it binds calmodulin and it effects gene expression via 
transcriptional regulators such as Crz1p. It is possible that exposure to azoles causes an 
intracellular calcium spike that induces this pathway (186). In C. glabrata, disruption of 
CgCRZ1 did not affect the antifungal activity of fluconazole; however, disruption of the 
gene encoding the calcineurin regulatory subunit B resulted in fungicidal activity of 
fluconazole (136). Thus, the precise mechanism calcineurin-dependent azole tolerance in 
C. glabrata remains to be elucidated. 
 
 
Molecular Mechanisms of Azole Resistance in C. glabrata 
 
 Development of high-level resistance to the azoles in C. glabrata has been 
reported in oral and bloodstream isolates from head and neck radiation patients, stem cell 
transplant patients, and HIV patients (21, 74, 185). Also, the development of azole 
resistance has been implicated in the fluconazole treatment failure and death of a patient 
suffering from C. glabrata candidemia (122). In Candida species, four primary 
mechanisms of azole resistance have been identified: (i) drug efflux mechanisms, (ii) 
changes in the gene expression of the target of fluconazole, lanosterol demethylase, (iii) 
amino acid changes in lanosterol demethylase that alter the binding of fluconazole, (iv) 
alterations in the sterol biosynthesis pathway that may bypass the accumulation of toxic 
sterols. In C. glabrata, the expression of drug efflux pumps and upregulation of the gene 
that encodes lanosterol demethylase, are the only two known mechanism of fluconazole 
resistance. 
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 Azole resistance in fungi has been linked to the upregulation of membrane-
associated protein pumps and, consequently, efflux of a wide range of molecules, 
including azoles. These transporter proteins consist of members of the ATP-binding 
cassette (ABC) or major facilitator superfamily (MFS) of transporters. ABC transporters 
are found in all cells of all organisms usually in the plasma membrane but also in the 
membranes of organelles. They are primary transporters that use the hydrolysis of ATP. 
The basic structure of the ABC transporters consist of two cytoplasmic nucleotide 
binding domains (NBDs), involved in ATP binding and hydrolysis and two 
transmembrane domains (TMDs) that span the membrane via putative α-helices. The 
arrangement of these domains depends on the type of ABC transporter (71, 86). In S. 
cerevisiae, these ABC transporters have been divided into subfamilies: pleiotropic drug 
resistance (PDR), multidrug resistance (MDR), and multidrug resistance-associated 
protein (MRP). The PDR ABC transporters usually contain the domain arrangement, 
from the N- terminus, (TMD-NBD)2, and the MDR and MRP ABC transporters usually 
have the arrangement, (NBD-TMD)2 (49). The subfamily of ABC transporters most often 
associated with antifungal drug resistance is the PDR subfamily. MFS transporters also 
comprise large superfamilies of proteins with high similarity to proteins found in plants, 
animals, bacteria, and fungi. These pumps are secondary transporters that utilize the 
proton-motive force across the plasma membrane. There are two subfamilies of MFS 
transporters involved in drug efflux. These subfamilies are defined by the number of 
transmembrane spans (TMS) within the TMD: DHA1 (12 TMS) and DHA2 (14 TMS).  
 
 C. glabrata contains 18 putative ABC transporters (six in the PDR subfamily) and 
15 putative MFS transporters (10 in the DHA1 subfamily and five in the DHA2 
subfamily) as predicted by comparison of the C. glabrata and S. cerevisiae genomes (72). 
Only four of these transporters have been implicated in fluconazole resistance in C. 
glabrata; the ABC transporters CgCdr1p, CgPdh1p, CgSnq2p, and CgAus1p. RNA 
analyses of fluconazole-resistant C. glabrata clinical isolates suggest that the 
predominant basis for azole resistance is the upregulation of CgCDR1 and to a lesser 
extent CgPDH1 (21, 135, 184, 185, 187, 216, 221). Deletion of CgCDR1 or CgCDR1-
CgPDH1 renders fluconazole-resistant C. glabrata isolates susceptible to fluconazole 
(90, 185). Interestingly, one study found a fluconazole-resistant isolate that did not over-
express CgCDR1 or CgPDH1, but upregulated another ABC transporter, CgSNQ2 (210). 
Disruption of CgSNQ2 decreased azole resistance. The expression of these transporters is 
controlled by CgPDR1 which will be discussed in detail in a later section.  
 
 Although not an efflux pump, CgAUS1 is a homolog of a S. cerevisiae gene that 
encodes an ABC transporter involved in uptake of sterols and anaerobic growth. 
Nakayama et al. investigated the effects of CgAUS1 under the control of a tetracycline-
regulatable promoter. In the presence of bovine serum, they found that cells were more 
susceptible to fluconazole in the CgAUS1 “knockdown” strain suggesting that sterol 
transport can counteract ergosterol deficiency and azole toxicity. 
 
 CgERG11 is the gene encoding the target of the azole antifungal agents, 
lanosterol demethylase. Two studies have shown an increase in CgERG11 expression in 
azole-resistant C. glabrata isolates (130, 174). In one of these studies this upregulation 
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was due to duplication of the entire chromosome containing the ERG11 gene; however, 
loss of the duplicated chromosome was seen when the isolate was grown in fluconazole-
free medium (130). Increased expression of CgERG11 may also be due to point 
mutations in the CgERG11 gene itself or in upregulation of a transcriptional regulator 
that controls CgERG11. While several point mutations in ERG11 have been linked to 
azole resistance in C. albicans, such mutations in C. glabrata have not been identified. A 
recent study examined a collection of azole resistant C. glabrata isolates and found no 
point mutations in CgERG11 that were associated with the azole-resistant phenotype 
(187). Recently, our laboratory found a single-nucleotide substitution in one UPC2 allele 
in C. albicans that resulted in an amino acid exchange in the encoded protein. 
Complementation of the mutated allele into a fluconazole susceptible strain resulted in 
upregulation of ERG11 (61). The molecular basis for constitutive upregulation of 
CgERG11 has not been elucidated in C. glabrata. 
 
 
TRANSCRIPTIONAL REGULATORS OF AZOLE RESISTANCE 
 
 
Gene Expression  
 
 The over-expression of aforementioned ABC transporters, CgCDR1, CgPDH1, 
and CgSNQ2 could be due to several mechanisms: gene amplification, increased half-life 
of mRNA, or increased transcription. Gene amplification occurs when there is 
chromosomal duplication. Recently, Polakova et al. found that while gene sequences 
were well-conserved among different strains of C. glabrata, their chromosome structures 
differed drastically (171). Aneuploidy by gain of small chromosomes and segmental 
aneuploidy were the most prevalent events on the left arm of chromosome F. 
Chromosome F encodes the ABC transporters, CgAUS1 as well as CgPDH1. The isolate 
carrying the minichromosome could tolerate 129.6 mg/L of fluconazole; however, the 
isolate which had lost the minichromosome could only tolerate 14.4 mg/L of fluconazole 
suggesting a role for aneuploidy in tolerance to azoles. However, when this isolate was 
grown in the absence of azoles, the loss of minichromosome was observed in 70% of the 
progeny. Although this study raises the possibility of aneuploidy contributing to the over-
expression of these ABC transporters in the presence of azoles, it does not explain the 
constitutive over-expression of these genes in fluconazole-resistant isolates. 
 
 Another possibility of increased expression of these transporters could be the 
possibility of posttranscriptional control. Large amounts of the ABC transporter proteins 
could correlate with increased stability of its mRNA and protein. One study has 
demonstrated that the over-expression of CgCDR1 in fluconazole-resistant C. albicans 
isolates is in part due to decreased mRNA turnover (125). However, transcriptional 
regulation is considered to be the key step accounting for basal and induced patterns of 
ABC transporter expression. There are two prominent families of transcriptional 
regulators in yeast that regulate PDR: zinc-cluster proteins and basic region-leucine 
zipper proteins. Since only the zinc-cluster proteins have been found to regulate 
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fluconazole PDR in C. glabrata, the remainder of this review will focus on this class of 
transcriptional regulators. 
 
 
Zinc-Cluster Transcription Factors 
 
 Zinc-binding proteins represent one of the largest families of transcriptional 
regulators in eukaryotes. They all contain a zinc finger motif in which they are 
categorized into various families according to these motifs. One family, the zinc-cluster 
or binuclear cluster protein family, are found only in fungus and possess a well-conserved 
motif, CysX2CysX6CysX5-12CysX2CysX6-8Cys (120). These cysteine residues bind to two 
zinc atoms and coordinate folding of the domain involved in DNA binding. At least 12 of 
these zinc-cluster proteins have been implicated multidrug resistance in S. cerevisiae 
(120).  
 
 Zinc-cluster proteins contain a DNA-binding domain (DBD), a regulatory 
domain, and an acidic domain. The cysteine-rich DBD is separated into three regions: the 
zinc finger, linker, and dimerization regions and is usually located at the N- terminus. 
There are six cysteine residues that are important for DNA binding and protein function 
(14, 51). The linker region, located C-terminally to the zinc-cluster motif, has no 
similarities to linker regions of other zinc-cluster proteins, and changes in this region alter 
the DNA-binding specificity (123). Therefore, it is proposed that this region provides a 
rigid scaffold that mediates DNA binding to a preferred sequence (123). The dimerization 
region is typically positioned C-terminally to the linker. Most zinc proteins contain this 
region and it is made up of heptad repeats that form a highly conserved coiled-coiled 
structure that is most likely for dimerization and protein-protein interaction (189).  
 
 The regulatory domain displays lesser homology among most members of the 
zinc-cluster protein class which is why it also termed the middle homology region 
(MHR). This domain is thought to play an inhibitory role since removal of this domain 
renders the zinc-cluster proteins constitutively active (169). Finally, the acidic domain 
acts as an activation domain (189). This domain is not well-defined as its function and 
structure within this superfamily is varied. Interestingly, gain-of-function mutations for 
Pdr1p and Pdr3p, transcriptional regulators involved in PDR, have been identified which 
make these transcriptional regulators constitutively activated.  
 
 Zinc-cluster proteins recognize elements containing trinucleotide sequences 
usually CGG triplets that can be everted, inverted, or direct repeats (120). The orientation 
of the trinucleotide sequences and the spacing between the triplets are very important 
determinants of DNA-binding specificity. There are several DNA-binding motifs (also 
termed “response elements”) that have been identified in S. cerevisiae zinc-cluster 
transcription factors (120).  
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Zinc-Cluster Transcription Factors and Azole Resistance 
 
 S. cerevisiae. Due to the phylogenetically close relationship, S. cerevisiae 
represents a well-characterized model for studying C. glabrata. S. cerevisiae is also one 
the most intensively studied eukaryotic model organisms in molecular and cell biology. 
The availability of the S. cerevisiae genome sequence and the complete set of deletion 
mutants have further enhanced the power of S. cerevisiae as a model for understanding 
the regulation of eukaryotic cells. Fluconazole resistance in S. cerevisiae is usually due to 
gain-of-function mutations within some of the zinc-cluster transcriptional regulators. Two 
of these, Pdr1p and Pdr3p, have been named the master regulators of drug resistance in S. 
cerevisiae. Together these proteins are responsible for the regulation of multiple genes in 
the PDR network, including the ABC transporters, PDR5, SNQ2, and YOR1. In fact, each 
of these genes contains at least one PDRE, pleiotropic drug response element, in its 
promoter region. Pdr1p and Pdr3p act by binding to PDREs in the promoters of target 
genes (95) . The PDRE contains the consensus sequence TCCGCGGA, which displays 
CGG triplets in an everted repeat orientation. The PDR3 gene promoter also contains two 
PDREs allowing for autoregulation as well as regulation by Pdr1p (95). Several studies 
have shown that single point mutations in the regulatory domain and in the activation 
domain of both ScPdr1p and ScPdr3p make these transcription factors hyperactive (34, 
46, 65).  
 
 Although our understanding of the molecular basis of regulation of ScPdr1p and 
ScPdr3p is incomplete, there have been several interesting observations regarding their 
regulation. Cells that have lost their mitochondrial genome (known as petite mutants and 
designated “ρ0”) strongly induce levels of ScPDR5 in a ScPdr3p-dependent manner (81). 
Also, zinc-cluster transcription factors, including Pdr3p, have been found to be negatively 
regulated by the Hsp70 protein Ssa1p (193). Most recently, downstream effectors of these 
transcription factors have been identified. Thakur et al. showed that regulation of 
ScPdr1p is similar to regulation of multidrug resistance (MDR) in vertebrates by the PXR 
nuclear receptor where ScPdr1p directly binds to fluconazole resulting in stimulation of 
drug efflux pumps. They also found a specific role of the Gal11p/MED15 subunit of the 
mediator co-activator and its activator-targeted KIX domain in antifungal-dependent 
regulation of MDR (207). 
 
 Yrr1p is a zinc-cluster transcriptional regulator found to also induce the 
expression of PDR genes in S. cerevisiae (228). Many Pdr1p, Pdr3p, and Yrr1p targets 
overlap suggesting cross-talk between regulators. YRR1, like PDR3, is also self regulated 
and contains a putative Yrr1p response element (YRRE) as well as a PDRE in its 
promoter (228). In addition, Yrr1p is regulated by zinc-cluster protein Yrm1p (228). 
Furthermore, Yrr1p has been shown to have point mutations in the regulatory domain 
which cause it to act as a hyperactive transcriptional regulator (228). 
 
 Other zinc-cluster proteins known to regulate drug resistance in S. cerevisiae 
include Pdr8p, Stb5p, Rds1p, Rds2p, and Rds3p and Rdr1p (120). Pdr8p is known to bind 
the promoters of PDR genes such as the ABC transporters YOR1, PDR15, and AZR1 
(MFS transporter) and disruption of this gene in S. cerevisiae increases ketoconazole 
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susceptibility (87). Disruption of STB5 leads to reduced expression of the ABC 
transporters SNQ5, PDR16, and PDR5 and increased susceptibility to cycloheximide but 
not ketoconazole. Furthermore, this same study showed evidence that Stb5p binds to the 
SNQ2 promoter in vivo (114). Disruption of RDS1 and RDS3 (Regulators of Drug 
Sensitivity) are involved in conferring resistance to cycloheximide while disruption of 
RDS2 confers resistance to ketoconazole. Lastly, a negative regulator of PDR genes has 
been identified named RDR1 for repressor of drug resistance (85). Disruption of RDR1 
significantly increased the expression of five genes which encode membrane or 
membrane-associated proteins and increased resistance to cycloheximide. Rdr1p appears 
to bind to the same PDREs as Pdr1p and Pdr3p and the authors of this study postulate the 
formation of heterodimers between Rdr1p and Pdr1p or Pdr3p that would impair the 
activation of target genes. However, whether Rdr1p represses the gene expression of its 
target genes by directly binding the PDRE has not been determined (85). 
 
 S. cerevisiae can also overcome the effects of fluconazole by up-regulating genes 
in the ergosterol biosynthesis pathway. Several zinc- cluster transcriptional regulators are 
involved in this process. The ERG genes of the ergosterol biosynthesis pathway are 
regulated by two highly homologous zinc-cluster proteins, Upc2p and Ecm22p. They 
regulate transcription by binding to sterol response elements (SREs) in the promoters of 
their targets (217). Eleven of the ERG genes encoding enzymes in the ergosterol 
biosynthesis pathway contain putative sterol response elements in their promoters. Upc2p 
also plays a role in the uptake of exogenous sterols through the activation of the ABC 
transporters, AUS1 and PDR11. Furthermore, it also has role in the upregulation of 
DAN/TIR genes. A gain-of-function mutation has been identified in Upc2p that was 
responsible for the upregulation of AUS1 and PDR11, DAN/TIR genes, as well as Upc2p 
itself in S. cerevisiae. Hap1p is another zinc-cluster transcriptional regulator known to 
regulate ERG11 which encodes the target of the azoles (213). HAP1 is also overexpressed 
in the presence of the Upc2p gain-of-function mutation, and it is postulated that a 
regulatory interaction may exist between Hap1p and Upc2p (224). Interestingly, Stb5p 
has also been identified as a regulator of ergosterol biosynthesis as it is a direct activator 
of ERG genes in the presence of oxidative stress (114).  
 
 C. glabrata. Multiple studies have linked the development of high-level azole 
resistance to the over-expression of ABC transporter genes in C. glabrata, such as 
CgCDR1, CgPDH1, and CgSNQ2 (21, 68, 210, 212, 215). These are homologs to the 
ScPDR5, ScPDR15, and ScSNQ2, respectively. These mechanisms are closely related to 
the resistance mechanisms described above for S. cerevisiae. A significant difference 
between S. cerevisiae and C. glabrata is that CgPdr1p represents a single best homolog 
of the ScPdr1p and ScPdr3p transcription factor heterodimer found in S. cerevisiae (216). 
Like with S. cerevisiae, single point mutations in the regulatory domain of CgPDR1 
make this transcription factor hyperactive resulting in high-level transcription of 
CgCDR1 and CgPDH1 as well as increased resistance to azoles (68, 210, 212, 215). The 
majority of this dissertation (Chapters 2 and 3) discusses the role of these gain-of-
function mutations in azole resistance in C. glabrata.  
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 As with S. cerevisiae, the over-expression of ABC transporters in C. glabrata 
petite mutants has been documented (184). CgPDR1 has been shown to be required for 
azole resistance due to mitochondrial deficiency (212). Moreover, it has also been shown 
that the regulation of CgPDR1 is analogous to the regulation of ScPDR1 where CgPDR1 
also directly binds to fluconazole resulting in stimulation of drug efflux pumps. The study 
also found a specific role of the Gal11p/MED15 subunit of the mediator co-activator and 
its activator-targeted KIX domain in antifungal-dependent regulation of MDR in C. 
glabrata (207). 
 
 
CENTRAL HYPOTHESIS AND RESEARCH OBJECTIVES 
 
 C. glabrata has emerged as the second major cause of mucosal and invasive 
fungal infection in the United States. The azole class of antifungal agents has proven 
effective management of Candida infections. Recent reports have described the 
acquisition of azole resistance in C. glabrata clinical isolates from hematopoietic stem 
cell transplant patients, AIDS patients, and patients receiving radiation for head and neck 
cancer. Not only does C. glabrata have the ability to develop high-level resistance, this 
fungal pathogen also displays an intrinsic reduced susceptibility to azole antifungal 
agents which makes this a significant problem in the management of candidiasis. 
Furthermore, fluconazole is fungistatic against Candida species. The fungistatic nature of 
the azoles allows the organism to survive in the presence of drug, a phenomenon known 
as drug tolerance. Yeasts have developed ways to adapt to its environment. Such 
adaptations are often regulated at the transcriptional level. For example, in S. cerevisiae, 
multidrug resistance is mostly due to gain-of-function mutations of the transcriptional 
regulators, Pdr1p and Pdr3p. It is likely that multiple transcriptional activation networks 
are involved in both azole resistance and azole tolerance in C. glabrata. Therefore, my 
central hypotheses are as follows: 1) Gain-of-function mutations in activators of 
transcriptional activation networks represent the primary mechanism for the development 
of high-level resistance in C. glabrata and 2) Key transcriptional activation networks are 
activated in C. glabrata in the presence of azole antifungal agents which allow this 
organism to survive at higher azole concentrations as compared to other Candida species. 
It is hoped that identification of transcriptional activation networks found to influence 
azole susceptibility will serve as targets for future work towards the development of 
compounds that will both abrogate resistance and enhance the therapeutic utility of this 
class of antifungal agent.  
 
 It has been previously reported that azole-resistant C. glabrata mutants (MIC ≥ 64 
μg/ml) of strain 66032 (MIC = 16 μg/ml) similarly show coordinate CgCDR1-CgPDH1 
upregulation, and in one of these (F15) a putative gain-of-function mutation was 
identified in the single homolog of S. cerevisiae transcriptional regulators, Pdr1p-Pdr3p 
(216). In the first chapter, we hypothesized that CgPdr1p plays a central role in 
development of azole resistance as well as intrinsic resistance to fluconazole. Our 
research aims were several-fold. First, we characterized the effect of PDR1 disruption as 
well as gene replacement on fluconazole susceptibility and the expression of the ABC 
transporters CgCDR1 and CgPDH1 in the fluconazole susceptible isolate 66032 as well 
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as the resistant isolate F15. To more directly assess the role of acquired or intrinsic 
resistance of the ABC transporter CgCDR1, we also characterized the effect of CgCDR1 
disruption in these same isolates. Next, we used genome-wide expression studies in C. 
glabrata to identify other putative Pdr1p targets that are co-regulated with CgCDR1. This 
work was the first to identify CgPdr1p as a key regulator of the ABC transporter genes 
CgCDR1 and CgPDH1 and azole resistance. 
 
 Since the publication of the above study, many novel gain-of-function mutations 
in C. glabrata clinical isolates have been reported (68, 210, 212). These mutations cause 
upregulation of the ABC transporters, CgCDR1, CgPDH1, and CgSNQ2, but to varying 
degrees. For example, one mutation resulted in upregulation of CgSNQ2 but not CgCDR1 
and CgPDH1. In Chapter 3, I hypothesized that the not only do these gain-of-function 
mutations in CgPDR1 result in different levels of azole resistance, but also different 
target gene expression. To determine genes co-regulated with CgCDR1, I examined the 
genome-wide gene expression profiles in four matched azole-susceptible and –resistant 
clinical isolate sets of C. glabrata in which CgCDR1 gene expression was upregulated in 
the resistant isolate. Next, we identified two gain-of-function mutations in two of the 
fluconazole resistant isolates and identified putative target genes specific to each 
mutation. We found that the different mutations do result in different levels of azole 
resistance and different target gene expression. 
 
 Understanding the initial stress response of C. glabrata to fluconazole may 
facilitate a better understanding of how this organism copes with such stresses to its 
environment. In Chapter 4, I hypothesized that C. glabrata responds to fluconazole 
treatment by upregulating transcriptional regulators that allow for this organism to 
survive in the presence of fluconazole. I examined the stress response of C. glabrata to 
exposure to fluconazole. Among the upregulated genes were the transcriptional regulators 
CgPDR1, RLM1, CRZ1, UPC2, CgAP1, and CIN5 and putative target genes for each of 
these regulators. Because the transcriptional regulator CgPdr1p is upregulated in response 
to fluconazole and has previously been shown to be involved in fluconazole intrinsic 
resistance, we studied the role of CgPDR1 in the initial response to fluconazole. Using a 
C. glabrata strain disrupted for CgPDR1, we identified putative CgPdr1p targets that 
respond to fluconazole in a CgPdr1p-dependent and –independent manner. Together this 
work suggests other transcriptional pathways associated with azole intrinsic resistance 
and azole tolerance. 
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CHAPTER 2. PDR1 REGULATES MULTIDRUG RESISTANCE IN CANDIDA 
GLABRATA: GENE DISRUPTION AND GENOME-WIDE EXPRESSION 
STUDIES 
 
 
INTRODUCTION 
 
 Increasing numbers of individuals are immunocompromised in association with 
AIDS, organ and tissue transplantation, aggressive treatments for cancer and immune-
related diseases, diabetes, premature birth and advanced age. These individuals are at 
high risk for opportunistic fungal infection, in particular mucosal or systemic candidiasis. 
In the previous decade, Candida glabrata emerged as a common cause of these infections 
(10–30% of yeast isolates), trailing only Candida albicans (156, 168, 179, 183). In some 
populations such as diabetics and the elderly, C. glabrata may be the dominant pathogen 
(55, 77, 78, 104).  In C. glabrata candidemia, mortality rates of 38–53% have been 
reported (102, 182, 220). Nevertheless, the basis for C. glabrata pathogenicity is not yet 
clear, because it is deficient in the virulence factors implicated in C. albicans infection: 
dimorphism, strong adhesion, secreted hydrolases and biofilm formation (59, 99, 150, 
188). On the other hand, C. glabrata demonstrates relative resistance to azoles, the most 
widely used antifungal group which includes topical imidazoles such as miconazole and 
oral/parenteral triazoles such as fluconazole. Specifically, the fluconazole MIC inhibiting 
50% of clinical isolates is 8 μg/ml, compared with 0.25 μg/ml for C. albicans (156, 167). 
Azoles inhibit lanosterol demethylase, product of the ERG11 gene (CYP51 in moulds), 
which results in depletion of the membrane component ergosterol and accumulation of 
toxic sterol products (3). The emergence of C. glabrata (from ≤ 5% of yeast isolates in 
the 1980s) parallels the introduction in the early 1990s of fluconazole and over-the-
counter imidazoles, along with widespread application of agricultural azole fungicides. 
Indeed, its intrinsic low-level azole resistance, the molecular basis for which remains 
undefined, may represent a C. glabrata 'virulence factor'. 
 
 C. glabrata also demonstrates a high capacity for acquired high-level azole 
resistance, with 8–27% of isolates demonstrating a fluconazole MIC ≥ 64 μg/ml (156, 
164, 182). RNA analysis of these clinical isolates suggests that the predominant basis for 
acquired azole resistance is the constitutively upregulated expression of multidrug 
transporter genes CgCDR1 and, to a lesser extent, CgPDH1 (135, 175, 184, 185, 187, 
216). In support of this, CgCDR1 or CgCDR1-CgPDH1 disruption was shown to confer 
azole hypersensitivity (90, 184). In this respect, C. glabrata resembles C. albicans and 
other fungi in which azole resistance has been attributed to upregulated expression of 
multidrug transporters (3). Initial laboratory studies of C. glabrata acquired azole 
resistance using standard glucose-supplemented medium yielded a virulent respiratory-
deficient mitochondrial mutants (30, 184). Using glycerol-supplemented medium, we 
isolated respiratory-competent mutants with coordinately upregulated CgCDR1-CgPDH1 
                                                   
 Vermitsky, J. P., K. D. Earhart, W. L. Smith, R. Homayouni, T. D. Edlind, and P. D. Rogers. 2006. Pdr1 
regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. 
Mol Microbiol 61:704-722. Reprinted by permission of publisher. (NOTE: Kelly D. Earhart was my name 
prior to current married name.) 
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analogous to that observed in azole-resistant clinical isolates (216). Coordinate 
upregulation of these genes was also observed following brief exposure of susceptible 
cells to azoles, representing a potential basis for intrinsic low-level resistance. 
 
 Coordinate CgCDR1-CgPDH1 upregulation implies a common transcription 
factor. Although very distinct in terms of niche and human pathogenicity, C. glabrata is 
an evolutionary close relative of Saccharomyces cerevisiae (16, 60). In the latter, the 
coordinate upregulation of multidrug transporter genes PDR5 and SNQ2 is mediated by 
the paralogous Pdr1p and Pdr3p zinc-cluster transcription factors (103). Many gain-of-
function mutations within Pdr1p–Pdr3p have been identified that result in constitutive 
upregulation of PDR5-SNQ2 along with a diverse group of additional genes (34, 52, 53). 
Our analysis of the recently released C. glabrata genome sequence (60) revealed a single 
PDR1–PDR3 homolog, and a putative gain-of-function mutation in this gene was 
identified in azole-resistant laboratory mutant F15 (216). Here we demonstrate the central 
role of C. glabrata PDR1 in acquired azole resistance, and identify a likely role in 
intrinsic resistance, by characterizing Δpdr1 derivatives of laboratory strains and clinical 
isolates. Furthermore, we report the first application of microarrays to this organism, 
which identified multiple genes co-regulated with CgCDR1-CgPDH1 that are likely to 
impact C. glabrata virulence. This work was done in collaboration with Dr. Tom Edlind 
at Drexel University who created the disruption and reintegrated CgPDR1 and CgCDR1 
mutants and performed the broth microdilution assays.  
 
 
MATERIALS AND METHODS 
 
 
Media, Inhibitors, and Strains 
 
 For most experiments, the medium employed was YPD (1% yeast extract, 2% 
peptone, 2% dextrose). Gene disruptants and ura3 mutants were selected on DOB 
(synthetic defined medium with dextrose) with complete supplement mixture (CSM) or 
CSM lacking uracil/uridine (-URA) (Qbiogene BIO 101). Drugs were obtained from the 
following sources: fluconazole (Pfizer), itraconazole (Janssen), terbinafine (Novartis); 
caspofungin (Merck), amphotericin B, miconazole and cyloheximide (Sigma-Aldrich). 
They were dissolved in dimethyl sulphoxide (DMSO); the final DMSO concentration 
was ≤ 0.5% in all experiments which had no detectable effect on growth. Sorbic acid, 
lactic acid, acetic acid and hydrogen peroxide (Sigma) were diluted as necessary in water. 
Strains were previously described (203) or constructed as described below. 
 
 
Isolation of ura3 Strains 
 
 Wild-type URA3 yeast strains are sensitive to 5-fluoroorotic acid (5FOA). To 
isolate 5FOA-resistant mutants, a single colony from a fresh YPD plate was streaked on 
DOB + CSM agar containing 0.1% 5FOA (Research Products International) and 
incubated at 35°C for 3 days. Colonies were streaked for isolation on YPD and DOB-
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URA; those that failed to grow on the latter were then tested for URA3 complementation 
by transformation with pRS416 (shuttle vector with S. cerevisiae URA3) and selection on 
DOB-URA plates. Yeast transformations employed the Frozen-EZ Yeast Transformation 
II Kit (Zymo Research) as previously described (63). 
 
 
Gene Disruption and Replacement 
 
 The PRODIGE method for PCR product-mediated gene disruption was employed 
(Figure 2-1) (63). Briefly, primers (80 mers; Table 2-1) were designed to precisely 
replace, after homologous recombination, a C. glabrata coding sequence (CDS) with the 
selection marker CDS. These primers consisted of approximately 60 nucleotides at the 5' 
end complementary to C. glabrata sequences directly upstream and downstream of the 
targeted CDS and approximately 20 nucleotides at the 3' end complementary to the S. 
cerevisiae URA3 CDS contained in plasmid template pRS416. PCR products generated 
with these primers were used to transform C. glabrata ura3 strains. Following selection 
on DOB-URA medium, transformants were screened by PCR with specific primer pairs 
(Table 2-1; Figure 2-1) to confirm replacement of the targeted CDS with URA3 CDS. 
DNA was generally prepared by phenol extraction of glass bead-disrupted cells (63); 
some screens employed colony PCR in which a small volume of cells was added directly 
to the PCR mix. 
 
 For PDR1 replacement, a PCR product representing the PDR1 CDS plus 430–680 
bp upstream and downstream sequence was amplified with primers PDR1uF-PDR1dR 
(Table 2-1) from 66032 or F15 genomic DNA. These products were used to transform 
66032Δpdr1 strain with selection on 1 μg/ml cycloheximide-containing YPD plates. 
Colonies were screened as above with primer pair PDR1uF2-PDR1iR (Table 2-1). 
 
 
Broth Microdilution Assay 
 
 Fresh overnight cultures from a single colony were diluted 1:100 in YPD, 
incubated for 3 h with aeration, and then counted in a haemocytometer and diluted again 
to 1 × 104 cells/ml. Aliquots of 100 μl were distributed to wells of a 96-well flat-
bottomed plate, except for row A which received 200 μl. Inhibitor was added to row A to 
the desired concentration and then serially twofold diluted to rows B through G; row H 
served as inhibitor-free control. Plates were incubated at 35°C for the indicated times. 
Absorbance at 630 nm was read with a microplate reader; background due to medium 
was subtracted from all readings. The MIC (minimum inhibitory concentration) was 
defined as the lowest concentration inhibiting growth at least 80% relative to the drug-
free control.  
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Figure 2-1.  Disruption of PDR1 and effects on azole sensitivity. A. Diagram illustrating 
PRODIGE primer design for disruption of PDR1 with URA3 CDS amplified from 
pRS416. Also shown are the upstream forward and two internal reverse primers used to 
screen transformants. B. PCR screen of representative ∆pdr1 transformants selected on 
DOB-URA and their parent 66032 and F15. DNA was purified from isolated colonies, 
amplified with the indicated primer pairs, and analyzed by gel electrophoresis; loss of the 
PdR1uF-PDR1iR product and formation of the PDR1uF-URA2iR product identified 
∆pdr1 clones. C. Broth microdilution assays examining fluconazole sensitivities of parent 
66032, azole-resistant mutant F15, and their respective ∆pdr1 disruptants. Absorbance at 
630nm was recorded after 24 or 48 h incubation as indicated; growth was plotted as 
percentage of drug-free control. 
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Table 2-1.  Primers used in this study (grouped by application). 
 
Primer name Primer sequence 
PRODIGE-based gene disruption  
  PDR1-URA3F  5'-GCCTTTTTTTTTAGAATATATTGGTAAAGTCATTCTTTAGC 
TACGTTATTGAGAGAATATGTCGAAAGCTACATATAAGG-3' 
  PDR1-URA3R  5'-TGATTTTTCAGATTAAATATAAAATTATACAGGCTATGCAC 
ACTGTCTAAATTAATAGCATTAGTTTTGCTGGCCGCATC-3' 
  CDR1-URA3F  5'-TACTTACAGGAAAAAGAATTTACAACTCTTGATATATACAAA
GTAAAGAAAAGTAACAATGTCGAAAGCTACATATAAGG-3' 
  CDR1-URA3R  5'-TTTTCCGAATGCAATATGTATTAATACCAGAGCCAGATTAT 
GAGCGCAGGCTAAATAAATTAGTTTTGCTGGCCGCATC-3' 
PCR screening and PDR1 replacement  
  PDR1uF 5'-GGCGTATTCATAGAATCCGAA-3' 
  PDR1uF2 5'-GGTCCTTCTAATAGTCATCTTT-3' 
  PDR1iR 5'-CCATAGTATTCGTCGAGAGCA-3' 
  PDR1dR 5'-GACCTCTGTGAAAAGCTACTG-3' 
  URA3iR 5'-CAGCAACAGGACTAGGATGAG-3' 
  CDR1uF 5'-GCAGCTATGAGTTGAGGAAG-3' 
  CDR1iR 5'-ACGCCACATCGGCATCCTT-3' 
DNA probes for RNA hybridization  
  ACT1F 5'-TTGACAACGGTTCCGGTATG-3' 
  ACT1R 5'-CCGCATTCCGTAGTTCTAAG-3' 
  CDR1F 5'-ACAATGTCTCTTGCAAGTGAC-3' 
  CDR1R 5'-AAGTGTTTTCTGATGTGCTTT-3' 
  PDH1F 5'-GTGATGAACCCCGATGA-3' 
  PDH1R 5'-TTCTTGATCTCGTTGGGCGT-3' 
  PDR1F 5'-AGTGCCACCACTAAGTCACT-3' 
  PDR1R 5'-CCATAGTATTGCTGCAGAGCA 
  YLR346F 5'-GGAACTGAAACGCAGAACCA-3' 
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Table 2-1 (continued). 
 
Primer name Primer sequence 
DNA probes for RNA hybridization, continued 
  YLR346R 5'-ATCCTTCCATGTGTCGGCAT-3' 
  YOR1F 5'-GAACAAGCCACAGACGTATC-3' 
  YOR1R 5'-CAAATTGCCAAGATGGCTGG-3' 
  YNL134F 5'-CCACCATGAAAGCTGCTGTA-3' 
  YNL134R 5'-AACTTAGGATCAGCTGGCAG-3' 
  YML131F 5'-AATGAACCCACACCGGGTTA-3' 
  YML131R 5'-TTCACCAGTTGCATCAACCAT-3' 
  RTA1F 5'-CGTTCGCGGTGTTGTTTCTT-3' 
  RTA1R 5'-CATCTTCAATATCGGCTTCGA-3' 
  MEC3F 5'-TAGCGTCATTACGGAGCCTT-3' 
  MEC3R 5'-TATCGGGACCGCTTTCTTGT-3' 
  YJL163F 5'-TAGGTGCCTCGCATTCTGAT-3' 
  YJL163R 5'-ATCTTGCCAGCTAATCCAGG-3' 
Real-time RT-PCR  
  18SrtF 5'-TCGGCACCTTACGAGAAATCA-3' 
  18SrtR 5'-CGACCATACTCCCCCCAGA-3' 
  CDR1rtF 5'-CATACAAGAAACACCAAAGTCGGT-3' 
  CDR1rtR 5'-GAGACACGCTTACGTTCACCAC-3' 
  PDH1rtF 5'-ACGAGGAGGAAGACGACTACGA-3' 
  PDH1rtR 5'-CTTTACTGGAGAACTCATCGCTGTT-3' 
  CSR1rtF 5'-TGGATTTTTTCTCCCATCTGGA-3' 
  CSR1rtR 5'-ACCACAGGGTCAAGCCATTTT-3' 
  PDR1rtF 5'-TTTGACTCTGTTATGAGCGATTAC-3' 
  PDR1rtR 5'-TTCGGATTTTTCTGTGACAATGG-3' 
  KAD2rtF 5'-AACCCGCAGTCATCGTGG-3' 
  KAD2rtR 5'-CCTGTCTCTCAGTTCTTGGAAACC-3' 
  YOR1rtF 5'-CCATCGGTGCTTGTGTAATGTTA-3' 
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Table 2-1 (continued). 
 
Primer name Primer sequence 
Real-time RT-PCR, continued 
  YOR1rtR 5'-TTGAGAGGCGTGGAAAAAATG-3' 
  RTA1rtF 5'-TCCTGTTTGTCATTAGGGTTAGGG-3' 
  RTA1rtR 5'-TGGCAATTTTGTTCTTATTCCTCAG-3' 
  QDR2rtF 5'-GACGAATGAGGACGAGGCTG-3' 
  QDR2rtR 5'-GGTTGGACCTGGTTCTGTAAATAGG-3' 
  SUT1rtF 5'-ACGAGAGCCAGAAGTTGATGG-3' 
  SUT1rtR 5'-TGGAGGCGATAGGAATTGGT-3' 
  RPN4rtF 5'-AGCCAGTATGCTGACCCGAG-3' 
  RPN4rtR 5'-ACACGCCACATCGCCC-3' 
  SAC7rtF 5'-CGCTGGAGACGCCTGG-3' 
  SAC7rtR 5'-TCGTATCCGCTTGCTGTTCC-3' 
  YBT1rtF 5'-AAGTGCTTCTTCCGCCTCATT-3' 
  YBT1rtR 5'-AACAGGAGCTGGTGTAGTACCCA-3' 
  MET8rtF 5'-TCCACCGCTATGCGATTTCT-3' 
  MET8rtR 5'-GGAGATGACCCATTGGATGAA-3' 
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RNA Hybridization 
 
 Log-phase cultures in YPD at 35°C were adjusted to 3 × 106 cells/ml and 
incubated for an additional 3 h. In some studies, cultures were divided into equal portions 
to which either fluconazole or a comparable volume of DMSO was added, followed by 
incubation for the indicated times. In all studies, culture volumes corresponding to 3 ×107 
cells were removed and centrifuged to pellet cells. RNA preparation and hybridization 
analysis were as previously described (195). Briefly, cell pellets were suspended in 
sodium acetate-EDTA buffer and stored frozen. After thawing, RNA was extracted by 
vortexing in the presence of glass beads, SDS and buffer-saturated phenol alternating 
with incubation at 65°C for 10–15 min. Samples were cooled on ice and centrifuged, and 
RNA was ethanol precipitated from the aqueous phase. RNAs were dissolved in water 
and denatured in formaldehyde-SSPE with incubation for 15 min at 65°C. Either 40 μl 
(for ACT1 probing) or 200 μl (for other probes) of denatured RNA (approximately 4 or 
20 μg, respectively) was applied to nylon membrane by using a slot blot apparatus. 
Membranes were rinsed in SSPE, UV cross-linked, hybridized to purified PCR products 
(Table 2-1) labeled with 32P by random priming (Takara), and exposed to film. 
 
 
Construction of C. glabrata Microarrays 
 
The nucleotide sequences corresponding to 5272 C. glabrata ORFs were 
downloaded from the Génolevures Consortium (http://cbi.labri.fr/Genolevures/about.php, 
Build 2). Following the Affymetrix Design Guide, two separate probe sets for each ORF 
were designed, each consisting of 13 perfect match and 13 mismatch overlapping 25 base 
oligonucleotides targeted to the 3' 600 bp region. For ORFs < 600 bp the sequence was 
divided in two equal segments for subsequent design procedures. For quality control and 
normalization purposes, we designed two to three additional probe sets spanning the C. 
glabrata 18 s rRNA, TDH1 and ACT1 genes in addition to standard Affymetrix controls 
(BioB, C, D, cre, DAP, PHE, LYS, THR). The probe selection was performed by the 
Chip Design group at Affymetrix, using their proprietary algorithm to calculate probe set 
scores, which includes a probe quality metric, cross-hybridization penalty, and gap 
penalty. The probe sets were then examined for cross-hybridization against all other 
sequences in the C. glabrata genome as well as a number of constitutively expressed 
genes and rRNA from other common organisms. Duplicate probe sets are made to 
distinct regions of the ORF, thereby allowing two independent measurements of the 
mRNA level for that particular gene. C. glabrata custom Affymetrix NimbleExpress 
Arrays were manufactured by NimbleGen Systems per our specification (4). 
 
 
RNA Preparation for Microarrays 
 
 Total RNA was isolated using the hot SDS-phenol method (190). Frozen cells 
were suspended in 12 ml of 50 mM sodium acetate (pH 5.2), 10 mM EDTA at room 
temperature, after which 800 μl of 25% sodium dodecyl sulphate and 12 ml of acid 
phenol (Fisher Scientific) were added. This mixture was incubated 10 min at 65°C with 
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vortexing each minute, cooled on ice for 5 min, and centrifuged for 15 min at 12 000g. 
Supernatants were transferred to new tubes containing 15 ml of chloroform, mixed and 
centrifuged at 200 × g for 10 min. The aqueous layer was removed to new tubes, RNA 
was precipitated with 1 volume isopropanol and 0.1 volume 2M sodium acetate (pH 5.0), 
and then collected by centrifugation at 17 000g for 35 min at 4°C. The RNA pellet was 
suspended in 10 ml of 70% ethanol, collected again by centrifugation, and suspended in 
diethyl pyrocarbonate-treated water. 
 
 
cRNA Synthesis and Labeling 
 
 Immediately prior to cDNA synthesis, the purity and concentration of RNA 
samples were determined from A260/A280 readings and RNA integrity was determined by 
capillary electrophoresis using the RNA 6000 Nano Laboratory-on-a-Chip kit and 
Bioanalyzer 2100 (Agilent Technologies) as per the manufacturer's instructions. First and 
second strand cDNA was synthesized from 15 μg total RNA using the SuperScript 
Double-Stranded cDNA Synthesis Kit (Invitrogen) and oligo-dT24-T7 primer (PrOligo) 
according to the manufacturer's instructions. cRNA was synthesized and labeled with 
biotinylated UTP and CTP by in vitro transcription using the T7 promoter-coupled 
double stranded cDNA as template and the Bioarray HighYield RNA Transcript Labeling 
Kit (ENZO Diagnostics). Double stranded cDNA synthesized from the previous steps 
was washed twice with 70% ethanol and suspended in 22 μl of Rnase-free water. The 
cDNA was incubated as recommended with reaction buffer, biotin-labeled 
ribonucleotides, dithtiothreitol, RNase inhibitor mix and T7 RNA polymerase for 5 h at 
37°C. The labeled cRNA was separated from unincorporated ribonucleotides by passing 
through a CHROMA SPIN-100 column (Clontech) and ethanol precipitated at −20°C 
overnight. 
 
 
Oligonucleotide Array Hybridization and Analysis 
 
 The cRNA pellet was suspended in 10 μl of RNase-free water and 10 μg was 
fragmented by ion-mediated hydrolysis at 95°C for 35 min in 200 mM Tris-acetate (pH 
8.1), 500 mM potassium acetate, 150 mM magnesium acetate. The fragmented cRNA 
was hybridized for 16 h at 45°C to the C. glabrata NimbleExpress GeneChip arrays. 
Arrays were washed at 25°C with 6 × SSPE, 0.01% Tween 20 followed by a stringent 
wash at 50°C with 100 mM MES, 0.1 M NaCl, 0.01% Tween 20. Hybridizations and 
washes employed the Affymetrix Fluidics Station 450 using their standard EukGE-
WS2v5 protocol. The arrays were then stained with phycoerythrein-conjugated 
streptavidin (Molecular Probes) and the fluorescence intensities were determined using 
the GCS 3000 high-resolution confocal laser scanner (Affymetrix). The scanned images 
were analyzed using software resident in GeneChip Operating System v2.0 (GCOS; 
Affymetrix). Sample loading and variations in staining were standardized by scaling the 
average of the fluorescent intensities of all genes on an array to a constant target intensity 
(250). The signal intensity for each gene was calculated as the average intensity 
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difference, represented by [Σ(PM – MM)/(number of probe pairs)], where PM and MM 
denote perfect-match and mismatch probes. 
 
 
Microarray Data Analysis 
 
 The scaled gene expression values from GCOS software were imported into 
GeneSpring 7.2 software (Agilent Technologies) for preprocessing and data analysis. 
Probesets were deleted from subsequent analysis if they were called absent by the 
Affymetrix criterion and displayed an absolute value below 20 in all experiments. The 
expression value of each gene was normalized to the median expression of all genes in 
each chip as well as the median expression for that gene across all chips in the study. 
Pairwise comparison of gene expression was performed for each matched experiment 
(F15 vs. 66032). Genes were included in the final data set if their expression changed by 
at least twofold between strain F15 and strain 66032 in two independent experiments. 
 
 
Quantitative Real-Time RT-PCR 
 
 First strand cDNAs were synthesized from 2 μg total RNA in a 21 μl reaction 
volume using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) as 
per the manufacturer's instructions. Quantitative real-time PCR was performed in 
triplicate using the 7000 Sequence Detection System (Applied Biosystems). Independent 
amplifications were performed using the same cDNA for both the gene of interest and 
18S rRNA, using the SYBR Green PCR Master Mix (Applied Biosystems). Gene-
specific primers were designed for the gene of interest and 18S rRNA using Primer 
Express software (Applied Biosystems) and the Oligo Analysis and Plotting Tool 
(Qiagen). The PCR conditions consisted of AmpliTaq Gold activation at 95°C for 10 
min, followed by 40 cycles of denaturation at 95°C for 15 s and annealing/extension at 
60°C for 1 min. A dissociation curve was generated at the end of each cycle to verify that 
a single product was amplified using software provided with the 7000 Sequence 
Detection System. The change in fluorescence of SYBR Green I dye in every cycle was 
monitored by the system software, and the threshold cycle (CT) above background for 
each reaction was calculated. The CT value of 18S rRNA was subtracted from that of the 
gene of interest to obtain a ΔCT value. The ΔCT value of an arbitrary calibrator (e.g. 
untreated sample) was subtracted from the ΔCT value of each sample to obtain a ΔΔCT 
value. The gene expression level relative to the calibrator was expressed as 2–ΔΔCT. 
 
 
RESULTS AND DISCUSSION 
 
 
PDR1 Disruption in F15 and Parent 
 
 The laboratory selection of spontaneous fluconazole-resistant mutants of C. 
glabrata ATCC strain 66032 was previously described (216). One of these mutants, F15, 
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exhibited strong upregulation of CgCDR1 and CgPDH1, modest upregulation of PDR1, 
and a single base change predicted to alter the Pdr1p amino acid sequence. We reasoned 
that disruption of CgPDR1 in F15 and parent 66032 would provide an initial test of the 
hypothesis that this single base change is responsible for the fluconazole resistance. To 
accomplish this, ura3 derivatives of F15 and 66032 were isolated by selection on 5FOA 
and screening for complementation by a URA3-encoding plasmid. Homologous 
recombination is relatively non-specific in C. glabrata, especially with short homology 
regions, but can be enhanced by promoter-dependent disruption of genes (PRODIGE) as 
previously described (63). This method was used to disrupt CgPDR1 (Figure 2-1A). 
Transformants were screened by polymerase chain reaction (PCR); loss of the uF-
PDR1iR product and generation of the PDR1uF-URA3iR product confirmed PDR1 
disruption (Figure 2-1B). 
 
 Broth microdilution assays were used to examine fluconazole susceptibility of 
F15Δpdr1, 66032Δpdr1 and their parents (Figure 2-1C). Similar to previous results with 
their parents (216), the 66032 and F15 ura3 derivatives generated 24 h fluconazole MICs 
of 8–16 and > 64 μg/ml, respectively. In contrast, their Δpdr1 derivatives were 
fluconazole hypersusceptible, with equivalent MICs of 2 μg/ml. Although susceptible, 
66032 exhibited trailing growth typical of many Candida species (178), and by 48 h was 
fully grown at all fluconazole concentrations tested (Figure 2-1C). Trailing growth was 
absent in the PDR1 disruptants. These results support the role of CgPdr1p in F15 
fluconazole resistance. Furthermore, the reduced MIC and trailing growth associated with 
PDR1 disruption in 66032 suggests that CgPdr1p is an important contributor to the 
intrinsic low-level resistance that is characteristic of this species. 
 
 As hypothesized, RNA analysis showed that PDR1 disruption reversed the 
constitutive upregulation of CgCDR1 and CgPDH1 in untreated mutant F15  
(Figure 2-2A). Moreover, expression of these genes was reduced relative to their 
expression in untreated parent 66032. This can explain the greater susceptibility of the 
Δpdr1 derivatives relative to 66032. As previously described (216), fluconazole treatment 
induced the expression of CgCDR1 and CgPDH1, most clearly in strains 66032 and F15 
respectively (Figure 2-2A). CgPDR1 disruption completely blocked this treatment-
dependent upregulation. Finally, we note that CgPDR1 itself, which is upregulated in F15 
(216), is also induced by fluconazole treatment in 66032 and F15 (Figure 2-2A). 
 
 
CgCDR1 Disruption 
 
 To more directly assess the role in acquired or intrinsic azole resistance of 
multidrug transporter gene CgCDR1, it was similarly disrupted in the ura3 derivatives of 
66032 and F15 (Figure 2-3A). This reversed the fluconazole resistance of F15  
(Figure 2-3B), although the MIC (16 μg/ml) remained eightfold above that observed with 
PDR1 disruption (Figure 2-1C). With respect to 66032, CgCDR1 disruption had minimal 
effect on fluconazole MIC at 24 h, but trailing growth most apparent at 48 h was 
eliminated as it was with PDR1 disruption. These results are consistent with CgCDR1 
being a major but not exclusive contributor to F15 azole resistance.
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Figure 2-2.  Expression of multidrug transporter genes CDR1 and PDH1 and 
transcriptional activator gene PDR1 in parent 66032, mutant F15 and their respective 
∆pdr1 disruptants. A. RNA was isolated from log phase cultures, slot-blotted to 
membranes, and hybridized to the indicated gene probes: ACT1 served as loading control. 
U, untreated cultures; T, treated with 256 μg/ml fluconazole for 2.5 h. B. Quantitative 
real-time RT-PCR analysis of relative CgCDR1 and PDH1 expression in F15 versus 
66032, F15∆pdr1 versus 66032, and 66032∆pdr1 versus 66032. Data are shown as mean 
± SD. 
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Figure 2-3.  Disruption of CgCDR1 and effects on azole sensitivity. A. PCR screen of 
representative ∆cdr1 transformants selected on DOB-URA and their parents 66032 and 
F15. DNA was purified from isolated colonies, amplified with the indicated primer pairs, 
and analyzed by gel electrophoresis; loss of CDR1uF-CDR1iR product and formation of 
CDR1uF-URA3iR product identified ∆cdr1 clones. B. Broth microdilution assays 
examining fluconazole sensitivities of parent 66032, azole-resistant mutant F15, and their 
respective ∆cdr1 disruptants. Absorbance at 630nm was recorded after 24 or 48 h 
incubation as indicated; growth was plotted as percentage of drug-free control.
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PDR1 Replacement 
 
 To rigorously test the role of F15 PDR1 in azole resistance, we employed gene 
replacement. The 66032Δpdr1 strain was transformed with PCR products representing 
wild-type and F15 PDR1, including 5' and 3' flanking sequences which should direct 
PDR1 to its native locus (Figure 2-4A). We initially attempted to select homologous 
recombinants on fluconazole-containing medium. However, this was precluded by a 
background of spontaneous fluconazole-resistant mutants in control (no added DNA) 
transformations. As an alternative, the protein synthesis inhibitor cycloheximide is a 
known substrate for Cdr1p-like multidrug transporters, and indeed C. glabrata Δpdr1 
strains are cycloheximide-hypersensitive (63). In contrast to fluconazole, cycloheximide-
containing plates yielded no spontaneous mutants while five or six transformants were 
obtained with addition of wild-type or F15 PDR1 respectively. PCR screening of these 
transformants confirmed homologous recombination into the native locus (Figure 2-4B). 
All F15 PDR1 replacements demonstrated fluconazole resistance comparable to F15 
itself, while all but one of the wild-type PDR1 replacements demonstrated wild-type 
sensitivity (Figure 2-4B). Sequencing of a representative F15 PDR1 replacement 
confirmed there were no mutations other than the previously described P927L (216). 
 
 
Characterization of CgPdr1p-Independent Azole Resistance 
 
 As noted above, a background of resistant mutants arose on fluconazole-
containing YP-glycerol medium in control transformations of strain 66032Δpdr1, which 
involved plating approximately 2 × 107 cells. To more rigorously examine this CgPdr1p-
independent resistance, equivalent numbers (3 × 105) of 66032 and 66032Δpdr1 cells 
were plated on YP-glycerol medium with fluconazole ranging from 0 to 256 μg/ml (184). 
After 4 days incubation, the MIC was 32 μg/ml for 66032, and about 30 mutant colonies 
(frequency = 1 × 10−4) were observed on each of the four plates at or above this 
concentration. With 66032Δpdr1, the MIC was 4 μg/ml, one or two colonies were 
observed at 4 and 8 μg/ml, and no colonies at 16–256 μg/ml (frequency < 3 × 10−6). 
Thus, CgPdr1p-independent azole resistance occurs at significantly reduced frequency. 
 
 
PDR1 Disruption in Azole-Resistant Clinical Isolates 
 
 Strain BG14, a model for C. glabrata pathogenesis (48), is a ura3 derivative of a 
clinical isolate from a patient who failed fluconazole therapy (32). Consistent with this, 
BG14 is fluconazole-resistant (MIC = 256 μg/ml), the molecular basis for which is 
unknown. PDR1 disruption in BG14, conferring cycloheximide hypersensitivity, was 
previously reported (63). Here we show that this disruption also largely reversed BG14 
azole resistance. The fluconazole MIC decreased 16-fold to 16 μg/ml (Figure 2-5A); i.e. 
comparable to the typical clinical isolate but eightfold above that observed for 
66032Δpdr1. Ketoconazole, itraconazole and miconazole MICs were similarly reduced in 
BG14Δpdr1, but susceptibilities to unrelated antifungals terbinafine, caspofungin and 
amphotericin B were unchanged. Expression of CgCDR1 and ERG11 was examined by 
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Figure 2-4.  PDR1 replacement confirms role in azole resistance. A. Diagram illustrating 
replacement and PCR screening strategies. B. PCR screen of representative PDR1 
replacements 66032R and F15R (wild-type and F15-derived PDR1, respectively) selected 
on cycloheximide-containing plates, and their parent 66032∆pdr1; strains 66032 and F15 
were included as positive controls. DNA was purified from isolated colonies, amplified 
with PDR1uF2-PdR1iR primer pair, and analyzed by gel electrophoresis; formation of 
product confirmed replacement of PDR1 into its native locus in 66032∆pdr1. C. Broth 
microdilution assay showing that replacement into 66032∆pdr1 of 66032-derived 
(66032R) or F15-derived (F15R) PDR1 conferred the expected low or high-level 
fluconazole resistance associated with 66032 and F15. Absorbance at 630 nm was 
recorded after 24 h incubation; growth was plotted as percentage of drug-free control. 
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Figure 2-5.  Antifungal sensitivities and CgCDR1-ERG11 expression in a Δpdr1 
derivative of azole-resistant clinical isolate BG14. A. MIC values (at 24 h) determined by 
broth microdilution for BG14 and BG14Δpdr1. A log scale was used to facilitate 
comparison of MICs over a wide range. Numbers above the BG14Δpdr1 bars indicate the 
fold-change relative to BG14. FLU, fluconazole; ITR, itraconazole; KET, ketoconazole; 
MIC, miconazole; TER, terbinafine; AMB, amphotericin B; and CAS, caspofungin. B. 
RNA was isolated from log-phase BG14 and BG14Δpdr1 cultures exposed to 256 μg/ml 
fluconazole for 0–2.5 h, slot-blotted to membranes, and hybridized to the indicated gene 
probes. 
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RNA hybridization (Figure 2-5B). In BG14, constitutive expression of CgCDR1 appeared 
to be modestly upregulated, but remained responsive to fluconazole-dependent 
upregulation. Both of these were strongly reduced in the Δpdr1 derivative, while no 
effects on ERG11 expression were observed. 
 
 Strain 8512 represents a second azole-resistant clinical isolate with high 
constitutive CgCDR1-CgPDH1 expression (216). Following 5FOA-mediated conversion 
to ura3, PDR1 was disrupted in strain 8512 (not shown). Broth microdilution assays 
demonstrated reduction of fluconazole MIC from > 256 to 32 μg/ml. Taken together, 
these data suggest that PDR1 is a major determinant of azole sensitivity in C. glabrata, 
although additional gene mutations may contribute to clinical resistance.  
 
 
Microarray Analysis: Upregulated Genes 
 
 In light of the major role played by transcription activator gene PDR1 in C. 
glabrata azole sensitivity, an examination of genome-wide changes in gene expression in 
mutant F15 was warranted. We first attempted this with S. cerevisiae microarrays, 
because these two yeasts are closely related. However, the only confirmable change was 
upregulation of the PDR5 (18-fold) and PDR15 (ninefold) homologs (data not shown); 
both of these genes share 73% nucleotide identity with CgCDR1. 
 
 Therefore, C. glabrata microarrays were developed for the Affymetrix platform 
(see Materials and Methods) and used to examine changes in F15 relative to 66032. In 
F15, 78 genes were upregulated ≥ twofold relative to 66032. These genes are listed in 
Table 2-2, grouped by probable function and ordered by expression level. Among the 
upregulated are homologs of nine genes previously identified in microarray studies of S. 
cerevisiae Pdr1p–Pdr3p gain-of-function mutants (52, 53). Five of these nine genes 
encode putative membrane proteins with roles in small molecule transport or lipid 
metabolism. These include, in addition to CgCDR1 and CgPDH1, the upregulated genes 
YOR1 involved in oligomycin efflux, RSB1 involved in sphingoid base-resistance, and 
RTA1 involved in 7-aminocholesterol resistance (see Saccharomyces Genome Database 
(SGD) website (http://www.yeastgenome.org) for further information on these genes and 
references). 
 
 The four remaining genes upregulated in both S. cerevisiae and C. glabrata gain-
of-function mutants include PDR1 itself (as previously reported; (216)), the stress-
induced RPN4 encoding a proteasome gene transcription factor, and the uncharacterized 
open reading frames (ORFs) YLR346C and YMR102C. The latter encodes a relatively 
large and evolutionarily conserved protein with a WD40 domain commonly found in 
signaling proteins, and its disruption has been associated with fluconazole resistance in S. 
cerevisiae (8). The YLR346C product, in contrast, is not conserved; indeed, the C. 
glabrata and S. cerevisiae genes are not detectably homologous in terms of sequence but 
rather in terms of chromosomal synteny, flanked in both yeast by unambiguous 
YLR345W and YLR347C homologs. Also, both YLR346C products are short (101 and 112 
amino acids) and highly charged in their C-terminal regions. In S. cerevisiae, Ylr346cp is 
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Table 2-2.  C. glabrata genes upregulated ≥ twofold in fluconazole-resistant mutant F15. 
 
Group Systematic name 
S. cerevisiae 
homologa 
C. glabrata 
designation Description 
Expressionb 
PDREc 
F15 F15/66032 
Small molecule transport IPF6352 dPDR5 (CDR1) CAGL0M01760g ABC transporter involved in azole/multidrug resistance 41 2.5 134, 298, 388, 516 
IPF9719 dPDR15(PDH1) CAGL0F02717g ABC transporter involved in azole/multidrug efflux 29 9.6 521, 557 
IPF1620 QDR2  CAGL0G08624g MFS transporter involved in quinidine/multidrug efflux 23 4.5 848 
IPF8922 dYOR1 CAGL0G00242g ABC transporter involved in multidrug efflux 16 11 648 
IPF982 YBT1  CAGL0C03289g ABC transporter involved in bile acid transport 13 7.7 450 
IPF3303 OAC1  CAGL0K11616g Mitochondrial inner membrane transporter 4.7 2.5 839 
Lipid, fatty acid, and  
sterol metabolism 
IPF5152 dRTA1  CAGL0K00715g Over-expression confers 7-aminocholesterol resistance 22 7.0 300, 379 
IPF2180 HFD1  CAGL0K03509g Putative mitochondrial fatty aldehyde dehydrogenase 13 5.6 218 
IPF4136 dRSB1  CAGL0L10142g Sphingolipid flippase 12 2.8 641, 881 
IPF8678 LCB5  CAGL0K05995g Minor sphingoid long-chain base kinase 12 2.4 804 
IPF8367 LAC1  CAGL0M10219g Ceramide synthase component 5.7 2.5 531 
IPF1002 ARE1  CAGL0C02981g acyl-CoA:sterol acyltransferase; sterol esterification 4.6 4.6 114 
IPF4884 ATF2  CAGL0D05918g Alcohol acetyltransferase; steroid detoxification 3.1 9.6 30, 195, 560, 772 
IPF2739 SPO14  CAGL0L03135g Phospholipase D 0.8 2.6 – 
IPF2620 CSR1  CAGL0D00946g Phosphatidylinositol transfer protein 0.4 3.8 239 
Cell stress IPF6847 HSP12  CAGL0J04202g Stress-induced membrane protein 29 4.0 849 
IPF3173 YNL134c  CAGL0K09702g Alcohol dehydrogenase motif; stress-induced 14 9.5 541 
IPF4605 YML131W  CAGL0K12958g Alcohol dehydrogenase motif, stress-induced 7.3 9.1 594 
IPF6629 HSP31  CAGL0C00275g Possible chaperone and cysteine protease 3.5 2.0 – 
IPF4140 YOR052C  CAGL0L10186g Uncharacterized; stress-induced 2.3 3.2 – 
IPF8736 TPS3  CAGL0H02387g Trehalose-6-phosphate synthase/phosphatase subunit 1.5 4.4 – 
IPF5558 HSP42  CAGL0E00803g Small cytosolic stress-induced chaperone 0.6 4.9 – 
Transcription IPF5076 dRPN4  CAGL0K01727g Transcription factor for proteasomegenes 16 3.9 378, 394, 552 
IPF5932 SUT1  CAGL0I04246g Transcription factor involved in sterol uptake 15 2.4 – 
IPF3325 dPDR1  CAGL0A00451g Transcription factor involved in multidrug resistance 9.6 2.3 557, 701 
IPF7202 TAF9  CAGL0M05005g Subunit of TFIID and SAGA complexes 1.0 6.3 – 
IPF6366 YPR013C  CAGL0M01870g Uncharacterized; potential zinc finger 0.8 2.9 – 
IPF2113 SIP3  CAGL0I01980g Activates transcription through DNA-bound Snf1 0.4 2.2 – 
IPF118 HOT1  CAGL0H08866g Transcription factor involved in osmostress response 0.1 4.9 228 
DNA replication and  
damage response 
IPF9036 YIM1 CAGL0M09713g Implicated in DNA damage response 40 12 127, 179 
IPF9035 MEC3  CAGL0M09735g DNA damage checkpoint 1.6 15 110, 162 
IPF2521 DBF4  CAGL0E04576g Regulatory subunit of Cdc7p-Dbf4p kinase complex 0.7 2.4 – 
IPF785 DPB3  CAGL0B03355g DNA polymerase II subunit 0.2 2.7 – 
Protein synthesis, 
modification, or  
degradation 
IPF3014 OCH1  CAGL0A01738g Mannosyltransferase of cis-Golgi apparatus 5.2 2.5 – 
IPF6742 UFD1  CAGL0J08096g Recognition of polyubiquitinated proteins 4.4 2.2 – 
IPF3846 NCE3  CAGL0G01540g Carbonic anhydrase-like; non-classical protein export 3.1 2.9 – 
IPF3072 RPN8  CAGL0K08866g Non-ATPase regulatory subunit of 26S proteasome 2.9 2.9 – 
IPF8484 PCI8  CAGL0M12749g Possible shared subunit of Cop9 signalosome and eIF3 0.2 2.4 – 
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Table 2-2 (continued). 
 
Group Systematic name 
S. cerevisiae 
homologa 
C. glabrata 
designation Description 
Expressionb 
PDREc 
F15 F15/66032 
Vesicular and protein  
transport 
IPF7414 GSF2  CAGL0L01485g ER membrane, hexose transporter secretion 10 2.4 208 
IPF8257 YPT52  CAGL0G07689g GTPase required for vacuolar protein sorting 1.6 2.8 – 
 IPF8439 MEH1  CAGL0L02211g Component of the EGO complex; microautophagy 0.5 5.7 – IPF4445 VPS28  CAGL0H05181g Component of ESCRT-I complex; protein trafficking 0.5 2.2 – 
 IPF4173 VTI1  CAGL0L10604g Involved in cis-Golgi membrane traffic 0.3 6.7 741 
 IPF3260 GYL1  CAGL0K10934g putativegAP for Ypt1 involved in polarized exocystosis 0.3 4.0 – 
 IPF271 VPS51  CAGL0H06809g Golgi-associated retrograde protein complex 0.2 6.1 – 
Signal transduction IPF1489 BAG7 CAGL0I07249g GAP for Rho1; cell wall and cytoskeleton homeostasis 1.6 2.9 – 
IPF8227 CDC25  CAGL0D06512g Membrane bound GEF for Ras1-Ras2 1.2 5.8 – 
IPF351 GAC1  CAGL0F04917g Regulatory subunit forglc7 protein phosphatase 0.9 4.7 – 
IPF2382 YNL234W  CAGL0J07502g Similar toglobins with haem-binding domain 0.5 3.1 – 
IPF512 GPG1  CAGL0F07117g Subunit of heterotrimericg protein, interacts withgrp1 0.4 2.6 – 
IPF5914 KIN3  CAGL0I04422g Protein kinase 0.2 5.6 – 
Mitochondrial IPF2122 FMP48  CAGL0K04301g Ser/Thr protein kinase; mitochondrial 11 2.8 – 
IPF7121 YGR046W  CAGL0G03861g Essential protein involved in mitochondria transport 0.4 4.4 – 
Cell wall IPF9549 FLO1  CAGL0E00209g Flo1-like family of cell wall proteins 2.6 3.0 284, 419 
Amino acid and  
carbohydrate metabolism 
IPF496 PYC1  CAGL0F06941g Pyruvate carboxylase isoform 4.6 2.3 – 
IPF4499 STR3  CAGL0L06094g Cystathionine beta-lyase 0.7 5.0 – 
IPF5315 MET8  CAGL0K06677g Bifunctional dehydrogenase and ferrochelatase 0.2 7.8 – 
Chromatin/chromosome 
structure 
IPF8319 SMD3  CAGL0M04631g Core Sm spliceosome protein Sm D3 0.9 3.7 – 
IPF390 SPC19  CAGL0F05467g Component of Dam1 spindle pole complex 0.5 13.1 – 
IPF8077 SPC97  CAGL0I02464g Component of microtubule-nucleating Tub4 complex 0.5 2.8 – 
IPF2730 SPC34  CAGL0L03223g Component of Dam1 spindle pole complex 0.4 2.5 – 
Other metabolism IPF6032  CAGL0M14091g Putative quinone reductase/NADPH dehydrogenase 3.8 9.8 244, 532 
IPF6034 ADH6  CAGL0M14047g NADPH-dependent cinnamyl alcohol dehydrogenase 2.3 2.7 – 
IPF1279 YPR1  CAGL0A02816g 2-methylbutyraldehyde reductase 0.6 5.6 – 
IPF4182 INP1  CAGL0L10736g Peripheral membrane protein of peroxisomes 0.2 5.5 – 
Uncharacterized IPF6116 YIL077C CAGL0M12947g Uncharacterized 20 38 472, 502 
IPF8009 YJL163C  CAGL0M08426g Uncharacterized; ARS in promoter 9.1 10 450 
IPF2520  CAGL0E04554g Uncharacterized; no similarities 8.8 6.4 – 
IPF2196 dYMR102C  CAGL0K03377g Transcribed along with MDRgenes by Yrr1/Yrm1 8.1 4.4 898 
IPF3019  CAGL0A01650g Uncharacterized; no similarities 7.2 4.4 564 
IPF3875 dYLR346C  CAGL0G01122g Uncharacterized; syntenic but minimal similarities 3.3 22 793, 803 
IPF3655 YLR177W  CAGL0B01078g Uncharacterized 2.7 2.5 – 
IPF1546  CAGL0G09603g Uncharacterized; very weak similarity to Yor186w 2.1 6.1 – 
IPF2382 YNL234W  CAGL0J07502g Similar toglobins with haem-binding domain 0.5 3.1 – 
IPF4149 YOR059C  CAGL0L10318g Uncharacterized 0.5 2.4 – 
IPF6420 YGR126W  CAGL0I10604g Uncharacterized 0.1 19 – 
IPF2249 YHL010C  CAGL0K02563g Uncharacterized; mammalian BRAP2 homolog 0.1 5.0 – 
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Table 2-2 (continued). 
 
aParentheses indicate a previously named C. glabrata gene.  
bExpression in C. glabrata 66032 is represented in arbitrary microarray units (for comparison, actin and β-tubulin gene homologs 
ACT1 and TUB2 had average expression levels of 66 and 8.6 respectively). F15/66032 represents the ratio of expression in the 
fluconazole-resistant mutant vs. its parent (for comparison, ACT1 and TUB2 had ratios of 0.6 and 0.8 respectively).  
cPromoter regions (900 bp) were searched for matches to the S. cerevisiae PDRE consensus TCCRYGSR. Numbers indicate the 
distance (in bp) upstream of the ATG start codon of the PDRE; hyphens (–) indicate the absence of a PDRE.  
dGenes similarly upregulated in S. cerevisiae Pdr1p–Pdr3p gain-of-function mutants (52, 53).  
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mitochondria-localized and forms a two-hybrid interaction with MAP kinase Slt2p, 
suggesting a possible role in mitochondria-nucleus retrograde signaling. 
 
 Among the 69 genes whose upregulation appears to be C. glabrata F15-specific 
(i.e. not similarly upregulated in S. cerevisiae) are three additional homologs encoding 
small molecule transporters including quinidine and bile acid efflux protein genes QDR2 
and YBT1. Additional lipid metabolism genes include ARE1 whose disruption in S. 
cerevisiae confers azole hypersensitivity (T. Edlind, unpublished data) and ATF2 
involved in fatty acid and steroid detoxification. A third group of well-represented genes 
are involved in the cell stress response, including membrane protein gene HSP12, and 
YML131W-YNL134C; the latter two are unrelated by blast but share an ADH_zinc_N 
domain (identified by CD-search; (128)) characteristic of zinc-dependent alcohol 
dehydrogenases-oxidoreductases. YML131W-YNL134C are also coordinately upregulated 
in S. cerevisiae in response to diverse stresses including heat, oxidizing agents, ethanol, 
nitrogen depletion and stationary phase ((70); see Expression Connection at 
http://www.yeastgenome.org). A similarly regulated S. cerevisiae gene is GRE2, also 
encoding an oxidoreductase and among the genes upregulated in Pdr1p–Pdr3p gain-of-
function mutants (52, 53). This provides an example of analogous but non-homologous 
genes upregulated in C. glabrata F15 and S. cerevisiae Pdr1p–Pdr3p mutants. 
 
 Notable among the remaining upregulated genes with significant expression 
levels are: SUT1 encoding a transcription factor involved in sterol uptake and hypoxic 
gene expression, YIM1 implicated in DNA damage response, OCH1 and GSF2 involved 
in Golgi-ER functions, proteasome-related genes UFD1 and RPN8, putative 
mitochondrial protein kinase gene FMP48, a quinone reductase-like gene curiously 
lacking in other fungal genomes but present in many bacteria and vertebrates, and the 
uncharacterized YIL077C whose product has been mitochondria-localized but interacts 
with a nuclear transcriptional complex. 
 
 
Microarray Analysis: Downregulated Genes 
 
 There were 31 genes downregulated ≥ twofold in F15 relative to parent 66032 
(Table 2-3). Only one of these was also downregulated in S. cerevisiae Pdr1p–Pdr3p 
gain-of-function mutants: membrane transporter gene PDR12 involved in efflux of weak 
organic acids such as sorbate. Additional genes with significantly downregulated 
expression include zinc transporter gene ZRT1, major facilitator genes including FLR1 
implicated in fluconazole efflux, and homologs of cell surface protein genes MUC1-
EPA2 and MKC7 implicated in adhesion and aspartic protease activity respectively. 
Finally, a gene was downregulated whose product has clear homology to the WRY 
family of putative membrane-anchored proteins previously identified only in C. albicans 
(unpublished annotation in NCBI database). This family has nine paralogs in C. albicans 
and seven in C. glabrata but none, surprisingly, in S. cerevisiae, suggesting a possible 
role in mammalian colonization.
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Table 2-3.  C. glabrata genes downregulated ≥ twofold in fluconazole-resistant mutant F15 compared with parent 66032. 
 
Group Systematic name 
S. cerevisiae 
homologa 
C. glabrata  
designation Description 
Expressionb 
PDRE 
F15 F15/66032 
Small molecule 
transport 
IPF5505 ZRT1  CAGL0E01353g High-affinity zinc transporter 10 0.5 – 
IPF4392 FLR1  CAGL0H06017g Multidrug efflux pump of major facilitator superfamily 6.1 0.4 – 
IPF6218 dPDR12  CAGL0M07293g ABC transporter of weak organic acids 4.5 0.2 – 
IPF7808 YHR048W  CAGL0J00363g Uncharacterized; major facilitator superfamily 2.2 0.4 – 
IPF867 ATR1  CAGL0B02343g Multidrug efflux pump of major facilitator superfamily 1.8 0.4 – 
IPF1568 SNG1  CAGL0G09273g Nitrosoguanidine resistance; putative transporter 1.3 0.1 – 
Cell stress IPF3249 CTA1  CAGL0K10868g Catalase A 8.8 0.4 – 
IPF11021 CRS5  CAGL0H04257g Copper-binding metallothionein-like protein 3.4 0.4 – 
IPF9018 LTV1  CAGL0J00891g Required for growth at low temperature 1.0 0.4 656 
IPF9641 SLG1  CAGL0F01507g Sensor of stress-activated Pkc1-Slt2 pathway 0.8 0.5 – 
IPF5937 CUP2(AMT1) CAGL0I04180g Metal-activated transcriptional factor 0.9 0.2 – 
Carbohydrate 
metabolism 
IPF986 SDH2  CAGL0C03223g Succinate dehydrogenase iron-sulphur protein subunit 4.9 0.4 – 
IPF6117 DOG2  CAGL0M12925g 2-deoxyglucose-6-phosphate phosphatase 1.6 0.3 – 
IPF290 PCK1  CAGL0H06633g Phosphoenolpyruvate carboxykinase 1.2 0.3 – 
Cell cycle control IPF2555 SDS22  CAGL0D00264g Nuclear regulatory subunit ofglc7 phosphatase 0.3 0.2 – 
RNA processing IPF8796 PNO1  CAGL0K09460g Nucleolar protein required for pre-rRNA processing 3.0 0.4 – 
IPF1130 AAR2  CAGL0A04543g Component of the U5 snRNP 1.0 0.4 – 
IPF9324 DIM1  CAGL0L07678g Essential 18S rRNA dimethylase 1.0 0.5 – 
IPF5272 NOP8  CAGL0B01397g Nucleolar protein required for ribosome biogenesis 0.7 0.4 – 
Cell surface and 
cytoskeleton 
IPF9500 MKC7  CAGL0J01793g Muc1/Epa2-like putative cell surface protein 4.2 0.3 – 
IPF8398  CAGL0E01771g GPI-anchored aspartyl protease 3.6 0.3 – 
IPF807 MNT3  CAGL0B03003g α-1,3-mannosyltransferase involved in O-glycosyltation 3.1 0.4 – 
IPF3539 ECM4  CAGL0G02101g Promoter insertion mutant is calcofluor-hypersensitive 1.6 0.3 – 
IPF810 MNT3  CAGL0B02992g α-1,3-mannosyltransferase involved in O-glycosyltation 1.4 0.3 – 
IPF821  CAGL0B02882g C. albicans WRY family; transmembrane domain 0.5 0.1 – 
IPF5228 ECM18  CAGL0B01969g Insertion mutant is calcofluor hypersensitive 0.3 0.3 – 
IPF7581 TPM2  CAGL0L08338g Minor isoform of tropomyosin 0.3 0.4 – 
Uncharacterized IPF493 YIR035C  CAGL0F06897g Uncharacterized; alcohol dehydrogenase domain 3.3 0.4 – 
IPF3428 YNL095C  CAGL0G06468g Uncharacterized; related to ECM3 2.7 0.4 – 
IPF7665 SIP5  CAGL0L06864g Uncharacterized; interacts withglc7 and Snf1 0.4 0.3 – 
IPF5688 FMP16  CAGL0G05269g Uncharacterized; mitochondrial 0.3 0.3 – 
aParentheses indicate a previously named C. glabrata gene.  
bExpression in C. glabrata 66032 is represented in arbitrary microarray units (for comparison, actin and β-tubulin gene homologs 
ACT1 and TUB2 had average expression levels of 66 and 8.6 respectively). F15/66032 represents the ratio of expression in the 
fluconazole-resistant mutant vs. its parent (for comparison, ACT1 and TUB2 had ratios of 0.6 and 0.8 respectively).  
cPromoter regions (900 bp) were searched for matches to the S. cerevisiae PDRE consensus TCCRYGSR. Numbers indicate the 
distance (in bp) upstream of the ATG start codon of the PDRE; hyphens (–) indicate the absence of a PDRE.  
dGenes similarly downregulated in S. cerevisiae Pdr1–Pdr3 gain-of-function mutants (52, 53).
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Confirmation of Microarray Results 
 
 As our studies represent the first application of these C. glabrata microarrays, it 
was important to validate the results by independent methods. RNA blots or real-time 
reverse transcription (RT)-PCR were used to examine the expression of selected genes 
identified as upregulated in the microarray (other than already confirmed CgCDR1, 
CgPDH1 and CgPDR1). For five of seven genes tested (YLR346C, YOR1, YNL134C, 
YML131W and RTA1), RNA blots confirmed F15 upregulation relative to the parent 
66032 strain (Figure 2-6A). The two exceptions (MEC3 and YJL163C) represent genes 
whose expression in both parent and F15 were below the level of detection by RNA blot 
(not shown). 
 
 For all nine genes tested by real-time RT-PCR (YOR1, RTA1, RPN4, QDR2, 
MET8, BAG7, CSR1, PDR1 and YBT1), the upregulation observed by microarray was 
confirmed (Figure 2-5B). For most of these, the results were quantitatively similar; e.g. 
YOR1 was upregulated 16-fold by microarray and 17-fold by RT-PCR and CSR1 was 
upregulated 3.8-fold by microarray and 2.9-fold by RT-PCR. Expression of ERG11 
encoding the azole target lanosterol demethylase was essentially unaltered by RT-PCR 
(not shown), in agreement with microarray analysis (F15/66032 = 0.6) and RNA 
hybridization (216). One anomaly in the microarray analysis was the relatively low 
upregulation of CgCDR1 (2.5-fold) compared with its high upregulation (approximately 
20-fold) in both RNA blots and RT-PCR (Figure 2-2). Furthermore, CgCdr1p was 
strongly upregulated on the protein level, as shown by SDS-PAGE of membrane 
preparations followed by mass spectrometric identification of eluted bands (181). 
Potential explanations for this anomaly include degradation or masking of the CgCDR1 
mRNA region targeted by the microarray, or a saturation effect due to the relatively high 
CgCDR1 basal expression. 
 
 
Promoter Sequence Analysis 
 
 To identify a Candidate C. glabrata Pdr1p response element (PDRE), we took 
advantage of the F15 microarray data, the available genome sequence, and the 
evolutionary relatedness of this yeast to S. cerevisiae. The promoter regions (900 bp 
upstream of the start codon) for all genes listed in Tables 2-2 and 2-3 were searched for a 
match to the consensus S. cerevisiae PDREs (52, 53): TCC(GA)(CT)G(GC)(AG). At 
least one match to this sequence was identified in 31 of the 78 genes (40%) upregulated ≥ 
two-fold. Moreover, one or more PDRE were identified in all nine genes upregulated in 
both C. glabrata and S. cerevisiae gain-of-function mutants, in 14 of 15 genes in the 
small molecule transport and lipid metabolism groups, and in 26 of 34 genes with 
expression level > 3 (arbitrary microarray units). Conversely, only one PDRE was 
identified among the 31 downregulated gene promoters (Table 2-3); similarly, none was 
identified in the promoters of representative housekeeping genes (ACT1, TEF1, TDH3) or 
azole target gene ERG11. This analysis therefore identifies TCC(AG)(TC)G(GC)(AG) as 
a strong Candidate for the C. glabrata PDRE. More specifically, we note a clear 
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Figure 2-6.  Confirmation of F15/66032 microarray results for selected genes by RNA 
hybridization and real-time RT-PCR. A. RNA was isolated from log phase cultures, slot-
blotted to membranes, and hybridized to the indicated gene probes; ACT1 served as 
loading control. B. Quantitative real-time RT-PCR analysis of relative gene expression in 
F15 versus 66032. Data are shown as mean ± SD. 
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preference for G as the penultimate base (95% of PDREs) and A as the final base (84%), 
although two of the four PDREs within the CgCDR1 promoter have G as the final base. 
 
 Two exceptions warrant discussion. The promoters of C. glabrata upregulated 
genes RPN8 and YOR052C lack a PDRE but include perfect matches to the S. cerevisiae 
Rpn4p transcription factor-binding site GGTGGCAAA (124); perfect or near-perfect 
matches are also found in the promoters of their S. cerevisiae homologs. As noted above, 
Rpn4p is upregulated in both C. glabrata Pdr1p and S. cerevisiae Pdr1p–Pdr3p gain-of-
function mutants. Thus, RPN8-YOR052C upregulation is likely Rpn4p-mediated and only 
indirectly Pdr1p-mediated. 
 
 
Candida glabrata F15 Exhibits Additional Phenotypes Predicted by Microarray 
Analysis Which May Alter Virulence 
 
 As coordinate CgCDR1-CgPDH1 upregulation is commonly observed in C. 
glabrata azole-resistant clinical isolates (21, 187, 216), the responsible mutations must 
have minimal effects on fitness. On the other hand, these mutations could alter C. 
glabrata in subtle ways that affect, for example, its relative virulence in the bloodstream 
versus mucosa. The F15 microarray results provided us with an opportunity to begin to 
test this general hypothesis. Specifically, we looked for phenotypes other than azole 
susceptibility predicted to be associated with altered expression of genes co-regulated 
with CgCDR1-CgPDH1. 
 
 Upregulation of the YOR1 transporter 11-fold (Table 2-2) predicts that azole-
resistant F15 should be cross-resistant to oligomycin, an inhibitor of mitochondrial F1F0 
ATPase and known S. cerevisiae Yor1p substrate. This was confirmed by broth 
microdilution assay (MIC = 0.5 μg/ml for F15 vs. 0.125 μg/ml for parent 66032), using 
medium with glycerol as respiratory carbon source. Yor1p also confers tolerance in S. 
cerevisiae to a wide range of organic anions such as leptomycin B and acetic acid, along 
with cadmium (47). PDR12, downregulated fivefold in F15, similarly encodes an efflux 
pump with specificity for organic acids, in particular sorbic acid (170). Spot assays 
(Figure 2-7) confirmed sorbate hypersensitivity of F15, although the effects on MIC were 
modest (4 mM for F15 vs. 8 mM for 66032). With respect to organic acid sensitivity, 
PDR12 downregulation may be largely offset by YOR1 upregulation. There was no 
detectable change in sensitivity to acetic, boric, or lactic acids (MICs = 64, 16 and 250 
mM respectively). 
 
 YML131W and YNL134C homologs were similarly upregulated approximately 
nine-fold in F15. As noted above, the products of these uncharacterized genes share a 
domain characteristic of alcohol dehydrogenases/oxidoreductases; furthermore, they are 
co-regulated in response to environmental stresses including heat shock and treatment 
with reactive oxygen species or ethanol (Expression Connection, SGD website). 
Conversely, catalase gene CTA1 was downregulated 2.5-fold. Consistent with this, F15 
demonstrated hypersensitivity to hydrogen peroxide by spot assay (Figure 2-7) and broth 
microdilution (MIC = 16 mM vs. 32 mM for 66032). Similarly, F15 demonstrated 
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Figure 2-7.  Spot assays examining sensitivity of 66032 and its azole-resistant mutant 
F15 to hydrogen peroxide, ethanol and sorbic acid. Approximately 300 cells were spotted 
on YPD agar with the indicated inhibitor. Plates were incubated for 2–4 days at 35°C. For 
comparison, 66032Δpdr1, F15Δpdr1 and the 66032Δpdr1-PDR1 replacement strains 
66032R and F15R were examined in parallel. 
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hypersensitivity to ethanol (Figure 2-7; MIC = 2% vs. 4% for 66032). Equivalent results 
were obtained with F15 PDR1 replacement clone F15R as compared with wild-type 
PDR1 replacement clone 66032R (Figure 2-7), confirming that these altered phenotypes 
resulted from the PDR1 gain-of-function mutation. (Note that the ura3 phenotype of 
66032R can account for its variable growth relative to 66032, an effect also observed 
with the 66032 ura3 strain; not shown.) Finally, we examined sensitivity to heat shock by 
exposing mid-log or early stationary phase cultures to 50°C for 10 min, following by 
plating on YPD with incubation at 35°C for 3 days to obtain colony counts. For F15 
versus 66032, viability was 6 versus 0.3% and 16 versus 5% in log and stationary phase 
cultures respectively. Taken together, these data suggest that regulatory mutations 
conferring azole resistance in C. glabrata may have both positive and negative effects on 
fitness and virulence. 
 
 
CONCLUSIONS 
 
 An important 'virulence factor' for the emerging opportunist C. glabrata appears 
to be its capacity for intrinsic low-level and acquired high-level azole resistance. The 
studies completed here with laboratory mutant F15, and initial studies with representative 
clinical isolates, identify the zinc-cluster transcriptional activator CgPdr1p as a key 
regulator of azole/multidrug transporter genes CgCDR1 and CgPDH1. Constitutive 
upregulation of these genes is observed in most azole-resistant clinical isolates; 
furthermore, they are transiently upregulated in sensitive isolates following azole 
exposure. Consistent with this, in PDR1 disruptants acquired resistance was reversed and 
intrinsic resistance was reduced. We have shown that F15 CgPdr1p has a gain-of-
function mutation analogous to those previously characterized in S. cerevisiae Pdr1p–
Pdr3p, and this mutation is sufficient to confer azole resistance. CgPdr1p mutation is not, 
however, necessary for resistance, because at least one resistant strain analyzed had 
unchanged CgPDR1(216). Azole resistance may potentially arise from mutations in 
upstream signaling proteins or transcription cofactors, both of which remain to be defined 
(although histone modifying enzymes represent likely cofactors). Moreover, we observed 
here that PDR1 disruptants, although azole hypersensitive, continued to yield 
spontaneous azole-resistant mutants at reduced frequency. These Pdr1p-independent 
resistance mechanisms, and their clinical relevance, warrant further study. 
 
 Microarray analysis of genome-wide gene expression has become a central tool in 
molecular genetics, and the arrays developed and tested here should be particularly useful 
in studies of C. glabrata in large part because of its close evolutionary relatedness to S. 
cerevisiae. Most genes with altered expression in F15 had well-characterized S. 
cerevisiae homologs. This allowed us to predict F15 phenotypes, a number of which were 
tested including sensitivity to organic acids, alcohols and oxidants. Ultimately, these data 
should help us to understand and possibly exploit the consequences for C. glabrata of 
regulatory mutations leading to azole resistance. F15 hypersensitivity to hydrogen 
peroxide is of particular interest, because this implies hypersensitivity to immune cells 
such as neutrophils and environments such as the lactobacillus-colonized vaginal tract in 
which hydrogen peroxide plays an important role. Although the relatedness of C. 
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glabrata and S. cerevisiae is invaluable in terms of predicting gene function, microarray 
analysis indicated that the Pdr1p and Pdr1p-Pdr3p gain-of-function mutants of these 
yeasts are more different than similar. This no doubt reflects the very different pressures 
placed on these organisms by their very different niches; e.g. the skin of a grape versus 
the human mucosa.
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CHAPTER 3. GENOME-WIDE EXPRESSION PROFILE ANALYSIS OF THE 
CANDIDA GLABRATA PDR1P REGULON 
 
 
INTRODUCTION 
 
 Over the past two decades, there has been an increase in Candida infections 
caused by non-albicans species with Candida glabrata being the second most common 
cause of mucosal and invasive fungal infections in humans (162). Development of high-
level resistance to the azoles, the most widely-used antifungal class for treatment of 
Candida infections, has been reported in C. glabrata oral and bloodstream isolates from 
head and neck radiation patients, stem cell transplant patients, and human 
immunodeficiency virus (HIV) patients (21, 175, 185). Furthermore, the development of 
azole resistance has been implicated in the fluconazole treatment failure and death of a 
patient suffering from C. glabrata candidemia (122). 
 
 Studies to determine the mechanisms of high level azole resistance in C. glabrata 
have demonstrated frequent constitutive over-expression of the ATP-binding cassette 
(ABC) transporters, CgCDR1, CgPDH1, and CgSNQ2, all of which contribute to this 
phenotype (135, 175, 185, 210, 216).  These transporters are regulated by the zinc 
binuclear cluster transcription factor Pdr1p, a single-gene homologue of Saccharomyces 
cerevisiae Pdr1p and Pdr3p heterodimeric transcription factor (215, 216). CgPDR1, 
CgCDR1, CgPDH1, and CgSNQ2 all contain at least one pleiotropic drug response 
element sequence (PDRE) in their promoters suggesting CgPdr1p may regulate its own 
expression, as well as that of the transporters, through binding these regulatory elements 
(210, 215). Recently it was shown that C. glabrata Pdr1p (and S. cerevisiae Pdr1p) 
directly bind to fluconazole resulting in activation of drug efflux pumps, a mechanism 
similar to regulation of multidrug resistance (MDR) by the PXR nuclear receptor in 
vertebrates (207). Furthermore, single point mutations in the putative functional domains 
of CgPDR1 result in increased transcription of CgCDR1, CgPDH1, and CgSNQ2 as well 
as increased resistance to azoles (68, 212, 215). A recent study demonstrated a high 
variability in these mutations and showed the Pdr1p gain-of-function mutations not only 
have an effect on azole susceptibility but also virulence (68). Collectively these studies 
indicate that Pdr1p is uniquely important to the ability of C. glabrata to not only resist 
antifungal therapy but to also cause disease. 
 
 With these aforementioned studies in mind, we endeavored to delineate the core 
genes of the Pdr1p regulon by first using genome-wide gene expression profiling to 
identify genes co-regulated with CgCDR1 among clinical matched azole-susceptible and 
–resistant C. glabrata isolates. We then identified mutations in CgPDR1 among these 
clinical isolates that conferred resistance to fluconazole. Gene expression profiling was 
again used to identify genes that were differentially expressed in the presence of these 
mutations. Our results identified a more comprehensive picture of the molecular effects 
of Pdr1p mutations in azole-resistant isolates and suggest other cellular functions in C. 
glabrata. 
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MATERIALS AND METHODS 
 
 
Antifungal Agents 
 
 Fluconazole was obtained from MP Biomedicals (Solon, Ohio). Stock solutions of 
10 mg/ml were made in dimethyl sulfoxide (DMSO, Sigma; St. Louis, Missouri) and 
stored at -20˚C. 
 
 
Strains and Growth Media 
 
 The isolates and strains used in this study are listed in Table 3-1. Three of these 
matched fluconazole-susceptible and -resistant clinical isolate sets have been described 
previously (122, 175, 209). Clinical isolates 62-16 and 62-17 were kindly provided by 
Dr. John Mohr at the University of Texas Health Science Center, Houston, TX. All 
isolates/strains used in these studies were grown in YPD (1% yeast extract, 2% peptone, 
and 1% dextrose) broth at 30˚C and stored as 20% glycerol stocks at -80˚C.  One Shot® 
Escherichia coli TOP10 chemically competent cells (Invitrogen; Carlsbad, California) 
were used as a host for plasmid construction and propagation. These strains were grown 
in Luria-Bertani (LB) broth or on LB plates supplemented with 100 μg/ml ampicillin 
(Sigma) or 50 μg /ml kanamycin (Fisher BioReagents; Fair Lawn, New Jersey) when 
required. 
 
 
Plasmid Constructions 
 
 All primer sequences are listed in Table 3-2. The CgPDR1 deletion cassette was 
constructed as follows: The upstream flanking region, containing ~900 bp upstream as 
well as the first 50 nucleotides of the PDR1 coding region, was amplified by PCR from 
C. glabrata isolate SM1 genomic DNA with the primers CgPDR1A and CgPDR1B.  
Likewise, the downstream flanking region of the PDR1 gene containing the last 50 
nucleotides of the PDR1 coding region as well as ~900 bp downstream, was amplified by 
PCR from genomic DNA from C. glabrata isolate SM1 using the primers CgPDR1C and 
CgPDR1D. Each PCR product was cloned using the TA cloning® kit (Invitrogen) as per 
the manufacturer’s instructions. The resulting downstream plasmid DNA was digested at 
the introduced SacI and SacII restriction sites and cloned downstream of the SAT1-
flipper cassette in the corresponding SacI and SacII sites in plasmid pSFS2A (176) to 
generate pPDR1CDS2. The upstream flanking sequence was digested at the introduced 
ApaI and XhoI restriction sites and cloned upstream of the SAT1 flipper cassette in the 
corresponding ApaI and XhoI sites in plasmid pPDR1CDS2 to generate pPDR1S2. The 
PDR1 replacement cassette was constructed in the following manner: The PDR1 ORF 
plus ~500 bp upstream and ~500 bp downstream of the PDR1 coding sequence was 
amplified by PCR from genomic DNA from each C. glabrata clinical isolate using Pfu 
DNA polymerase (Stratagene; La Jolla, California) with the primers CgPDR1E and 
CgPDR1F. The resulting PCR product was cloned using the ZeroBlunt® TOPO®
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Table 3-1.  C. glabrata isolates/strains used in this study. 
 
Strain/Isolate Parent Relevant characteristics or genotype Reference 
SM1 -- Clinical isolate, fluconazole susceptible (122) 
SM3 SM1 Clinical isolate, fluconazole resistant  
6856 -- Clinical isolate, fluconazole susceptible (175) 
6955 6856 Clinical isolate, fluconazole resistant  
7754 -- Clinical isolate, fluconazole susceptible (209) 
7755 7754 Clinical isolate, fluconazole resistant  
62-16 -- Clinical isolate, fluconazole susceptible This study 
62-17 62-16 Clinical isolate, fluconazole resistant This study 
SM1∆pdr1 SM1 pdr1: : FRT This study 
SM1∆PDR1SM1 SM1∆pdr1 pdr1∆/PDR1 SM1-caSAT1 This study 
SM1pdr1/ PDR1T2837C SM1∆pdr1 pdr1∆/PDR1 T2837C-caSAT1 This study 
SM1∆PDR16856 SM1∆pdr1 pdr1∆/PDR1 6856-caSAT1 This study 
SM1pdr1/ PDR1G822T SM1∆pdr1 pdr1∆/PDR1 G822T-caSAT1 This study 
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Table 3-2.  Primers used in this study. 
 
Primer/Gene Primer paira,b Amplicon 
size (bp) 
Primers used for plasmid construction 
CgPDR1A F, 5′-AAACATTTCCTCATAGggCccATCTTTTAC-3′ 1080 
CgPDR1B R, 5′-ATTACATTTTATTTTCCTCgagCTACAGC-3′  
CgPDR1C F, 5′-CACTTATAAccgcGGAACTTTAGATGAGT-3′ 1000 
CgPDR1D R, 5′-AACCCGATACTGagcTcTTAAGTAAGGA-3′  
CgPDR1E F, 5′-ATAATTGTGGGTAccACTAGGTATTAGG-3′ 4295 
CgPDR1F R, 5′-TATAATAAATGggCccATCAACGAAGGT-3′  
   
Primers used for quantitative real-time PCR expression analysis  
18S rRNA F, 5′-TCGGCACCTTACGAGAAATCA-3′ 
R, 5′-CGACCATACTCCCCCCAGA-3′ 
52 
CgPDR1 F, 5′-TTTGACTCTGTTATGAGCGATTACG-3′ 
R, 5′-TTCGGATTTTTCTGTGACAATGG-3′ 
51 
CgCDR1 F, 5′-CATACAAGAAACACCAAAGTCGGT-3′ 
R, 5′-GAGACACGCTAACGTTCACCAC -3′ 
71 
CgPDH1 F, 5′-ACGAGGAGGAAGACGACTACGA-3′ 
R, 5′-CTTTACTGGAGAACTCATCGCTGT-3′ 
63 
CgSNQ2 F, 5′-CGTCCTATGTCTTCCTTACACCATT-3′ 
R, 5′-TTTGAACCGCTTTTGTCTCTGA-3′ 
57 
 
Primers used for sequencing CgPDR1 
CgPDR1seq F, 5′-GGTAAAGTCATTCTTTAGCTACG-3′ 
R, 5′-TACAGGCTATGCACACTGTCT-3′ 
3393 
CgPDR1seqA1 F, 5′-GAAACTCCTATGTCCTCAACA-3′  
CgPDR1seqA2 F, 5′-AAACTGATGAAAGAGACCT-3′  
CgPDR1seqA3 F, 5′-ACATCTGTTGCTTCTTCTTGA-3′  
CgPDR1seqA4 F, 5′-TAAAGAAGATACAGCAGCAGC-3′  
CgPDR1seqA5 F, 5′-TCTACCTCCGATGCTTCTA-3′  
CgPDR1seqB1 R, 5′-TACAGGAAGGCATTGACTTG-3′  
CgPDR1seqB2 R, 5′-TCTGCCATATTGATTAGCCT-3′  
CgPDR1seqB3 R, 5′-TTCAAAACCATAGTATTCGTCG-3′  
CgPDR1seqB4 R, 5′-TGGCTCATAAAGGTGAACAC-3′  
CgPDR1seqB5 R, 5′-CAGAAAGACCTCTATGGCAT-3′  
aF, Forward; R, Reverse 
bRestriction sites introduced into primers are underlined. 
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cloning kit (Invitrogen) as per manufacturer’s instructions. The resulting plasmid DNA 
was digested at the introduced KpnI and ApaI sites and cloned upstream of the SAT1 
flipper cassette in the corresponding KpnI and ApaI sites of plasmid pPDR1ABS2 to 
generated pPDR1SM1S2 (containing the CgPDR1 gene from isolate SM1), 
pPDR1SM3S2 (containing the CgPDR1 gene from isolate SM3), and pPDR16955S2 
(containing the CgPDR1 gene from isolate 6955). 
 
 
PDR1 Gene Disruption and Replacement by the SAT1-Flipper Method 
 
 Gene disruption and replacement was performed via the SAT1-flipper method 
described by Reuss et al. (2004). C. glabrata cells were transformed by the lithium 
acetate method (12) using about 1 μg DNA. Transformants were selected on YPD agar 
containing 200 μg/ml nourseothricin (Nou200) as described previously (176). The correct 
genomic integration was confirmed by Southern hybridization.  Subsequently, correct 
integrants were grown in YPD for 6-24 hours in order to induce expression of the flipper 
recombinase (FLP gene).  Individual colonies were replica plated on both YPD agar and 
YPD + Nou200 agar plates to select for cells in which successful excision of the SAT1-
flipper cassette had taken place; further confirmation of cassette excision was performed 
by Southern hybridization. 
 
 
Isolation of Genomic DNA and Southern Hybridization 
 
 Genomic DNA from C. glabrata was isolated as previously described (134). For 
confirmation by Southern hybridization, approximately 10 μg of genomic DNA was 
digested with the appropriate restriction enzymes, separated on a 1% agarose gel 
containing ethidium bromide, transferred by vacuum blotting onto a nylon membrane and 
fixed by UV-crosslinking. Hybridization was performed with the Amersham ECL Direct 
Nucleic Acid Labeling and Detection System (GE Healthcare; Little Chalfont 
Buckinghamshire, UK) as per manufacturer’s instructions. 
 
 
Drug Susceptibility Tests  
 
 Microdilution broth susceptibility testing was performed in duplicate according to 
the CLSI M27-A3 method in RPMI 1640 (Sigma) growth medium buffered with MOPS 
(Sigma). Microtiter trays containing serial dilutions of fluconazole were inoculated and 
incubated at 37˚C, and the minimum inhibitory concentration (MIC) was read at 24 and 
48 hours. The MIC was defined as the lowest concentration of drug that causes a 
significant decrease in turbidity (> 50%) compared to growth control. Candida krusei 
ATCC 6258 served as the quality control isolate. 
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Culture Growth for Microarray Experiments 
 
 For microarray performed on clinical isolates, one colony was grown overnight in 
YPD. Cells were then grown to mid-log phase (OD600 = 0.6-1.0) in 200 ml YPD and were 
harvested by centrifugation at 3,500 x g at 4˚C for 5 minutes. The medium was 
completely removed by aspiration and the cell pellets were stored at -80˚C until RNA 
preparation. 
 
 
RNA Preparation for Microarrays 
  
 Total RNA was isolated using the hot phenol method (190). Cells were suspended 
in 12 ml AE buffer (50 mM sodium acetate (pH 5.2), 10 mM EDTA), 800 μl 25% sodium 
dodecyl sulphate, and 12 ml acid phenol (Fisher Scientific) was added. This mixture was 
incubated for 10 min at 65˚C, vortexing every minute, stored on ice for 5 min, and 
subjected to centrifugation for 15 minutes at 12 000 x g. Supernatants were transferred to 
new tubes containing 15 ml chloroform, mixed, and subjected to centrifugation for 10 
minutes at 200 x g. The aqueous layer was transferred to a new tube containing 0.1 
volume 2M sodium acetate and 1X volume room temperature isopropanol and mixed. 
Total RNA was then collected by centrifugation at 17 000 x g for 40 minutes at which 
point the supernatant was discarded. The RNA pellet was washed with 5 ml 70% ethanol, 
and the resulting RNA was suspended in diethyl pyrocarbonate (DEPC)-treated water. 
 
 
Microarray cRNA Synthesis and Hybridization 
  
 C. glabrata microarrays were constructed as described previously (215). These 
custom Affymetrix NimbleExpress Arrays were manufactured by NimbleGen Systems 
per our specification (4). Two independent sets of RNA were used in these studies to 
prepare two independent cDNA samples. The purity and concentration of the RNA was 
examined by capillary electrophoresis using the RNA 6000 Nano laboratory-on-a-Chip 
kit and Bioanalyzer 2100 (Agilent Technologies; Waldbronn, Germany) as per 
manufacturer’s instructions. Fifteen μg total RNA was used for first- and second-strand 
cDNA synthesis using the SuperScript Double-Stranded cDNA synthesis kit (Invitrogen) 
and an oligo-dT24-T7 primer (Sigma) according to the manufacturer’s instructions. 
Using the T7 promoter-coupled double stranded cDNA as a template and the Bioarray 
High Yield RNA Transcript labeling kit (ENZO Diagnostics; Farmingdale, NY), cRNA 
was synthesized and labeled with biotinylated-UTP and -CTP by in vitro transcription. 
The synthesized double stranded cDNA was washed twice with 70% ethanol and 
suspended in 22 μl of DEPC-treated water. Reaction buffer, biotin-labeled 
ribonucleotides, dithiothreitol, RNase inhibitor mix and T7 RNA polymerase were added 
to the cDNA and incubated for 5 hours at 37˚C. The labeled cRNA was purified using a 
CHROMA SPIN-100 column (Clontech; Mountain View, CA) and precipitated with 
ethanol overnight at -20˚C. 
 
 53
 
 After the cRNA pellet was suspended in 10 μl of RNase-free water, 10 μg was 
fragmented by ion-mediated hydrolysis at 95˚C for 35 min in 100 mM Tris-acetate (pH 
8.1), 500 mM potassium acetate, 150 mM magnesium acetate. Using the Affymetrix 
Fluidics Station 450 and its standard EukGEWS2v5 protocol, the fragmented cRNA was 
hybridized to the C. glabrata NimbleExpress GeneChip arrays for 16 hours at 45˚C and 
then washed at 25˚C with 6X SSPE (1X SSPE: 0.18M NaCl, 10 mM NaH2PO4, 1 mM 
EDTA (pH 7.7)) + 0.01% Tween-20 followed by a stringent wash at 50˚C with 100 mM 
MES (2-(N-morpholino)ethanesulfonic acid), 0.1 M NaCl, 0.01% Tween-20. The arrays 
were stained with phycoerythrein-conjugated streptavidin (Molecular Probes; Eugene, 
OR) and the fluorescence intensities were determined using the GCS 3000 high-
resolution confocal laser scanner (Affymetrix, Santa Clara, CA). These images were 
analyzed using software resident in GeneChip Operating System v2.0 (GCOS; 
Affymetrix). Sample loading and variations in staining were standardized by scaling the 
average of the fluorescent intensities of all genes on an array to a constant target intensity 
of 250. The signal intensity for each gene was calculated as the average intensity 
difference, represented by [Σ(PM – MM)/number of probe pairs)], where PM and MM 
denote perfect-match and mismatch probes. 
 
 
Microarray Data Analysis   
 
 The scaled gene expression values from GCOS software were processed and 
analyzed using GeneSpring 7.2 software (Agilent Technologies). Probe sets were 
removed from analysis if they were called absent by the Affymetrix criterion and 
displayed an absolute value below 20 in all experiments. The expression value of each 
gene was normalized to the median expression of all genes in each chip as well as the 
median expression of that gene across all chips in the study. Pairwise comparison of gene 
expression was performed for each matched experiment. 
 
 
Quantitative Real-Time RT-PCR 
 
 An aliquot of RNA samples used in the microarray experiments was saved for 
follow-up quantitative RT-PCR studies along with a set of independently-obtained RNA 
samples from the same strains analyzed by microarray. First strand cDNAs were 
synthesized from 2 μg total RNA using the SuperScript First-Strand Synthesis System for 
RT-PCR (Invitrogen) as per the manufacturer’s instructions. All quantitative real-time 
PCR experiments were performed in triplicate using the 7000 Sequence Detection 
System (Applied Biosystems, Inc.; Foster City, CA). Independent PCRs were performed 
using the same cDNA for both the gene of interest and 18S rRNA, using the SYBR 
Green PCR Master Mix (Applied Biosystems). Gene-specific primers were designed for 
the gene of interest and 18S rRNA using Primer Express software (Applied Biosytems). 
The PCR conditions were as follows: AmpliTaq Gold activation at 95˚C for 10 minutes, 
40 cycles of a combination of denaturation at 95˚C for 15s and annealing/extension at 
60˚C for 1 min. A dissociation curve was generated at the end of each cycle to verify that 
a single product was amplified using the software provided with the 7000 Sequence 
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Detection System. The system software monitored the change in fluorescence of SYBR 
Green I dye in every cycle, and the threshold cycle (CT) above background for each 
reaction was calculated. The CT value of 18S rRNA was subtracted from that of the gene 
of interest to obtain ∆CT value. The ∆CT of an arbitrary calibrator (e.g. fluconazole-
susceptible isolate or untreated sample) was subtracted from the ∆CT value of each 
sample to obtain a ∆∆CT value. The gene expression level relative to the calibrator was 
expressed as 2-2∆∆CT. Statistical analysis was performed using Microsoft Office Excel 
2007. Relative changes were compared using the Student’s t-test. The statistical 
significance threshold was fixed at α -0.05. 
 
 
Sequence Analysis of C. glabrata CgPDR1    
 
 PDR1 coding sequences were amplified by PCR (Pfu DNA polymerase; 
Stratagene) of C. glabrata genomic DNA using the primers PDR1seqF and PDR1seqR 
(Table 3-2). Products were cloned into pCR-BLUNTII-TOPO® using the Zero Blunt® 
TOPO® PCR Cloning Kit (Invitrogen) and transferred into E. coli TOP10 cells with 
selection on LB agar plates containing 50 μg/ml kanamycin. Plasmid DNA was purified 
(QIAprep®; Qiagen; Germantown, MD) and sequenced on the ABI Model 3130XL 
Genetic Analyzer using the universal primers M13R and T7 and a set of ten primers 
(Table 3-2) that span both strands of the PDR1 coding sequence. The sequencing was 
performed using three sets of clones derived from three independent PCRs for each 
strain/isolate sequenced. 
 
 
RESULTS 
 
 
Genes Coregulated with CgCDR1 among Matched Sets of Clinical Isolates 
 
 As over-expression of CgPDR1 and several efflux pump genes regulated by 
Pdr1p (CgPDR1, CgCDR1, CgPDH1, and CgSNQ2) have previously been shown to be a 
mechanism of high-level azole resistance (21, 185, 210, 215), we first examined 
expression of these genes by real-time RT-PCR in four azole-resistant C. glabrata 
isolates as compared to their azole-susceptible parents.  Genes were considered to be 
differently expressed if the expression of that gene changed by at least ≥ 1.5 in the 
resistant isolate when compared to the matched susceptible isolate in three independent 
experiments.  We observed distinctly different expression patterns for CgPDR1, 
CgCDR1, CgPDH1, and CgSNQ2 in each of the azole-resistant isolates we examined 
(Figure 3-1). For example, CgPDR1 and CgPDH1 were upregulated in isolates SM3, 62-
17, 7755, but not 6955, CgCDR1 was upregulated in all four of the clinical azole-resistant 
isolates, and CgSNQ2 was only upregulated in isolate SM3.  
 
 Because CgCDR1 was upregulated in all four azole-resistant isolates, we analyzed 
the genome-wide gene expression profiles of each isolate pair using microarray analysis 
in order to identify genes co-regulated with this transporter gene. Two independent RNA 
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Figure 3-1.  Quantitative real-time RT-PCR analysis of CgPDR1, CgCDR1, CgPDH1, 
and CgSNQ2 in SM3 versus SM1 (Set 1), 62-17 versus 62-16 (Set 2), 7755 versus 7754 
(Set 3), and 6955 versus 6856 (Set 4). Data are shown as mean +/- standard error. 
Relative changes were compared using the Student’s t-test. Gene expression values with 
an asterisk indicate statistical significance (P < 0.05) in all three experiments. 
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samples per isolate were hybridized to custom C. glabrata Affymetrix microarrays and 
analyzed as detailed in the Materials and Methods section. Genes were considered to be 
differentially expressed if the expression of that gene changed by at least ≥ 1.5 in the 
resistant isolate when compared to the matched susceptible isolate in both independent 
experiments. There were 495 upregulated genes and 477 down-regulated genes in isolate 
SM3 compared to isolate SM1, 463 upregulated genes and 386 down-regulated genes in 
isolate 6955 compared to isolate 6856, 599 upregulated genes and 592 down-regulated 
genes in isolate 7755 compared to isolate 7754, and 181 upregulated genes and 152 
down-regulated genes in isolate 62-17 compared to isolate 62-16 (Figure 3-2). Genes that 
were upregulated and down-regulated in at least three of the four clinical isolate sets are 
listed in Tables 3-3 and 3-4, respectively. 
 
 Of all the genes identified in the gene expression profiles for these four matched 
pairs, there were nine genes that were commonly coordinately upregulated with 
CgCDR1: YOR1, LCB5, RTA1, YIM1, YIL077c, POG1, HFD1, GLK1, and FMS1. One of 
these genes encodes the homolog of S. cerevisiae Yor1p, which like CgCDR1 is a plasma 
membrane ABC transporter. Another encodes the homolog of S. cerevisiae Lcb5p which 
is a minor sphingoid long-chain base kinase involved in synthesis of long-chain base 
phosphates which function as signaling molecules (144). RTA1, YIM1, and YIL077c are 
homologs of S. cerevisiae genes and encode molecules involved in stress response. For 
example, the S. cerevisiae homolog of RTA1 is involved in 7-aminocholesterol resistance 
(201). In addition to the aforementioned upregulated genes, there were three down-
regulated genes common to all four sets of clinical isolates. These include the 
uncharacterized gene CAGL0A03608g and homologs of S. cerevisiae SNG1 and SUR7.  
 
 There were 43 genes upregulated in at least three of the clinical matched sets of 
isolates. Among these genes were CgPDR1 and the ABC transporter, CgPDH1, both 
consistent with our real-time RT-PCR results. In addition to CgPDH1, there were two 
other upregulated genes encoding transporters, namely, YBT1 and QDR2. Also, 
upregulated in this set were RPN4 and YMR102c, genes whose S. cerevisiae homologs 
were previously shown to be ScPdr1p and ScPdr3p targets (8, 157). Other notable genes 
upregulated in at least three sets included MNT3 and MKC7, whose S. cerevisiae 
homologs are involved in cell wall function, and YMR102c and YML131w, each encoding 
putative alcohol dehydrogenases involved in stress responses. There were 16 genes 
down-regulated in at least three of the matched sets; among these are genes encoding the 
major facilitator transporters HXT3 and FLR1, genes encoding cell wall organization 
molecules UTR1 and ZEO1, the cytochrome c oxidase gene COX12, and the iron-
regulating gene FRA2.  
 
 
Identification of PDR1 Mutations in Azole Resistant Clinical Isolates 
 
  The findings that the expression of CgCDR1 and CgPDH1 as well as homologs of 
other known S. cerevisiae Pdr1p and Pdr3p targets were increased in many of the 
fluconazole-resistant clinical isolates suggested that the resistant isolate in each set may 
contain CgPDR1 gain-of-function mutations. We therefore sequenced the CgPDR1gene 
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Figure 3-2.  Venn Diagram showing the number of genes that are upregulated (A) or 
down-regulated (B) in the fluconazole-resistant isolates SM3, 62-17, 7755, and 6955 as 
compared to their matched fluconazole-susceptible isolates SM1, 62-16, 7754, and 6856, 
respectively. 
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Table 3-3.  Genes upregulated in all four of the clinical matched isolate sets (A) and in at least three of the clinical matched sets (B, C, 
D, and E).  
 
Letter 
designationc 
Systematic 
name  
S. cerevisiae 
homologa 
C. glabrata 
designation  Description
b 
A IPF1617 POG1 CAGL0G08646g Putative transcriptional activator  
A IPF2180 HFD1 CAGL0K03509g Putative fatty aldehyde dehydrogenase 
A IPF3783 GLK1 CAGL0F00605g Glucokinase 
A IPF5152 RTA1 CAGL0K00715g Protein involved in 7-aminocholesterol resistance 
A IPF6116 YIL077c CAGL0M12947g Putative protein of unknown function 
A IPF6352 PDR5 (CDR1) CAGL0M01760g Plasma membrane ATP-binding cassette (ABC) transporter 
A IPF8922 YOR1 CAGL0G00242g Plasma membrane ATP-binding cassette (ABC) transporter 
A IPF9036 YIM1 CAGL0M09713g Protein of unknown function 
A IPF9610 FMS1 CAGL0M07612g Polyamine oxidase 
A IPF8678 LCB5 CAGL0K05995g Minor sphingoid long-chain base kinase 
B IPF2441 IMH1 CAGL0E03454g Protein involved in vesicular transport 
B IPF2464 ECM29 CAGL0E03828g Major component of the proteasome 
B IPF3052 YCR061w CAGL0K09218g Protein of unknown function 
B IPF5973 FLO10 (EPA1) CAGL0E06644g Lectin-like protein with similarity to Flo1p, thought to be involved in flocculation 
B IPF7416 RSE1 CAGL0L01507g Protein involved in pre-mRNA splicing 
B IPF926 MNT3 CAGL0C03916g Alpha-1,3-mannosyltransferase 
B IPF3655 YLR177w CAGL0B01078g Putative protein of unknown function 
B IPF8402 MKC7 CAGL0E01837g GPI-anchored aspartyl protease (yapsin) involved in protein processing 
C IPF8399 YAP3 CAGL0E01793g Aspartic protease 
D IPF1455 MAG1 CAGL0I06809g 3-methyl-adenine DNA glycosylase  
D IPF4638 CAK1 CAGL0K12496g Cyclin-dependent kinase-activating kinase  
D IPF8257 YPT52 CAGL0G07689g GTPase 
D IPF4699 DOG2 CAGL0D04092g 2-deoxyglucose-6-phosphate phosphatase 
D IPF6780 YNL305c CAGL0M03839g Putative protein of unknown function 
E IPF119 DDR48 CAGL0H08844g DNA damage-responsive protein 
E IPF1620 QDR2 CAGL0G08624g Multidrug transporter of the major facilitator superfamily 
E IPF1748 YML018c CAGL0F03641g Putative protein of unknown function 
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Table 3-3 (continued). 
 
Letter 
designationa 
Systematic 
name  
S. cerevisiae 
homologb 
C. glabrata 
designation  Description
c 
E IPF2196 YMR102c CAGL0K03377g Protein of unknown function 
E IPF2382 YNL234w CAGL0J07502g Similar to globins and has a functional heme-binding domain 
E IPF2392 ZWF1 CAGL0J07612g Glucose-6-phosphate dehydrogenase (G6PD) 
E IPF3019 N/A CAGL0A01650g Uncharacterized 
E IPF3173 YNL134c CAGL0K09702g Putative protein of unknown function  
E IPF3325 PDR1 CAGL0A00451g Zinc-cluster transcription factor  
E IPF3846 NCE3 CAGL0G01540g Carbonic anhydrase 
E IPF3875 N/A CAGL0G01122g Uncharacterized 
E IPF4064 AIM6 CAGL0C05533g Putative protein of unknown function 
E IPF4550 UTH1 CAGL0L05434g Mitochondrial outer membrane and cell wall localized SUN family member  
E IPF4605 YML131w CAGL0K12958g Putative protein of unknown function  
E IPF4884 ATF2 CAGL0D05918g Alcohol acetyltransferase 
E IPF5076 RPN4 CAGL0K01727g Transcription factor that stimulates expression of proteasome genes 
E IPF6034 ADH6 CAGL0M14047g NADPH-dependent medium chain alcohol dehydrogenase 
E IPF6722 MET2 CAGL0J08316g L-homoserine-O-acetyltransferase 
E IPF734 MET3 CAGL0B03839g ATP sulfurylase 
E IPF7414 EFF2 CAGL0L01485g ER localized integral membrane protein 
E IPF7952 YNL144c CAGL0J05830g Putative protein of unknown function 
E IPF7953 IRC24 CAGL0J05852g Putative benzil reductase 
E IPF8009 YJL163c CAGL0M08426g Putative protein of unknown function 
E IPF9549 FLO1 CAGL0E00209g Lectin-like protein involved in flocculation 
E IPF9719 PDR15 (PDH1) CAGL0F02717g Plasma membrane ABC transporter 
E IPF982 YBT1 CAGL0C03289g Transporter of the ABC family involved in bile acid transport 
E IPF558 EAR1 CAGL0F07799g Specificity factor required for Rsp5p-dependent ubiquitination  
E IPF6631 CPS1 CAGL0C00319g Vacuolar carboxypeptidase yscS 
E IPF6862 WTM2 CAGL0J03960g Transcriptional modulator 
aLetters correspond to Figure 3-2A. 
bParentheses indicate a previously named C. glabrata gene. 
cDescriptions of S. cerevisiae homologs (see SGD website http://www.yeastgenome.org). 
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Table 3-4.  Genes down-regulated in all four of the clinical matched isolate sets (A) and in at least three of the clinical matched sets 
(C, D, and E).  
 
Letter 
designationa 
Systematic 
name 
S. cerevisiae 
homolog  
C. glabrata  
designation Description
 b 
A IPF1222 N/A CAGL0A03608g Uncharacterized 
A IPF1568 SNG1 CAGL0G09273g Protein involved in nitrosoguanidine (MNNG) resistance 
A IPF7418 SUR7 CAGL0L01551g Putative integral membrane protein 
C IPF14492 N/A CAGL0I00550g Uncharacterized 
D IPF1070 UTR2 CAGL0C02211g Cell wall protein that functions in the transfer of chitin to beta(1-6)glucan 
D IPF14989 COX12 CAGL0A03542g Subunit VIb of cytochrome c oxidase 
D IPF1884 CIT1 CAGL0H03993g Citrate synthase 
D IPF2023 NDH1 CAGL0I00748g Mitochondrial external NADH dehydrogenase 
D IPF2970 HXT3 CAGL0A02321g Low affinity glucose transporter of the major facilitator superfamily 
D IPF3326 PUF4 CAGL0A00473g Member of the PUF protein family 
D IPF4392 FLR1 CAGL0H06017g Plasma membrane multidrug transporter of the major facilitator superfamily 
D IPF453 FET3 CAGL0F06413g Ferro-O2-oxidoreductase  
D IPF8122 PNS1 CAGL0L04378g Protein of unknown function 
D IPF126 PUF2 CAGL0H08778g Member of the PUF protein family 
D IPF3165 SHE2 CAGL0K07612g RNA-binding protein that binds specific mRNAs and interacts with She3p 
E IPF14693 FRA2 CAGL0I06985g Protein involved in negative regulation of transcription of iron regulon 
E IPF3506 FMP45 CAGL0G05566g Integral membrane protein localized to mitochondria (untagged protein) 
E IPF9174 ZEO1 CAGL0E02255g Peripheral membrane protein of the plasma membrane that interacts with Mid2p
E IPF9228 BUD22 CAGL0M07678g Protein involved in bud-site selection 
aLetters correspond to Figure 3-2B. 
bDescriptions of S. cerevisiae homologs (see SGD website http://www.yeastgenome.org). 
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from each of the susceptible and resistant isolates. Of the four resistant isolates, two 
contained nucleotide changes in CgPDR1 as compared to their corresponding susceptible 
parent isolates. Isolate SM3 contained a T2837C mutation which is predicted to result in 
the amino acid substitution L946S, located in the putative transcriptional activation 
domain of Pdr1p as assumed by similarity with ScPdr1p and ScPdr3p (216). Isolate 6955 
contained a G822T mutation which is predicted to result in the amino acid substitution 
K274N, located near the putative inhibitory domain (Figure 3-3). Although no mutation 
was found in the resistant isolate 62-17, the susceptible isolate 62-16 was found to 
contain a nucleotide deletion, resulting in a frameshift which would presumably lead to a 
truncated Pdr1p in this isolate. We also aligned the sequences from all published 
CgPDR1 sequences from fluconazole-susceptible isolates and identified two mutations 
unique to CgPdr1p in 62-16 and 62-17 that resulted in N768D and S888L amino acid 
substitutions (68, 210, 212). Surprisingly, no PDR1 mutation was found in isolate 7755 
when compared to the susceptible matched isolate 7754.  
 
 
T2837C and G822T Are Gain-of-Function Mutations in CgPDR1 and Each Confer 
Increased Resistance to Fluconazole 
 Single point mutations in CgPDR1 in C. glabrata have previously been shown to 
play a role in azole resistance (68, 215). Therefore, to test whether the L946S and K274N 
substitutions in CgPdr1p are responsible for the increase in fluconazole MIC in isolates 
SM3 and 6955, respectively, we expressed the mutated CgPDR1 from SM3 and 6955 in 
the isolate SM1 background. For this purpose, we deleted CgPDR1 from isolate SM1 
using the SAT1-flipping method strategy to generate strain SM1pdr1(176). The mutated 
CgPDR1 alleles, PDR1T2837C and PDR1G822T, were then introduced individually into the 
CgPDR1 locus in strain SM1pdr1 to generate strains SM1pdr1/ PDR1L946S and 
SM1pdr1/ PDR1K274N. We also created the corresponding control strains by introducing 
CgPDR1 alleles from the susceptible isolates SM1 and 6856 to generate strains 
SM1pdr1/ PDR1SM1 and SM1pdr1/ PDR16856. Replacement of the different CgPDR1 
mutations was verified by sequencing the cloned CgPDR1 ORF PCR product as detailed 
in the Materials and Methods section.  
 
 Introduction of the two PDR1 mutations into the susceptible background 
(SM1pdr1) resulted in fluconazole MICs equivalent to those of the strains from which 
each CgPDR1 was originally identified (Table 3-5). Specifically, introduction of 
PDR1L956S resulted in a fluconazole MIC of 64 g/ml, and introduction of PDR1K274N 
resulted in a fluconazole MIC of 16 g/ml; whereas, the fluconazole MICs of SM1pdr1/ 
PDR1SM1 and SM1pdr1/ PDR16856 were measured as 2 g/ml and 1 g/ml, respectively 
(Table 3-5). As introduction of the CgPDR1 mutated alleles in the SM1 isolate 
background resulted in increased fluconazole MICs as compared to introduction of the 
alleles from isolates SM1 and 6856 in the same background, we have demonstrated that 
these CgPDR1 gain-of-function mutations are responsible for conferring decreased 
susceptibility to fluconazole in these C. glabrata isolates. Expression of the 62-17  
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Figure 3-3.  Location of gain-of-function mutations found in previous studies (63, 197, 199, 202) and in the present study (bolded). 
Putative DBD (DNA binding domain) and MHR (Middle homology region) were previously found by Pfam analysis (63). Putative 
AD (transcriptional activation domain) and ID (inhibitory domain) were previously inferred by similarity with Pdr1p and Pdr3p from 
S. cerevisiae (202). The region with diagonal lines corresponds to the xenobiotics binding domain (XBD) (194). 
W297S L328F R376W K274N F575L Y584C T588A T607S P822L D876Y P927L L946S D1082G E1083Q 
DB ID MH AD 
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Table 3-5.  Fluconazole MICs for each of the revertant strains as compared to the parent strains. 
 
Isolate set Isolate names WT MIC (μg/ml) SM1∆pdr1/PDR1 MIC (μg/ml) 
1 SM1 2  
 SM1∆pdr1 0.5  
 SM3 64 64 
2 62-16 0.5  
 62-17 16 16 
3 7254 16  
 7255 > 64 N/A 
4 6856 1  
 6955 16 16 
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CgPDR1 allele in the susceptible background also showed an increase in fluconazole 
resistance suggesting that this also represents a gain-of-function mutation (Table 3-5). 
 
 
Identification of Putative CgPDR1 Target Genes  
 
 In order to identify putative CgPDR1 target genes whose expression is affected by 
these gain-of-function mutations, we compared gene expression profiles of SM1pdr1/ 
PDR1T2837C and SM1pdr1/ PDR1G822T to SM1pdr1/ PDR1SM1 and SM1pdr1/ 
PDR16856, respectively. Again, two independent RNA samples per isolate were 
hybridized to custom C. glabrata Affymetrix microarrays and analyzed as detailed in the 
Methods section. Genes were considered to be differentially expressed if the expression 
of that gene changed by at least ≥ 1.5 when compared to the strains expressing the wild-
type CgPDR1 allele in the two independent experiments. There were142 genes were 
upregulated in the reconstituted strain expressing PDR1T2837C and of these genes 39 were 
also upregulated in SM3 compared to SM1. Thirty-four genes are upregulated in the 
reconstituted strain expressing PDR1G822T, and of these genes only six were also 
upregulated in 6955 compared to 6856. 626 genes were down-regulated in the 
transformants expressing PDR1T2837C, and of these genes 58 are also down-regulated in 
SM3 compared to SM1. Seventy-two genes are down-regulated in the transformants 
expressing PDR1G822T, and of these, ten genes are also down-regulated in 6955 compared 
to 6856. We defined putative core CgPdr1p target genes to be the genes that were not 
only upregulated in the transformants but also in the clinical isolate sets. These are 
summarized in Tables 3-6 and 3-7. As seen for SM3 compared to SM1, real-time RT-
PCR confirmed upregulation of CgCDR1, CgPDH1, and CgSNQ2 in SM1pdr1/ 
PDR1T2837Ccompared to SM1pdr1/ PDR1SM1. Also, as expected, real-time RT-PCR 
confirmed upregulation of CgCDR1 but not CgPDH1 and CgSNQ2 in SM1pdr1/ 
PDR1G822T compared to SM1pdr1/ PDR16856 (Figure 3-4).  
 
 In order to determine which genes’ promoters contain a putative PDRE, the 
promoter region (defined for this purpose as 1000 bp immediately upstream from the start 
codon of the ORF) of each gene listed in Tables 3-6 and 3-7 was examined for a match to 
the consensus S. cerevisiae PDRE. Twenty-two of the 39 genes in Table 3-6 and four of 
the six genes in Table 3-7 contained at least one consensus sequence.  
 
 
DISCUSSION 
 
 C. glabrata Pdr1p is the single-gene homolog of two S. cerevisiae zinc cluster 
transcription factors ScPdr1p and ScPdr3p, which regulate the expression of genes 
involved in multidrug resistance. ScPdr1p and ScPdr3p act by binding to PDREs in the 
promoters of target genes (95). Furthermore, it has been found that ScPdr1p is 
constitutively bound to its target DNA (65). In S. cerevisiae, gain-of-function mutations 
in Pdr1p and Pdr3p can result in decreased susceptibility to fluconazole by up-regulation 
of multidrug efflux pumps. In C. glabrata, CgPdr1p has been shown to regulate to 
varying degrees the expression of the ABC transporter genes CgCDR1, CgPDH1, and  
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Table 3-6.  Genes upregulated in SM1pdr1/ PDR1L946S compared to SM1pdr1/ PDR1SM1as well as SM3 compared to SM1. 
 
 
Group 
C. glabrata 
designation 
S. cerevisiae 
homolog Description 
Expression 
PDRE SM3 
vs. 
SM1 
PDR1SM3 
vs. 
PDR1SM1 
Transport CAGL0G08624g QDR2 MFS transporter  3.5 2.7 848 
CAGL0I04862g SNQ2 ABC transporter 3.7 5.4 218, 792 
CAGL0M01760g PDR5 ABC transporter 10.2 8.6 134, 227, 387, 515, 969 
CAGL0G00242g YOR1 ABC transporter 10.5 5.1 648 
CAGL0J09900g POR1 Mitochondrial porin 1.6 2.6 - 
CAGL0F02717g PDR15 ABC transporter 10.5 7.4 521, 557 
CAGL0C03289g YBT1 ABC transporter  8.1 3.9 450 
Transcription CAGL0A00451g PDR1 Transcription factor  5.2 3.6 557, 701 
CAGL0L05434g UTH1 Mitochondrial outer membrane and cell wall protein  2.9 2.3 - 
CAGL0K01727g RPN4 Transcription  3.1 3.4 378, 394, 552 
Response to  
stress 
CAGL0H08844g DDR48 DNA damage-responsive protein 5.1 1.7 - 
CAGL0I05874g RHR2 DL-glycerol-3-phosphatase 2.0 1.8 - 
CAGL0J04202g HSP12 Plasma membrane localized protein  4.1 16.4 849 
CAGL0M09713g YIM1 Protein of unknown function 11.5 11.8 127, 179 
CAGL0E00209g FLO1 Lectin-like protein  10.0 1.9 292, 427 
CAGL0D05918g ATF2 Alcohol acetyltransferase 7.2 6.8 30, 195, 560, 722 
CAGL0K00715g RTA1 Protein involved in 7-aminocholesterol resistance 5.0 3.6 300, 379 
CAGL0M12947g YIL077c Putative protein of unknown function 23.5 26.0 472, 502 
CAGL0I10120g AGA1 Anchorage subunit of a-agglutinin of a-cells 4.7 1.8 - 
Lipid  
metabolism 
CAGL0H04653g ERG6 Delta(24)-sterol C-methyltransferase 1.6 2.1 - 
CAGL0E04334g ERG11 Lanosterol 14-alpha-demethylase 1.9 1.9 _ 
CAGL0J11770g PLB1 Phospholipase B  2.3 2.8 754 
CAGL0A00429g ERG4 C-24(28) sterol reductase 2.0 1.8 - 
CAGL0F01793g ERG3 C-5 sterol desaturase 1.9 3.6 _ 
CAGL0I02970g ERG24 C-14 sterol reductase 1.9 2.0 226 
CAGL0M10219g LAC1 Ceramide synthase component 2.3 3.1 531 
Heterocycle 
metabolism 
CAGL0K12100g HEM13 Coproporphyrinogen III oxidase 2.9 1.9 - 
CAGL0M14047g ADH6 NADPH-dependent medium chain alcohol dehydrogenase  3.0 5.4 - 
Other CAGL0K03509g HFD1 Putative fatty aldehyde dehydrogenase 4.4 6.2 218 
CAGL0K10164g SED1 Major stress-induced structural GPI-cell wall glycoprotein  2.6 1.9 1046 
CAGL0M07942g FRE8 Protein with sequence similarity to iron/copper reductases 2.0 1.6 - 
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Table 3-6 (continued). 
 
Group C. glabrata designation 
S. cerevisiae 
homolog Description 
Expression 
PDRE SM3 
vs. 
SM1 
PDR1SM3 
vs. 
PDR1SM1 
Biological process 
unknown 
CAGL0K09702g YNL134c Putative protein of unknown function  13.0 7.6 549 
CAGL0G02717g SGA1  uncharacterized 2.5 2.6 - 
CAGL0F01287g GAS5 1,3-beta-glucanosyltransferase 1.7 5.8 - 
CAGL0G01122g N/A uncharacterized 4.2 3.9 803, 793 
CAGL0M08426g YJL163c Putative protein of unknown function 9.1 3.3 450 
CAGL0G07667g PRY1 Protein of unknown function 2.2 2.2 - 
CAGL0D06402g MET25 Methionine and cysteine synthase  4.9 1.7 - 
CAGL0A04906g STA1 GPI-anchored cell surface glycoprotein (flocculin)  25.9 11.7 - 
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Table 3-7.  Genes upregulated in SM1pdr1/ PDR1L946S compared to SM1pdr1/ PDR16856as well as 6955 compared to 6856. 
 
Group S. cerevisiae homolog 
C. glabrata 
designation Description 
Expression 
PDRE 6955 vs. 
6856 
PDR16955 vs. 
PDR16856 
Transport PDR5 CAGL0M01760g Plasma membrane ABC transporter 2.1 6.8 969, 515, 387, 227, 134 
 YOR1 CAGL0G00242g ABC transporter 1.8 2.4 648 
Response to stress YIM1 CAGL0M09713g Protein of unknown function 2.8 3.0 179, 127 
RNA metabolism PRP39 CAGL0L01441g U1 snRNP protein involved in splicing 1.7 1.6 - 
Other 
FLO10 CAGL0E06644g Lectin-like protein 1.9 3.3 571 
FLO5 CAGL0M14069g Lectin-like cell wall protein (flocculin)  2.1 1.6 - 
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Figure 3-4.  Quantitative real-time RT-PCR analysis of CgPDR1, CgCDR1, CgPDH1, 
and CgSNQ2 in SM1pdr1/ PDR1T2837Ccompared to SM1pdr1/ PDR1SM1 (Set 1), 
SM1pdr1/ PDR162-17compared to SM1pdr1/ PDR162-16 (Set 2), SM1pdr1/ PDR1G822T 
compared to SM1pdr1/ PDR16856 (Set 4). Data are shown as mean +/- standard error. 
Relative changes were compared using the Student’s t-test. Gene expression values with 
an asterisk indicate statistical significance (P < 0.05) in all three experiments. 
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CgSNQ2 and has been shown to be responsible for azole resistance in this organism. 
Recently, strains with CgPdr1p gain-of-function mutations were shown to not only result 
in fluconazole treatment failure in a mouse model but also to result in increased virulence 
in mice as compared to isolates with wild type alleles (68).  
 
Previously, we examined the gene expression profile of a set of fluconazole-
susceptible and laboratory-derived, fluconazole-resistant C. glabrata strains (215). In that 
analysis, we identified genes co-regulated with CgCDR1 in the F15 fluconazole-resistant 
strain which carries a CgPdr1p allele with a P927L amino acid substitution. In the present 
study we delineated core genes of the Pdr1p regulon by first using genome-wide gene 
expression profiling to identify genes co-regulated with CgCDR1 among four clinical 
matched fluconazole-susceptible and –resistant C. glabrata isolate pairs. We identified 
nine genes co-regulated with CgCDR1 in all four of the matched sets of clinical isolates. 
Of these nine genes, six of these, HFD1, RTA1, YIL077c, LCB5, YOR1, and YIM1, were 
also co-regulated with CgCDR1 in the laboratory-derived, fluconazole-resistant C. 
glabrata strain. Likewise, of the three genes found to be down-regulated in all four of the 
matched sets of isolates in this study, only one, SNG1, was found to be down-regulated in 
strain F15. Also in this study we identified 43 genes upregulated in at least three sets of 
clinical isolates. Of these, 13 genes, YLR177w, YPT52, PDR1, FLO1, YMR102c, RPN4, 
QDR2, YBT1, ATF2, CgPDH1, YNL134c, YJL163c, and NCE3 were also upregulated in 
strain F15. Likewise, of the 16 genes down-regulated in at least three sets, only one, 
FLR1, was also down-regulated in strain F15.  These findings suggest a broad repertoire 
of genes regulated by Pdr1p, but with subsets of these genes being differentially regulated 
possibly depending on how Pdr1p is activated.  
 
 Two novel gain-of-function mutations in CgPdr1p have been described in this 
study. Not only do these mutated CgPDR1 alleles cause up-regulation of CgCDR1 when 
expressed in a susceptible wild-type isolate, but they also result in the same fluconazole 
MIC as the original isolate from which the mutated allele was identified. In previous 
studies, 12 distinct experimentally confirmed activating CgPdr1p mutations from 
fluconazole-resistant isolates have collectively been identified that lead to constitutive 
up-regulation of ABC transporter genes as well as decreased susceptibility to fluconazole 
(68, 210, 212, 216). Three of these mutations were found in the putative inhibitory 
domain, four were found in the xenobiotic binding domain, and five were found in the 
putative activation domain of CgPdr1p. Interestingly, when examined collectively, the 
gain-of-function mutations identified in previous studies and the present study 
demonstrate varying patterns of ABC transporter expression. For example, in one of the 
previous studies, one gain-of-function mutation led to the over-expression of SNQ2 but 
not CgCDR1 and CgPDH1 (210). In our study, we identified mutations resulting in an 
amino acid substitution near the putative inhibitory domain (K274N) and in an amino 
acid substitution in the putative activation domain (L946S) of Pdr1p (68, 216). The 
K274N amino acid substitution resulted in up-regulation of CgCDR1, CgPDH1, and 
CgSNQ2 while the L946S amino acid substitution resulted in up-regulation of only 
CgCDR1. These findings suggest that different amino acid changes in CgPdr1p may each 
result in the activation of a unique subset of genes. Like Pdr1p in S. cerevisiae, CgPdr1p 
may bind constitutively to the promoters of a repertoire of genes and activate a subset of 
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them based on the mechanism by which Pdr1p is activated (65). Gain-of-function 
mutations in the activation domain may result in constitutive activation of CgPdr1p, 
while mutations in the inhibitory domain may block inhibitory proteins from binding thus 
allowing transcription of CgPDR1. Another possibility for constitutive activation of 
CgPdr1p is gain-of-function mutations in the xenobiotic binding domain. It has been in 
shown that Pdr1p in S. cerevisiae and C. glabrata bind directly to ketoconazole resulting 
expression of ABC transporters. In the aforementioned studies, four mutations have been 
identified in this domain; these gain-of-function mutations may allow for constitutive 
activation of CgPdr1p without the binding of xenobiotics to this domain (68, 212). 
 
 Using genome-wide analysis of these different mutations in the same background 
strain, we were able to identify a core set of Pdr1p activated genes that are co-regulated 
with CgCDR1. YOR1, YIM1, CgPDR1, and YNL134c were all co-regulated with CgCDR1 
specifically in the presence of both of these two mutations. In S. cerevisiae, YOR1 
encodes an ABC transporter that is involved in oligomycin resistance (96), and YIM1 and 
YNL134c encode proteins of unknown function; however, both genes may play a role in 
the stress response to DNA damaging drugs (22, 115). All five of these genes contain at 
least one PDRE in their promoters suggesting CgPdr1p may regulate their expression 
through binding these regulatory elements. Of note, both YOR1 and YIM1 were also 
upregulated in all four of the matched sets of clinical isolates. Further studies are needed 
to determine if these genes contribute to fluconazole resistance. 
 
 Table 3-6 summarizes the genes found to be both upregulated due to the L946S 
amino acid substitution and genes found to be upregulated in the resistant isolate SM3 
when compared to the susceptible isolate SM1. We have defined these genes as the core 
Pdr1p putative target genes activated in this resistant isolate. Interestingly, there were 
several ABC transporters co-regulated with CgCDR1 by Pdr1p, including CgSNQ2, 
CgPDH1, YOR1, and YBT1. Also, upregulated was the MFS transporter, QDR2. All of 
these transporters contain at least one PDRE in their promoter region. The role of 
CgCdr1p, CgPdh1p, and CgSnq2p in azole resistance has been established in C. glabrata 
(90, 210, 215). In the first of these studies, disruption of CgPDR1 in a resistant C. 
glabrata isolate resulted in fluconazole hypersusceptibility with an MIC of 2 g/ml, 
whereas the susceptible isolate had an MIC 16 g/ml; however, disruption of CgCDR1 in 
this same strain resulted in an MIC of 16 g/ml (215).  This suggested CgPdr1p targets 
other than CgCDR1 play a role in the fluconazole resistance. Indeed, disruption of 
CgSNQ2 in a fluconazole-resistant clinical isolate that does not over-express CgCDR1 or 
CgPDH1 decreased azole resistance (210). Furthermore, disruption of CgPDH1 in a 
fluconazole resistant strain had no effect on susceptibility to fluconazole; however, 
restoring CgPDH1 expression in a mutant disrupted for both CgCDR1 and CgPDH1 
decreased susceptibility to fluconazole as compared to the double disruptant. The role of 
YBT1 and QDR2 in fluconazole resistance has yet to be studied in C. glabrata.  
 
 In S. cerevisiae, Upc2p is a zinc-cluster protein known to not only regulate 
expression of ergosterol biosynthesis genes, including the target of the azoles encoded by 
the gene ERG11, but also genes encoding proteins involved in exogenous sterol uptake, 
cell wall mannoproteins (DAN/TIR genes), as well Upc2p itself (224). Interestingly, 
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UPC2 as well as its known S. cerevisiae homolog target genes, ERG11, ERG3, AUS1, 
DAN4, TIR3, and TIR4 are upregulated in SM3 (1, 217, 224). Also upregulated in isolate 
SM3 are the zinc-cluster protein-encoding genes HAP1 and STB5. In S. cerevisiae, HAP1 
encodes a transcription factor that regulates expression of the ERG11 gene, and it has 
been postulated that this may occur by an interaction with Upc2p (213, 217). In S. 
cerevisiae, STB5 also encodes a transcription factor that has been identified as a regulator 
of ergosterol biosynthesis as it is a direct activator of ERG11 in the presence of oxidative 
stress (114). Based on the hypothesis that mutations in one of these transcription factors 
may be responsible for the over-expression of ERG11 in SM3, we sequenced both UPC2 
S. cerevisiae homologs (CAGL0C01199g and CAGL0G07018g), ERG11 
(CAGL0E04334g), HAP1 (CAGL0K05841g), and STB5 (CAGL0I02552g) from isolates 
SM1 and SM3. However, no mutations were found in these genes in SM3 as compared to 
SM1 (data not shown). Surprisingly, several genes encoding proteins involved in the 
ergosterol biosynthetic pathway were also found to be CgPdr1p-dependent unique to this 
gain-of-function mutation including ERG11 and four enzymes downstream from Erg11p 
in this biosynthetic pathway encoded by the genes ERG24, ERG6, ERG3, and ERG4. Of 
these only ERG24 contains a PDRE in its promoter region. Further study will be needed 
to determine if ERG11 is directly or indirectly regulated by this hyperactive CgPDR1 
allele.  
 
 Other genes found to be Pdr1p-dependent unique to this gain-of-function mutation 
included the S. cerevisiae homolog of the transcription factor RPN4 which also contains 
two PDREs in its promoter. In S. cerevisiae, RPN4 is a transcription factor whose 
expression is dependent on ScPdr1p and ScPdr3p, that stimulates expression of 
proteasome genes, and is required for normal cell tolerance to various cytotoxic 
compounds including cycloheximide, a known ABC transporter substrate (157). Together 
these findings suggest the proteosome may be influenced by Pdr1p via RPN4 expression; 
however, its role in azole resistance has not been elucidated. Lastly, other genes found to 
be CgPdr1p-dependent unique to this gain-of-function mutation included the homologs of 
the S. cerevisiae genes that encode proteins involved in stress response such as DDR48, 
HSP12, YIM1, FLO1, ATF2, and RTA1. As with YIM1, RTA1 is also upregulated in all 
four of the matched sets of clinical isolates. In S. cerevisiae, RTA1, which is also known 
to be regulated by ScPdr1p and ScPdr3p, encodes a protein member of the fungal lipid-
translocating exporter family and is involved in 7-aminocholesterol resistance; however, 
the role of RTA1 in azole resistance has not been studied in S. cerevisiae or C. glabrata. 
In C. albicans, over-expression of RTA2, which encodes a S. cerevisiae homolog of 
RTA1, in a C. albicans strain with deletions of CDR1, CDR2, and MDR1 conferred 
increased resistance to azoles suggesting a role for this protein family in azole resistance 
(92).  
 
 Recently, it was shown that C. glabrata strains expressing hyperactive CgPDR1 
alleles were more virulent in mice than the C. glabrata strains expressing wild-type 
alleles (68). Our study has also allowed for the identification of CgPdr1p targets that may 
play a role in virulence. Of note, PLB1, the homolog of the S. cerevisiae gene that 
encodes phospholipase B, is not only upregulated in the resistant isolate SM3 but also 
was found to be CgPdr1p-dependent. Moreover, PLB1 contains a PDRE in its promoter.  
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In C. albicans, phospholipase B activity is involved in the spread of the organism from 
the gastrointestinal tract as well as in hematogenous dissemination (57, 142). To date, no 
published studies have analyzed the role of PLB1 in C. glabrata; however, one 
unpublished study did find an association between phospholipase B activity and 
persistent C. glabrata candidemia (74). 
 
 Consistent with the idea that adhesion of C. glabrata to host epithelial tissue plays 
an important role in virulence, the genes FLO1, FLO5, FLO9, FLO10, and FLO11, were 
found to be Pdr1p dependent.  The C. glabrata FLO genes are homologs of S. cerevisiae 
genes encoding proteins involved in cell adhesion (80). Only FLO1 and FLO10 contain 
PDREs in their promoters. In S. cerevisiae, FLO1, FLO5, FLO9, and FLO10 are all 
involved in cell-cell adhesion (flocculation), while FLO11 is involved in adhesion to 
substrates. Although FLO10 in S. cerevisiae is involved in flocculation, in C. glabrata 
this gene (named CgEPA1) is required for efficient in vitro adherence to human epithelial 
cells proving a role for CgEPA1 in adherence to abiotic materials (40). FLO5 and FLO9 
(CgEPA13) have been reported as members of the EPA family of adhesion proteins in C. 
glabrata; however, their role in adherence has not been directly studied. Moreover, the 
SM3 CgPDR1 hyperactive allele causes up-regulation of FLO1, FLO9, and FLO11, and 
the 6955 CgPDR1 hyperactive allele causes up-regulation of FLO5 and FLO10. 
Adhesion proteins in C. albicans have been shown to confer distinct adhesion profiles 
towards human proteins and cells (194). This may explain the difference in adhesion gene 
expression in our study as these isolates were isolated from different human tissues, SM3 
was isolated from the blood, and 6955 was isolated from the oral mucosa.  
 
 In this study, we also found two fluconazole-resistant isolates that did not contain 
a CgPDR1 mutation when compared to its susceptible match; however, both sets over-
expressed CgPDR1, CgCDR1, and CgSNQ2 when comparing the resistant isolate to its 
susceptible counterpart. However, the susceptible isolate 62-16 was found to have a 
nucleotide deletion resulting in a putative truncated CgPdr1p which may lead to its 
inactivation; this finding is consistent with the fluconazole MIC of this isolate. We 
compared the coding sequences of CgPDR1 in this isolate set to all published CgPDR1 
sequences and found two unique mutations whose expression in the susceptible 
background resulted in an increase in fluconazole MIC as well as over-expression of 
CgCDR1, suggesting that one or both of these represent gain-of-function mutations. 
Isolate 7755 had no mutation when compared to not only the susceptible isolate 7754 but 
all the published CgPDR1 sequences from susceptible isolates. Interestingly, CgPDR1 is 
constitutively overexpressed in isolate 7255 suggesting the existence of alternate 
mechanisms by which CgPDR1 can be activated. 
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CHAPTER 4. GENOME-WIDE GENE EXPRESSION PROFILING OF THE 
RESPONSE TO FLUCONAZOLE IN CANDIDA GLABRATA 
 
 
INTRODUCTION 
 
 Azole antifungal resistance has emerged as a significant problem in the 
management of infections caused by fungal species including Candida glabrata (21, 175, 
185).  Unlike Candida albicans, C. glabrata exhibits intrinsic reduced susceptibility to 
the azoles, including fluconazole. Consistent with this observation, multiple studies have 
shown that fluconazole use is a risk factor for development of invasive candidiasis caused 
by non-albicans candida species, including C. glabrata (25, 36, 147, 203). Furthermore, 
due to the fungistatic nature of fluconazole, C. glabrata and other Candida species 
demonstrate tolerance to this antifungal.  Tolerance is defined as the capacity of an 
organism to survive in the presence of a drug at growth-inhibiting concentrations. Azole 
tolerance may limit the efficacy of this class of antifungals, especially in 
immunocompromised patients, where the organism is able to survive in the presence of 
the drug and the immune system less able to clear the fungus. This may also contribute to 
the development of high level azole resistance in this patient population.  
 
 The ability of any organism to alter gene expression allows for adjustment to 
changes in its environment which is essential for its survival. Genome-wide expression 
studies of drug responses in Saccharomyces cerevisiae and Candida albicans have shown 
that such responses may be specific, reflecting the molecular target of the drug or may 
represent a more general stress response (2, 118). Moreover, the organism can also cope 
to changes in the environment with mechanisms that are neither general nor specific to 
the stressor. For example, not only do C. albicans upregulate genes in the ergosterol 
biosynthesis pathway in response to fluconazole, an antifungal drug that inhibits the 
ergosterol biosynthesis pathway, but also induces expression of drug efflux pumps (118). 
Understanding the initial stress response of C. glabrata to fluconazole may facilitate a 
better understanding of how this organism copes with such stresses to its environment. 
Moreover, such information may provide insight into the problem of intrinsic low-level 
resistance as well as azole tolerance in C. glabrata.  
 
 In an effort to characterize the initial stress responses of C. glabrata to 
fluconazole, we used microarray analysis to examine the gene expression profile of C. 
glabrata after exposure to this drug. As CgPDR1, a zinc cluster transcription factor, has 
been implicated as a key regulator of azole resistance and has been shown to be activated 
in response to azole exposure, we also identified genes that respond to fluconazole 
exposure in a CgPDR1-dependent fashion. Our results provide a more comprehensive 
picture of the gene expression changes of C. glabrata in response to fluconazole. Genes 
found to influence both intrinsic reduced susceptibility and tolerance to azoles will 
ultimately serve as targets for future work toward the development of compounds that 
will both abrogate resistance and enhance the therapeutic utility of this class of antifungal 
agent.  
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MATERIALS AND METHODS 
 
 
Antifungal Agent  
  
 Fluconazole was obtained from MP Biomedicals (Solon, Ohio). Stock solutions of 
10 mg/ml were made in dimethyl sulfoxide (DMSO, Sigma; St. Louis, Missouri) and 
stored at -20˚C. 
 
 
Strains and Growth Media  
 
 Strain 200989 (ura3/his3∆/trp1∆) was obtained from ATCC and strain 
200989∆pdr1 was kindly provided by Dr. Tom Edlind at Drexel University, Philadelphia, 
PA (63, 100). All isolates/strains used in these studies were grown in YPD (1% yeast 
extract, 2% peptone, and 1% dextrose) broth. All isolates/strains were grown at 30˚C and 
stored in 20% glycerol stocks at -80˚C.   
 
 
Cell Culture and Fluconazole Exposure for Microarray Experiments  
 
 A total of six 100 ml cultures of YPD medium were inoculated from an overnight 
(saturated) culture of C. glabrata to an initial A600 0.005 and grown at 30˚C until the A600 
reached 1.0 (~ 12 hours). The culture was then diluted to an A600 of 0.1 and grown until 
an A600 of 0.2 was reached (~ 2 hours). Fluconazole was then added at a final 
concentration of 64 μg/ml (two times the MIC) to three of the flasks). An equal volume 
of DMSO was added to the remaining three flasks to serve as the diluent control. DMSO 
concentrations were less than 0.05% and did not affect the growth curves of control 
cultures (data not shown). The cultures were grown for 2.5 hours. All cultures were 
harvested by centrifugation at 3,500 x g at 4˚C for 5 minutes. The medium was 
completely removed by aspiration and the cell pellets were stored at -80˚C until RNA 
preparation. 
 
 
Microarray cRNA Synthesis and Hybridization 
 
 C. glabrata microarrays were constructed as described previously (215). These 
custom Affymetrix NimbleExpress Arrays were manufactured by NimbleGen Systems 
per our specification (4). Two independent sets of RNA were used in these studies to 
prepare two independent cDNA samples. The purity and concentration of the RNA was 
examined by capillary electrophoresis using the RNA 6000 Nano laboratory-on-a-Chip 
kit and Bioanalyzer 2100 (Agilent Technologies; Waldbronn, Germany) as per 
manufacturer’s instructions. Fifteen μg total RNA was used for first- and second-strand 
cDNA synthesis using the SuperScript Double-Stranded cDNA synthesis kit (Invitrogen) 
and oligo-dT24-T7 primer (Sigma) according to the manufacturer’s instructions. Using 
the T7 promoter-coupled double stranded cDNA as a template and the Bioarray High 
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Yield RNA Transcript labeling kit (ENZO Diagnostics; Farmingdale, NY), cRNA was 
synthesized and labeled with biotinylated-UTP and -CTP by in vitro transcription. The 
synthesized double stranded cDNA was washed twice with 70% ethanol and suspended 
in 22 μl of DEPC-treated water. Reaction buffer, biotin-labeled ribonucleotides, 
dithiothreitol, RNase inhibitor mix and T7 RNA polymerase were added to the cDNA 
and incubated for 5 hours at 37˚C. The labeled cRNA was purified using a CHROMA 
SPIN-100 column (Clontech; Mountain View, CA) and precipitated with ethanol 
overnight at -20˚C. 
 
 After the cRNA pellet was suspended in 10 µL of RNase-free water, 10 μg was 
fragmented by ion-mediated hydrolysis at 95˚C for 35 min in 100 mM Tris-acetate 
(pH8.1), 500 mM potassium acetate, 150 mM magnesium acetate. Using the Affymetrix 
Fluidics Station 450 and its standard EukGEWS2v5 protocol, the fragmented cRNA was 
hybridized to the C. glabrata NimbleExpress GeneChip arrays for 16 hours at 45˚C and 
then washed at 25˚C with 6X SSPE (1X SSPE: 0.18M NaCl, 10 mM NaH2PO4, 1 mM 
EDTA (pH 7.7)) + 0.01% Tween-20 followed by a stringent wash at 50˚C with 100 mM 
MES (2-(N-morpholino) ethanesulfonic acid), 0.1 M NaCl, 0.01% Tween-20. The arrays 
were stained with phycoerythrein-conjugated streptavidin (Molecular Probes; Eugene, 
OR) and the fluorescence intensities were determined using the GCS 3000 high-
resolution confocal laser scanner (Affymetrix, Santa Clara, CA). These images were 
analyzed using software resident in GeneChip Operating System v2.0 (GCOS; 
Affymetrix). Sample loading and variations in staining were standardized by scaling the 
average of the fluorescent intensities of all genes on an array to a constant target intensity 
of 250. The signal intensity for each gene was calculated as the average intensity 
difference, represented by [Σ (PM – MM)/number of probe pairs)], where PM and MM 
denote perfect-match and mismatch probes. 
 
 
Microarray Data Analysis   
 
 The scaled gene expression values from GCOS software were processed and 
analyzed using GeneSpring 7.2 software (Agilent Technologies). Probe sets were 
removed from analysis if they were called absent by the Affymetrix criterion and 
displayed an absolute value below 20 in all experiments. The expression value of each 
gene was normalized to the median expression of all genes in each chip as well as the 
median expression of that gene across all chips in the study. Pairwise comparison of gene 
expression was performed for each matched experiment. 
 
 
Quantitative Real-Time RT-PCR   
 
 An aliquot of RNA samples used in the microarray experiments was saved for 
follow-up quantitative RT-PCR studies along with a set of independently-obtained RNA 
samples from the same strains analyzed by microarray. First-strand cDNAs were 
synthesized from 2 μg total RNA using the SuperScript First-Strand Synthesis System for 
RT-PCR (Invitrogen) as per the manufacturer’s instructions. All quantitative real-time 
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PCR experiments were performed in triplicate using the 7000 Sequence Detection 
System (Applied Biosystems, Inc.; Foster City, CA). Independent PCRs were performed 
using the same cDNA for both the gene of interest and 18S rRNA, using the SYBR 
Green PCR Master Mix (Applied Biosystems). Gene-specific primers were designed for 
the gene of interest and 18S rRNA using Primer Express software (Applied Biosytems) 
(Table 4-1). The PCR conditions were as follows: AmpliTaq Gold activation at 95˚C for 
10 minutes, 40 cycles of a combination of denaturation at 95˚C for 15s and 
annealing/extension at 60˚C for 1 min. A dissociation curve was generated at the end of 
each cycle to verify that a single product was amplified using the software provided with 
the 7000 Sequence Detection System. The system software monitored the change in 
fluorescence of SYBR Green I dye in every cycle, and the threshold cycle (CT) above 
background for each reaction was calculated. The CT value of 18S rRNA was subtracted 
from that of the gene of interest to obtain ∆CT value. The ∆CT of an arbitrary calibrator 
(e.g. fluconazole-susceptible isolate or untreated sample) was subtracted from the ∆CT 
value of each sample to obtain a ∆∆CT value. The gene expression level relative to the 
calibrator was expressed as 2-2∆∆CT. Statistical analysis was performed using Microsoft 
Office Excel 2007. Relative changes were compared using the Student’s t-test. The 
statistical significance threshold was fixed at α = 0.05. 
 
 In order to find putative targets of PDR1, UPC2, RLM1, and CRZ1 we used the 
Yeastact (Yeast Search for Transcriptional Regulators And Consensus Tracking) program 
available at http://www.yeastract.com/index.php  (137, 206). This program allows for the 
identification of transcription factor regulatory associations with target genes in S. 
cerevisiae based on more than 1000 bibliographic references. All genes (S. cerevisiae 
homologs) upregulated in response to fluconazole were uploaded to this program and 
direct or indirect target genes were searched. The promoters of these genes (1000bp 
upstream from start codon) were also searched for putative S. cerevisiae binding motifs 
(Pleiotropic Drug Response Element (PDRE); SRE (steroid response element); CDRE 
(Calcineurin Dependent Response Element); RRE (Rlm1p response element). 
 
 
RESULTS 
 
 
Global Changes in Gene Expression in Response to Fluconazole 
 
  An understanding of the initial stress responses of C. glabrata to fluconazole 
should allow for a better understanding of intrinsic azole resistance and tolerance in this 
organism. To identify genes that respond to fluconazole treatment, we used gene 
expression profiling to examine the initial response of C. glabrata in the presence of 
fluconazole. We exposed ATCC strain 200989 to 64 μg/ml fluconazole (2X MIC) for 2.5 
hours. Genes were considered to be differentially expressed if the expression of that gene 
changed reproducibly by at least ≥ 1.5 in the fluconazole-treated strain compared to the 
untreated strain. There were 714 genes, approximately 13% of the entire C. glabrata 
genome, was upregulated in response to fluconazole. Among these genes were S. 
cerevisiae homologs that are involved in transport, lipid metabolism, cell wall
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Table 4-1.  Primers used for quantitative real-time PCR expression analysis. 
 
Primer/Gene Primer paira Amplicon size (bp) 
18S rRNA F, 5′-TCGGCACCTTACGAGAAATCA-3′ 
R, 5′-CGACCATACTCCCCCCAGA-3′ 
52 
CgPDR1 F, 5′-TTTGACTCTGTTATGAGCGATTACG-3′ 
R, 5′-TTCGGATTTTTCTGTGACAATGG-3′ 
51 
CgCDR1 F, 5′-CATACAAGAAACACCAAAGTCGGT-3′ 
R, 5′-GAGACACGCTAACGTTCACCAC-3′ 
71 
CgYOR1 F, 5′-CCATCGGTGCTTGTGTAATGTTA-3′ 
R, 5′-TTGAGAGGCGTGGAAAAAATG-3′ 
68 
CgYBT1 F, 5′-AAGTGCTTCTTCCGCCTCATT-3′ 
R, 5′-AACAGGAGCTGGTGTAGTACCCA-3′ 
67 
CgFLR1 F, 5′-TGGCCTACTTCGGATTCTGTG-3′ 54 
 R, 5′-CCAAAAGGATGATGTATGCAAAAAT-3′  
CgUPC2 F, 5′-TTCTCTGGCTGCCGAATCA-3′ 51 
 R, 5′-ATCTTGCCTTTTTGCTCATCATAA-3′  
CgCSR1 F, 5′-TGGATTTTTTCTCCCATCTGGA-3′ 53 
 R, 5′-ACCACAGGGTCAAGCCATTTT-3′  
CgSAC7 F, 5′-TCTGGACGCAACGGGTTC-3′ 52 
 R, 5′-ACTCCTCAAGCGAGACACCAA-3′  
CgRTA1 F, 5′-TCCTGTTTGTCATTAGGGTTAGGG-3′ 51 
 R, 5′-TGGCAATTTTGTTCTTATTCCTCAG-3′  
aF, Forward; R, Reverse. 
 78
 
maintenance, and response to stress (Figure 4-1). Also upregulated were the  
transcriptional regulator PDR1, and homologs of the S. cerevisiae transcriptional 
regulators UPC2, CRZ1, RLM1, CIN5, and YAP1. Many targets and binding motifs of 
these transcription factors have been identified in S. cerevisiae. We used the World Wide 
Web based program, Yeastract, to identify putative targets of these transcriptional 
regulators (137, 206). The Yeastract program allows for analysis of transcription factor 
associations based on Chromatin immunoprecipitation (ChiP) as well as the effects of 
deletion of the transcription factor in S. cerevisiae. Furthermore, because of the 
evolutionary relatedness of S. cerevisiae and C. glabrata and the fact that binding motifs 
are usually highly conserved, the promoter region (defined for this purpose as 1000 bp 
immediately upstream from the start codon of the ORF) of each putative target gene was 
examined for a match to the consensus S. cerevisiae sequences for these transcription 
factors. Tables 4-2, 4-3, and 4-4 list the genes found to be putative targets of these 
transcriptional regulators as well as contain at least one putative binding motif. 
 Other genes of S. cerevisiae homologs found to be responsive to fluconazole 
treatment include genes involved in response to stress such as DDR48 (DNA damage-
responsive protein), and YIM1 (protein of unknown function). Additionally, several other 
stress response genes were upregulated in response to fluconazole treatment including 
genes encoding calcium-regulated signaling proteins CCH1 (voltage-gated high-affinity 
calcium channel), CMP2 (calcineurin A), PMR1 (Ca2+/Mn2+ P-type ATPase), CMK2 
(calmodulin-dependent protein kinase) and the aforementioned transcription factor, 
CRZ1. There were 905 genes, approximately 17% of the C. glabrata genome, were 
down-regulated by ≥ 1.5 fold in response to fluconazole (Figure 4-2). Real-time RT-PCR 
was used to confirm the expression of selected genes (Figure 4-3). 
 
 
Effects of CgPDR1 on Global Gene Expression Responses to Fluconazole 
  
 It has previously been shown that CgPDR1 is induced after treatment with 
fluconazole, suggesting a role for CgPdr1p in the initial stress response to fluconazole 
(215). To assess the role of Pdr1p on the stress response to fluconazole, we used a 
previously described strain in which CgPDR1 had been disrupted (200989∆pdr1), and we 
repeated the above experiment (63). Genes were defined as being CgPdr1p-dependent if 
the expression of that gene decreased by 50% after disruption of CgPDR1 in the presence 
of fluconazole in two independent experiments.  Surprisingly, only six genes were found 
to be Pdr1p-dependent (Table 4-5); however, only two of these genes were also 
upregulated in response to fluconazole. Among these were the aforementioned gene 
CgCDR1.  
 
 
DISCUSSION 
 
 Most C. glabrata isolates demonstrate intrinsic resistance to azole antifungals. 
Moreover, C. glabrata exhibits tolerance to azoles which allows this organism to survive 
in the presence of drug at growth-inhibiting concentrations. In an effort to identify genes 
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Figure 4-1.  Distribution of genes upregulated by ≥ 1.5 fold in response to fluconazole. Genes were annotated and assigned to 
functional categories based on the gene ontology (GO) annotation of its S. cerevisiae homolog.
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Table 4-2.  C. glabrata putative target genesa of Pdr1p upregulated by ≥ 1.5 fold in response to fluconazole. 
 
C. glabrata 
designation 
S. cerevisiae 
homolog Description 
Fold  
changeb PDRE
c 
CAGL0F08745g TMA10 Protein of unknown function that associates with ribosomes 28.3 -644 
CAGL0C00275g HSP31 Possible chaperone and cysteine protease  7.4 -932 
CAGL0M08426g YJL163c Putative protein of unknown function 7.2 -450 
CAGL0K10164g SED1 Major stress-induced structural GPI-cell wall glycoprotein  4.9 -996 
CAGL0K00715g RTA1 Lipid-translocating exporter (LTE) family of protein 4.3 -379;-300 
CAGL0A00451g PDR1 Zinc cluster transcription factor  3.8 -701;-557 
CAGL0M08822g HSP78 Oligomeric mitochondrial matrix chaperone  3.7 -298 
CAGL0G05962g YHR140w Putative integral membrane protein of unknown function 3.6 -276 
CAGL0M01760g PDR5  Plasma membrane ATP-binding cassette (ABC) transporter 3.5 -969; -515; -387; -227; -133 
CAGL0K09702g YNL134c Putative protein of unknown function  3.5 -549 
CAGL0K12958g YML131w Putative protein of unknown function  3.5 -594 
CAGL0G00242g YOR1 Plasma membrane ATP-binding cassette (ABC) transporter 3.2 -648 
CAGL0F02717g PDR15  Plasma membrane ATP binding cassette (ABC) transporter 2.6 -557;-521 
CAGL0A01199g DIP5 Dicarboxylic amino acid permease 2.5 -737 
aTranscription factor targets identified using Yeastract website (http://www.yeastract.com/index.php) (124, 193). 
bFold change defined as the ratio of fluconazole-treated 200989 versus untreated 200989. 
cPDRE (TCC(GA)(CT)G(GC)(AG). 
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Table 4-3.  C. glabrata putative target genesa of Upc2p, Crz1p, Rlm1p, and Cin5p upregulated by ≥ 1.5 fold in response to 
fluconazole. 
 
C. glabrata 
designation 
S. cerevisiae 
homolog Description 
Fold  
changeb Binding motif
c 
Putative Upc2p targets  SREc 
CAGL0K03421g PGM2 Phosphoglucomutase 3.9 -806 
CAGL0I02970g ERG24 C-14 sterol reductase, acts in ergosterol biosynthesis 1.8 -127 
CAGL0L10714g ERG2 C-8 sterol isomerase, acts in ergosterol biosynthesis 1.7 -926; -738 
Putative Crz1p targets CDREc 
CAGL0F08745g TMA10 Protein of unknown function that associates with ribosomes 27.3 -917‡ 
CAGL0J04158g WSP1 Protein of unknown function 6.8 -805† 
CAGL0K00715g RTA1 Lipid-translocating exporter (LTE) 3.3 -659‡ 
CAGL0A00517g PMC1 Vacuolar Ca2+ ATPase 2.6 -62‡ 
CAGL0C04961g ECM27 Non-essential protein of unknown function 2.6 -659† 
CAGL0J03432g ARK1 Serine/threonine protein kinase  2.3 -470‡ 
CAGL0M08206g YJL171c GPI-anchored cell wall protein  2.3 -520† 
CAGL0M02211g PEP4 Vacuolar aspartyl protease  2.0 -321‡ 
Putative Rlm1p targets RREc 
CAGL0F08195g MGA1 Protein similar to heat shock transcription factor 7.8 -328 
CAGL0H02563g YDR524c ADP-ribosylation factor  4.5 -144 
CAGL0H08844g DDR48 DNA damage-responsive protein 4.1 -975 
CAGL0J04466g YLR414c Putative protein of unknown function 3.7 -299 
CAGL0M12320g FLC2 Putative FAD transporter 3.6 -121 
CAGL0M04191g YPS1 Aspartic protease 3.5 -129 
CAGL0J00539g SLT2 Serine/threonine MAP  3.4 -269 
CAGL0G09449g CRH1 Putative chitin transglycosidase 3.4 -406 
CAGL0J11506g CHS1 Chitin synthase I 3.2 -197 
CAGL0G08646g POG1 Putative transcriptional activator  2.9 -295 
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Table 4-3 (continued). 
 
C. glabrata 
designation 
S. cerevisiae 
homolog Description 
Fold  
changeb Binding motif
c 
Putative Rlm1p targets, continued 
CAGL0B03619g PRB1 Vacuolar proteinase B (yscB) 2.7 -391 
CAGL0J01463g CWP1 Cell wall mannoprotein 2.6 -219 
CAGL0L00935g APQ12 Protein involved in nucleocytoplasmic transport of mRNA 2.3 -130 
CAGL0M08206g YJL171c GPI-anchored cell wall protein  2.3 -60 
CAGL0E01969g SMF1 Divalent metal ion transporter  2.2 -496 
CAGL0G04433g PRM10 Pheromone-regulated protein 1.9 -955 
CAGL0M03663g RIM21 Component of the RIM101 pathway 1.8 -212 
CAGL0H05621g RLM1 MADS-box transcription factor 1.8 -483 
Putative Cin5p targets CREc 
CAGL0K10164g SED1 GPI-cell wall glycoprotein  3.9 -143 
CAGL0K08162g GPT2 Glycerol-3-phosphate/dihydroxyacetone phosphate  3.2 -574;2190 
CAGL0G02937g PDC1 Major of three pyruvate decarboxylase isozymes 2.0 -444;-429 
CAGL0F07799g EAR1 Specificity factor required for Rsp5p ubiquitination  2.0 -613 
CAGL0J01353g YTA12 Protein of unknown function 1.8 -318 
CAGL0H05621g RLM1 MADS-box transcription factor 1.8 -393 
CAGL0E05610g CDC19 Pyruvate kinase 1.6 -937 
CAGL0K10890g OYE2 Widely conserved NADPH oxidoreductase  1.6 -517 
CAGL0M03377g GLC3 Glycogen branching enzyme 1.6 -900 
CAGL0D05698g MMM1 Mitochondrial outer membrane protein 1.6 -363 
aTranscription factor targets identified using Yeastract website (http://www.yeastract.com/index.php). 
bFold change defined as the ratio of fluconazole-treated 200989 versus untreated 200989. 
cSRE (5’-TCGTATA-3’) (217), CDRE (5’-GAGGCTG-3’)† or (GNGGC(G/T)CA) ‡ (227), RRE (5’-NTA(A/T)TAG-3’) (56), CRE 
(5’-TTACTAA-3’)(67).
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Table 4-4.  C. glabrata putative target genesa of CgAp1p upregulated by ≥ 1.5 fold in response to fluconazole. 
 
C. glabrata 
designation 
S. cerevisiae 
homolog Description 
Fold 
changeb 
Binding motif c 
A B C D 
CAGL0F08745g TMA10 Protein of unknown function that associates with ribosomes 27.3 - -443 - - 
CAGL0K04609g VHT1 High-affinity plasma membrane H+-biotin symporter 10.2 - -864;-474 - - 
CAGL0C02321g PHM8 Protein of unknown function 7.2 - - - -246 
CAGL0I06644g SED1 GPI-cell wall glycoprotein 6.0 - - -452 -708 
CAGL0L00759g HIS1 ATP phosphoribosyltransferase 6.0 - -173 - - 
CAGL0J00561g YHI9 Protein of unknown function 5.9 - -132 - -723 
CAGL0F07029g MET13 Major isozyme of methylenetetrahydrofolate reductase 5.5 - -485 - - 
CAGL0A04081g SRP40 Nucleolar, serine-rich protein  4.7 - - - -482 
CAGL0H06721g UBP7 Ubiquitin-specific protease  4.1 -526 - - -558 
CAGL0K10164g SED1 GPI-cell wall glycoprotein 3.9 -143 - - -155 
CAGL0G08338g YLR241w Putative protein of unknown function 3.5 -760;-225 - -  
CAGL0M11682g YLR108c Protein of unknown function 3.5 - - - -537;-281 
CAGL0H07359g PHO8 Repressible alkaline phosphatase 3.4 - - - -117 
CAGL0J03762g MET7 Folylpolyglutamate synthetase 3.4 -490 - - - 
CAGL0G09449g CRH1 Putative chitin transglycosidase 3.4 - - - -285 
CAGL0B03883g YMC1 Mitochondrial protein 3.3 - - -95 -920 
CAGL0H04983g PSA1 GDP-mannose pyrophosphorylase  3.2 -377;-59 - - - 
CAGL0K08162g GPT2 Glycerol-3-phosphate/dihydroxyacetone phosphate  3.2 -574  - - 
CAGL0D00770g IDP1 Mitochondrial NADP-specific isocitrate dehydrogenase 3.1 - -243 - - 
CAGL0I03806g BPL1 Biotin:apoprotein ligase 3.1 -  -357 - 
CAGL0M02167g PRM4 Pheromone-regulated protein 3.0 - - -408 - 
CAGL0M10417g RCR2 Vacuolar protein  2.9 - - - -39 
CAGL0H06699g GUT2 Mitochondrial glycerol-3-phosphate dehydrogenase 2.8 -47 - - - 
CAGL0A04477g UBP13 Putative ubiquitin carboxyl-terminal hydrolase 2.8 - - - -699;-134 
CAGL0I10626g YGR125w Putative protein of unknown function 2.7 - - -469 - 
CAGL0E02035g MCH4 Protein with similarity to monocarboxylate permeases 2.7 - -102 - -346 
CAGL0M06611g AVT7 Putative transporter 2.7 - - -470 - 
CAGL0I01210g CTM1 Cytochrome c lysine methyltransferase 2.7 - - - -678 
CAGL0M13189g MSN4 Transcriptional activator related to Msn2p 2.6 - -730 - - 
CAGL0K12034g ENA1 P-type ATPase sodium pump 2.6 - - - -26 
CAGL0E03025g YGR146c Putative protein of unknown function 2.6 - - - -607 
CAGL0A02574g TRP4 Anthranilate phosphoribosyl transferase  2.6 - -170 - - 
CAGL0L12012g TMT1 Trans-aconitate methyltransferase, 2.6 - - - -785;-211 
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Table 4-4 (continued). 
 
C. glabrata 
designation 
S. cerevisiae 
homolog Description 
Fold 
changeb 
Binding  motif c 
A B C D 
CAGL0J01463g CWP1 Cell wall mannoprotein 2.6 - - - -703;-173 
CAGL0M13651g PRC1 Vacuolar carboxypeptidase Y (proteinase C) 2.6 - - - -671 
CAGL0L02321g MET14 Adenylylsulfate kinase 2.6 - - - -741 
CAGL0L02607g YHR202w Putative protein of unknown function 2.6 - - - -12 
CAGL0M01760g PDR5 Plasma membrane ABC transporter 2.5 - - -540 - 
CAGL0K12958g YML131w Putative protein of unknown function  2.5  - - -909 
CAGL0E02409g CSI2 Protein of unknown function 2.4 - - - -91 
CAGL0H05687g SSU1 Plasma membrane sulfite pump 2.4 -633;-333 -570 - - 
CAGL0C02167g YFR039c Putative protein of unknown function 2.4 - - - -713 
CAGL0G05698g GDH2 NAD(+)-dependent glutamate dehydrogenase 2.4 -259 -952 - - 
CAGL0E01771g MKC7 GPI-anchored aspartyl protease (yapsin)  2.4 - - - -399 
CAGL0D02728g FMP34 Putative protein of unknown function 2.2 - - - -576 
CAGL0E04026g CBP2 Mitochondrial protein 2.2 - -304 - - 
CAGL0M08734g YDR262w Putative protein of unknown function 2.1 -565;-203 - - - 
CAGL0L01265g UTR1 ATP-NADH kinase 2.1 - - - -845 
CAGL0L04598g DCS1 Non-essential hydrolase involved in mRNA decapping, 2.1 -203 - - - 
CAGL0A00781g VPS8 Membrane-associated protein that interacts with Vps21p  2.0 - - - -688 
CAGL0G02937g PDC1 Major of three pyruvate decarboxylase isozymes 2.0 -444;-429 - -616 - 
CAGL0M11484g ARO1 Pentafunctional arom protein 2.0 - -111 - - 
CAGL0J08118g IST1 Protein with a role in the multivesicular body sorting pathway 1.9 -319 - - - 
CAGL0J06402g LYS21 Homocitrate synthase isozyme 1.9 - -718 -382 - 
CAGL0H08954g MRM2 Mitochondrial 2' O-ribose methyltransferase 1.9 - - - -447 
CAGL0J01353g YTA12 Protein of unknown function 1.8 -318 - - - 
CAGL0H05621g RLM1 MADS-box transcription factor 1.8 -393 - - -666;-75 
CAGL0F07359g YGL117w Putative protein of unknown function 1.8 - -288 - - 
CAGL0F04697g YLR257w Putative protein of unknown function 1.8 - -  -862 
CAGL0H04587g AVT6 Vacuolar amino acid transporter 1.7 - - -72 - 
CAGL0G05918g CHS7 Protein of unknown function 1.7 - - - -172 
CAGL0G05335g TPS2 Phosphatase of the trehalose-6-phosphate synthase/phosphatase  1.7 - - -712 - 
CAGL0G07293g USA1 Protein involved in ER-associated protein degradation (ERAD) 1.7 - - - -899 
CAGL0M04741g MPD1 Member of the protein disulfide isomerase (PDI) family 1.7 - - - -169 
CAGL0H05599g YDC1 Alkaline dihydroceramidase 1.7 - - -588 - 
CAGL0C02409g ZRG8 Protein of unknown function 1.7 - - - -498 
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Table 4-4 (continued). 
 
C. glabrata 
designation 
S. cerevisiae 
homolog Description 
Fold 
changeb 
Binding  motif c 
A B C D 
CAGL0H04103g UFO1 F-box receptor protein 1.7 - - - -133 
CAGL0A01243g GIT1 Plasma membrane permease 1.6 - - - -795 
CAGL0A01826g HXT5 Hexose transporter with moderate affinity for glucose 1.6 - - - -294 
CAGL0F06633g UBX4 UBX (ubiquitin regulatory X) domain-containing protein  1.6 - - - -34 
CAGL0J04752g TUS1 Guanine nucleotide exchange factor (GEF)  1.6 -400 - - - 
CAGL0L10912g TPO4 Polyamine transport protein 1.6 - - - -31 
CAGL0M04675g YOR285w Protein of unknown function 1.6 - - - -484 
CAGL0E05610g CDC19 Pyruvate kinase 1.6 -937 - - - 
CAGL0K10890g OYE2 Widely conserved NADPH  1.6 -517 - - -242 
CAGL0H03223g GUP1 Plasma membrane protein involved in remodeling GPI  1.6 - - - -701;-25 
CAGL0I01012g PEP12 Target membrane receptor (t-SNARE)  1.6 - - -930 - 
CAGL0D01584g JID1 Probable Hsp40p co-chaperone 1.5 - - - -376 
aTranscription factor targets identified using Yeastract website (http://www.yeastract.com/index.php). 
bFold change defined as the ratio of fluconazole-treated 200989 versus untreated 200989. 
cBinding motifs A 5’-TTACTAA-3’(67), B 5’-TGACTCA-3’(67), C 5’-TGACTAA-3’(149), D 5’-T(G/T)ACAAA-3’(84).
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Figure 4-2.  Distribution of genes downregulated by ≥ 1.5 fold in response to fluconazole. Genes were annotated and assigned to 
functional categories based on the gene ontology (GO) annotation of its S. cerevisiae homolog.
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Figure 4-3.  Quantitative real-time RT-PCR analysis of relative gene expression in 
200989 and 200989∆pdr1 treated with fluconazole versus 200989 treated with DMSO 
(control). Data are shown as mean ± standard error. Relative changes were compared 
using the Student’s t-test. Gene expression values with an asterisk indicate statistical 
significance (P < 0.05) in all three experiments. 
2009  
2009 Δ dr1 
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Table 4-5.  C. glabrata genes found to be Pdr1p-dependent in response to fluconazole. 
 
C. glabrata 
designation 
S. cerevisiae 
homolog Description 
Fold changea 
PDREb 200989F/
200989D 
200989∆pdr1F/ 
200989D 
CAGL0M01760g PDR5 Plasma membrane ABC transporter 2.8 0.6 134, 227, 387, 515, 969 
CAGL0C02915g YOR268c Putative protein of unknown function 2.2 1.0 - 
CAGL0D03652g SPT21 Protein required for normal transcription at 
several loci including HTA2-HTB2 and 
HHF2-HHT2 0.7 0.3 - 
CAGL0K07700g BUD27 Protein involved in bud-site selection, 
nutrient signaling, and gene expression 
controlled by TOR kinase 0.6 0.1 - 
CAGL0E02937g CGR1 Protein involved in nucleolar integrity and 
processing of the pre-rRNA for the 60S 
ribosome subunit 0.3 0.1 - 
CAGL0H09064g FUR1 Uracil phosphoribosyltransferase 0.4 0.2 - 
aFold change defined as the ratio of fluconazole-treated 200989 versus untreated 200989 or 200989∆pdr1 versus untreated 200989. 
bPDRE (TCC(GA)(CT)G(GC)(AG). 
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that may contribute to these phenotypes, we examined the response of C. glabrata to 
fluconazole treatment using genome-wide gene expression profiling.  
 
 As expected, fluconazole treatment induced the expression of CgPDR1 and many 
known genes encoding homologs of the S. cerevisiae ScPdr1p and ScPdr3p target genes. 
In S. cerevisiae, ScPdr1p and ScPdr3p have been named the master regulators of drug 
resistance, including resistance to azoles (141). In C. glabrata, CgPdr1p has been 
identified as the single homolog of ScPdr1p and ScPdr3p (215). This zinc cluster 
transcription factor is known to regulate the ATP binding cassette (ABC) transporters 
CgCDR1 and CgPDH1 which are also upregulated in the present study (215). The role of 
CgPdr1p in azole resistance has been studied extensively. Gain-of-function mutations in 
this transcriptional regulator have been shown to be responsible for the up-regulation of 
these ABC transporters and subsequent decrease in susceptibility to fluconazole (68, 210, 
212, 215). Recently it was shown that the regulation of C. glabrata Pdr1p is similar to 
regulation of multidrug resistance (MDR) in vertebrates by the PXR nuclear receptor as 
Pdr1p directly binds to fluconazole resulting in activation of drug efflux pumps (207). 
Consistent with this finding, in a previous study expression of CgPDR1 and its target 
genes, CgCDR1 and CgPDH1 are induced after treatment with fluconazole (215). 
Furthermore, in this same study disruption of CgPDR1 in a fluconazole susceptible 
isolate (fluconazole MIC of 16 μg/ml) resulted in fluconazole hypersusceptibility 
(fluconazole MIC of 2 μg/ml) suggesting that CgPDR1 plays an important role in the 
intrinsic fluconazole resistance of this species. To date, no study has conclusively studied 
the role of CgPdr1p in azole tolerance. 
 
  A recent study identified 22 genes that were essential for S. cerevisiae survival in 
the presence of fluconazole (91). Among the genes identified was the CgCDR1 S. 
cerevisiae homolog ScPDR5. Disruption of ScPDR5 in S. cerevisiae rendered fluconazole 
fungicidal to this mutant. Alternatively, disruption of CgCDR1 in C. glabrata in a 
fluconazole susceptible isolate (MIC 16 μg/ml) had no effect on fluconazole MIC; 
however, trailing growth, a phenomenon typical of Candida species, was eliminated 
(178, 216). The effect of CgCDR1 on the minimum fungicidal concentration (MFC) has 
not been measured in C. glabrata. Because disruption of CgPDR1 but not CgCDR1 
results in azole hypersensitivity, these results suggest that other CgPdr1p targets may be 
playing a role in intrinsic resistance. In order to determine which fluconazole-responsive 
genes are regulated by Pdr1p, we identified genes that respond to fluconazole in a Pdr1p-
dependent fashion by assessing which genes are no longer differentially expressed in 
response to fluconazole treatment in a pdr1 C. glabrata strain. As expected, CgCDR1 
was found to be upregulated in a CgPdr1p-dependent fashion; however, other known 
ScPdr1p-ScPdr3p target genes were not. This suggests that there are fluconazole-
responsive transcriptional factors, in addition to CgPdr1p, are able to regulate CgPdr1p 
target genes. In fact, of the putative Pdr1p targets listed in Table 4-2, TMA10 and RTA1 
are also putative Crz1p targets. Also, of all the genes YOR268c was also found to be 
Pdr1p-dependent. The function of this gene is unknown, but a S. cerevisiae strain 
disrupted for the homolog of this gene was found to be selenomethionine resistant (23). 
Surprisingly, only five other genes were found to be Pdr1p dependent; however, none of 
these were activated in response to fluconazole.  
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 Fluconazole acts by inhibiting lanosterol demethylase (ERG11) in the ergosterol 
biosynthesis pathway. A S. cerevisiae homolog of UPC2 which is known to induce 
transcription of both sterol biosynthesis genes and DAN/TIR genes was also upregulated 
in response to fluconazole. In addition, homologs of ScUpc2p target genes were also 
induced in the present study in response to fluconazole. These included genes encoding 
proteins involved in the ergosterol biosynthesis pathway (ERG1, ERG2, and ERG24) and 
heme biosynthesis (HEM13 and HEM14). It has been suggested that in S. cerevisiae 
heme may play an important role in sterol biosynthesis and regulate the transcription of 
several genes involved in this process (161). Upregulation of genes involved in sterol 
biosynthesis is consistent with inhibition of this pathway by fluconazole and has also 
been observed in S. cerevisiae and C. albicans (2, 118). Also upregulated in response to 
fluconazole were the homologs of S. cerevisiae Upc2p target genes involved in cell wall 
maintenance (DAN4, TIR1, and TIR3).  
 
 Another interesting observation is the up-regulation of homologs of the S. 
cerevisiae genes involved in calcium signaling (CCH1, CMP2, CRZ1, GSC2, and PMR1). 
In S. cerevisiae, CCH1 encodes a voltage-gated high-affinity calcium channel involved in 
calcium influx in response to some environmental stresses. A study in C. glabrata found 
that strains defective in the putative plasma membrane calcium channel (Cch1-Mid1) 
were not only defective in calcium uptake in response to fluconazole exposure but also 
showed a significant loss of viability upon prolonged fluconazole exposure (98). The 
authors concluded that in the absence of calcium signaling, fluconazole has a fungicidal 
effect on C. glabrata suggesting a role for calcium signaling in tolerance to azoles.  
Calcium influx leads to stimulation of the heterodimer protein phosphatase calcineurin 
which is encoded by CMP2 (catalytic A subunit) and CNB1 (calcium-binding regulatory 
unit) (Figure 4-4). In C. glabrata disruption of CNB1, the calcium-binding subunit of 
calcineurin, resulted in not only increased fluconazole susceptibility but also fungicidal 
activity to fluconazole in C. glabrata (136). The homolog of the S. cerevisiae gene CNB1 
is not upregulated in the present study; however, CMP2 which encodes one isoform of 
the catalytic subunit A of calcineurin is upregulated. Calcineurin dephosphorylates the 
transcription factor CRZ1 which then activates its target genes which include GSC2 
(encodes β-1, 3-glucan synthase) and PMR1 (encodes a Golgi-localized Ca2+/Mn2+ 
importer). In S. cerevisiae, disruption of CRZ1 enhanced azole sensitivity; however, 
disruption in of the CRZ1 homolog in C. glabrata does not (136). Thus, the precise 
mechanism calcineurin-dependent azole tolerance in C. glabrata remains to be 
discovered. Of note, of the Crz1p putative targets listed in Table 4-3 one gene encoding 
the S. cerevisiae homolog RTA1 is also upregulated. In S. cerevisiae, RTA1, which is also 
known to be regulated by ScPdr1p and ScPdr3p, encodes a protein member of the fungal 
lipid-translocating exporter family and is involved in 7-aminocholesterol resistance. In C. 
albicans, over-expression of RTA2, which encodes a S. cerevisiae homolog of RTA1, in a 
C. albicans strain with deletions of CDR1, CDR2, and MDR1 conferred increased 
resistance to azoles suggesting a role for this protein family in azole resistance (92). 
However, the role of RTA1 in azole tolerance has not been studied in S. cerevisiae or C. 
glabrata.  
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Figure 4-4.  Proposed model for the calcium-signaling pathway in C. glabrata. Calcium 
influx leads to stimulation of the heterodimer protein phosphatase calcineurin. 
Calcineurin dephosphorylates the transcription factor CRZ1 which then activates its target 
genes which include GSC2 (encodes β-1, 3-glucan synthase) and PMR1 (encodes a 
Golgi-localized Ca2+/Mn2+ importer).
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 In S. cerevisiae, the calcineurin and cell wall integrity (CWI) pathways function 
in parallel to induce FKS2 (CgGSC2) function in response to heat (229). The CWI 
pathway is the major signaling pathway regulated cell wall assembly. Of note, several 
genes encoding proteins involved in the CWI pathway were differentially expressed in 
response to fluconazole. Among these genes was the S. cerevisiae homologs MID2 which 
encodes a sensor for cell wall integrity signaling, SAC7 which encodes a GTPase 
activating protein for Rho1p, RLM1 which encodes a MADS-box transcription factor 
which is phosphorylated and activated by the MAP-kinase Slt2p, which is also 
upregulated in response to fluconazole (Figure 4-5). Recently, in S. cerevisiae SLT2 has 
been found to be essential for survival in the presence of fluconazole. Disruption of SLT2 
in S. cerevisiae decreased the MFC suggesting a role for SLT2 in fluconazole tolerance 
(91). In S. cerevisiae, Rlm1p is the transcription factor that regulates much of the 
transcriptional change upon Slt2p activation (93). We identified several putative Rlm1p 
targets involved in cell wall maintenance upregulated in response to fluconazole in this 
study such as the cell wall proteins CRH1 (putative chitin transglycosidase), CHS1 
(Chitin synthase I), CWP1 (Cell wall mannoprotein), and YJL171c (GPI-anchored cell 
wall protein). The activation of the cell wall integrity pathway may be vital in the 
presence of fluconazole for maintaining the structure of the cell wall to counteract the 
effects of reduced ergosterol production. 
 
 Also upregulated in response to fluconazole treatment were two bZIP 
transcription factors, YAP1 (CgAP1) and CIN5. CgAP1 and CIN5 both belong to the YAP 
(yeast activator protein) family of bZIP trans-activators that have been implicated in 
various forms of stress response in S. cerevisiae (180). In fact, YAP1 is known as the 
major regulator of oxidative stress in S. cerevisiae. In C. glabrata, a homolog of the S. 
cerevisiae YAP1 has been identified (CgAP1) and its function in multidrug resistance has 
been studied (37). Disruption of CgAP1 had no effect on fluconazole resistance. Also, a 
target of CgAP1 was identified, the major facilitator superfamily transporter FLR1. 
Interestingly, FLR1 in the present study was found to be down-regulated in response to 
fluconazole. In S. cerevisiae, FLR1 can be activated by not only Yap1p but also Pdr3p 
(29). In fact, of all putative Pdr1p direct and indirect target genes identified using 
Yeastact in this study, 43 genes were identified as also being putative Yap1p direct or 
indirect targets. Of note, PDR5, the S. cerevisiae homolog of CgCDR1 was among these 
genes. This supports the hypothesis that other fluconazole-responsive transcriptional 
factors, in addition to CgPdr1p, are able to regulate CgPdr1p target genes. The roles of 
these other transcriptional regulators (UPC2 and RLM1) in azole tolerance are under 
investigation. 
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Figure 4-5.  Cell wall integrity pathway in S. cerevisiae (116). Signals are initiated at the 
plasma membrane through cell surface sensors (Wsc1-4p and Mid2p). These sensors 
stimulate nucleotide exchange on Rho1p which then activates the Pkc1p-MAP kinase 
cascade. The MAP kinase, Slt2p, is activated by Pkc1p and downregulated by the MAP 
kinase phosphatases, Msg5p, Ptp2p, and Sdp1p. Slt2p then phosphorylates and activates 
Rlm1p. C. glabrata homologs of these genes that are upregulated in response to 
fluconazole in the present study are in red and homologs downregulated in response to 
fluconazole in the present study are in green. 
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CHAPTER 5. SUMMARY 
 
 
 Over the past two decades, Candida glabrata has become the one of the most 
common causes of fungal infections in humans, only second to Candida albicans. The 
azole class of antifungals is the most widely used antifungal for treatment of Candida 
infections. However, development of high-level resistance to the azoles has been reported 
in oral and bloodstream isolates from head and neck radiation patients, stem cell 
transplant patients, and human immunodeficiency virus (HIV) patients(122, 174, 175). C. 
glabrata, in addition, exhibits intrinsic increased susceptibility to the azoles, including 
fluconazole and can develop tolerance due to the fungistatic nature of azole antifungals. 
The fungistatic activity of fluconazole not only hampers its efficacy in 
immunocompromised patient populations but may also contribute to the development of 
high-level azole resistance.  
 
 Azole resistance in C. glabrata has been associated with the upregulation of the 
ABC transporters, CgCDR1 and CgPDH1. We have identified a transcriptional regulator 
of these transporters, CgPdr1p. Disruption of CgPDR1 not only resulted in decreased 
expression of these transporters, but also resulted in azole hypersusceptibility in a 
laboratory-derived fluconazole resistant C. glabrata isolate (Figure 5-1). This phenotype 
was attributed to a previously identified putative gain-of-function mutation. We next 
identified novel gain-of-function mutations in fluconazole-susceptible and –resistant 
matched sets of clinical isolates. These mutations conferred different levels of 
fluconazole susceptibility. Through genome-wide profiling, we also identified a core set 
of commonly differentially-expressed genes as well as genes uniquely regulated by 
specific mutations.  
 
 We have also demonstrated that the transcriptional regulator, CgPdr1p, in C. 
glabrata not only influences the development of azole resistance but also influences 
intrinsic resistance to azoles as disruption of CgPDR1 in a fluconazole-susceptible isolate 
rendered the strain hypersusceptible to fluconazole. However, disruption of CgCDR1 had 
minimal effect on the fluconazole susceptibility in the same susceptible isolate suggesting 
other CgPdr1p targets contribute to intrinsic resistance. An understanding of the initial 
stress response to fluconazole may not only facilitate a better understanding of intrinsic 
resistance but also how this organism is able to survive at growth inhibiting 
concentrations of fluconazole (tolerance).  As seen previously, our microarray data 
revealed that C. glabrata responds to the exposure to fluconazole by overexpressing 
CgPDR1 and two of its known target genes, CgCDR1 and CgPDH1, as well other 
putative CgPdr1p target genes. However, disruption of CgPDR1 only decreased the 
expression of CgCDR1 in response to fluconazole suggesting other transcriptional 
activators are able to regulate CgPdr1p target genes. Indeed, several other transcriptional 
regulatory pathways were also upregulated in response to fluconazole that have 
redundant Pdr1p targets in S. cerevisiae.  It is possible that these transcriptional 
regulatory pathways also contribute to this phenotype that are independent of the 
regulation of CgPdr1p targets. The roles of these additional transcriptional regulators in 
azole tolerance are under investigation.
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Figure 5-1.  Mechanism of CDR1 induction by Pdr1p. Fluconazole enters the cell by an 
unknown mechanism. It then inhibits lanosterol demethylase in the ergosterol 
biosynthesis pathway leading loss of normal sterols in the plasma membrane and a toxic 
metabolite. CgPdr1p is then activated either by gain-of-function mutations in CgPdr1p 
itself or by fluconazole directly binding to CgPdr1p thereby activating this transcriptional 
regulator by an unknown mechanism. CgPdr1p binds to the PDRE in the promoter of 
CgCDR1 allowing for transcription of this gene and ultimately efflux of fluconazole out 
of the cell.
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 Two of the transcriptional regulators, CgPdr1p and CgUpc2p, identified in these 
studies belong to a class of fungal specific transcriptional regulators, the zinc-cluster 
proteins. Development of a drug that inhibit these transcription factors could be used in 
combination with the azoles that not only overcome intrinsic resistance but also make this 
class fungicidal which may also attenuate the development of azole resistance in C. 
glabrata. Furthermore, this information can possibly be used for the timely diagnosis of 
the more azole resistant Candida species such as C. glabrata and also possibly for 
identification of resistance mechanisms in this species.  Currently the diagnosis of 
candidiasis relies on blood cultures or tissue biopsy specimens which may require 2-5 
days for growth and identification. Furthermore, antifungal susceptibility testing requires 
another 48 hours for results. Therefore, development of molecular diagnostic tests that 
can not only quickly identify the Candida species, but also predict the susceptibility of 
the organism to an array of antifungals is needed. Early diagnosis and species 
identification leads to earlier initiation of optimal treatment which has been shown to 
improve clinical outcome (69). Clearly, further studies regarding the role of CgPdr1p 
hyperactive alleles and other azole-responsive transcription regulators on the downstream 
targets responsible for azole tolerance and development of high level resistance are 
needed. The hope is that such studies will lead to improved therapies and patient 
outcomes. 
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